Phenytoin B-drug B-drug
: O O
Serum O O
phenytoin B-drug B-drug
levels O O
may O O
be O O
increased O O
by O O
aspirin B-brand B-brand
. O O

Pharmacologic O O
studies O O
indicate O O
that O O
there O O
may O O
be O O
additive O O
effects O O
in O O
prolonging O O
AV O O
conduction O O
when O O
using O O
beta-blockers B-group B-group
or O O
digitalis B-group B-group
concomitantly O O
with O O
Tiazac B-brand B-brand
. O O

Amprenavir B-drug B-drug

No O O
abortifacient O O
or O O
teratogenic O O
effects O O
were O O
observed O O
in O O
cynomolgus O O
monkeys O O
following O O
intravenous O O
bolus O O
injections O O
of O O
AMEVIVE B-brand B-brand
administered O O
weekly O O
during O O
the O O
period O O
of O O
organogenesis O O
to O O
gestation O O
. O O

Therefore O O
, O O
concomitant O O
use O O
of O O
TORADOL B-brand B-brand
and O O
probenecid B-drug B-drug
is O O
contraindicated O O
. O O

( O O
54 O O
) O O
microtubules O O
per O O
axon O O
. O O

Primary O O
and O O
secondary O O
magnesium B-drug B-drug
deficiencies O O
constitute O O
the O O
sole O O
indication O O
of O O
physiological O O
oral O O
magnesium B-drug B-drug
therapy O O
. O O

Antacid B-group B-group
: O O
The O O
effect O O
of O O
an O O
aluminum B-drug B-drug
hydroxide- O O
and O O
magnesium B-drug B-drug
hydroxide-containing O O
antacid B-group B-group
( O O
Maalox B-brand B-brand
) O O
* O O
on O O
the O O
pharmacokinetics O O
of O O
capecitabine B-drug B-drug
was O O
investigated O O
in O O
12 O O
cancer O O
patients O O
. O O

Antacids B-group B-group
, O O
kaolin-pectin B-drug B-drug
, O O
sulfasalazine B-drug B-drug
, O O
neomycin B-drug B-drug
, O O
cholestyramine B-drug B-drug
, O O
certain O O
anticancer O B-group
drugs O I-group
, O O
and O O
metoclopramide B-drug B-drug
may O O
interfere O O
with O O
intestinal O O
digoxin B-drug B-drug
absorption O O
, O O
resulting O O
in O O
unexpectedly O O
low O O
serum O O
concentrations O O
. O O

Close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
dosage O O
are O O
required O O
when O O
this O O
drug O O
is O O
given O O
concomitantly O O
with O O
anticholinergic B-group B-group
or O O
sympathomimetic B-group B-group
drugs I-group I-group
. O O

Acetaminophen B-drug B-drug
diminished O O
the O O
binding O O
of O O
theophylline B-drug B-drug
to O O
human O O
serum O O
by O O
a O O
net O O
change O O
of O O
5.7 O O
% O O
( O O
percentage O O
increase O O
in O O
free O O
drug O O
fraction O O
[ O O
FDF O O
] O O
, O O
11.0 O O
% O O
) O O
at O O
662 O O
micromol/L O O
and O O
by O O
a O O
net O O
change O O
of O O
7.1 O O
% O O
( O O
percentage O O
increase O O
in O O
FDF O O
, O O
13.7 O O
% O O
) O O
at O O
1324 O O
micromol/L O O
. O O

This O O
paper O O
attempts O O
to O O
provide O O
a O O
basis O O
for O O
the O O
understanding O O
and O O
identifications O O
of O O
important O O
drug O O
interactions O O
. O O

Effects O O
of O O
etofibrate B-drug B-drug
upon O O
the O O
metabolism O O
of O O
chylomicron-like O O
emulsions O O
in O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

Hypersensitivity O O
Reactions O O
: O O
Patients O O
with O O
a O O
history O O
of O O
severe O O
hypersensitivity O O
reactions O O
to O O
products O O
containing O O
Cremophor O O
EL O O
( O O
eg O O
, O O
cyclosporin B-drug B-drug
for O O
injection O O
concentrate O O
and O O
teniposide B-drug B-drug
for O O
injection O O
concentrate O O
) O O
should O O
not O O
be O O
treated O O
with O O
TAXOL B-brand B-brand
. O O

Rare O O
reports O O
of O O
more O O
severe O O
events O O
such O O
as O O
phlebitis O O
, O O
cellulitis O O
, O O
induration O O
, O O
skin O O
exfoliation O O
, O O
necrosis O O
, O O
and O O
fibrosis O O
have O O
been O O
received O O
as O O
part O O
of O O
the O O
continuing O O
surveillance O O
of O O
TAXOL B-brand B-brand
safety O O
. O O

Cocaine B-drug B-drug
sometimes O O
proves O O
to O O
be O O
fatal O O
when O O
used O O
in O O
combination O O
with O O
heroin B-drug_n B-drug_n
. O O

Nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
aminoglycoside B-group B-group
antibiotics I-group I-group
and O O
cephalosporin B-group B-group
antibiotics I-group I-group
. O O

Of O O
the O O
229 O O
patients O O
who O O
had O O
potassium B-group B-group
depleting I-group I-group
diuretics I-group I-group
added O O
to O O
their O O
concomitant O O
medications O O
in O O
the O O
DIAMOND O O
trials O O
, O O
the O O
patients O O
on O O
TIKOSYN B-brand B-brand
had O O
a O O
non-significantly O O
reduced O O
relative O O
risk O O
for O O
death O O
of O O
0.68 O O
( O O
95 O O
% O O
CI O O
0.376 O O
, O O
1.230 O O
) O O
. O O

Azlocillin B-drug B-drug
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
amikacin B-drug B-drug
, O O
ciprofloxacin B-drug B-drug
, O O
gentamicin B-drug B-drug
, O O
netilmicin B-drug B-drug
, O O
or O O
tobramycin B-drug B-drug
. O O

Itraconazole B-drug B-drug
plasma O O
concentrations O O
should O O
be O O
monitored O O
when O O
Itraconazole B-drug B-drug
and O O
isoniazid B-drug B-drug
are O O
coadministered O O
. O O

Moreover O O
, O O
its O O
activity O O
was O O
enhanced O O
when O O
it O O
was O O
combined O O
with O O
either O O
azithromycin B-drug B-drug
or O O
minocycline B-drug B-drug
with O O
90 O O
% O O
parasite O O
reduction O O
at O O
the O O
highest O O
concentration O O
tested O O
. O O

Whether O O
abnormal O O
topoisomerase O O
quantity O O
and O O
specific O O
activity O O
are O O
associated O O
with O O
resistance O O
or O O
sensitivity O O
to O O
topoisomerase-targeted O O
chemotherapy O O
in O O
the O O
clinic O O
is O O
now O O
being O O
studied O O
. O O

Cardiac B-group B-group
glycosides I-group I-group

The O O
color O O
reverses O O
when O O
the O O
test O O
sample O O
is O O
acidified O O
in O O
vitro O O
to O O
a O O
pH O O
below O O
4 O O
. O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
propafenone B-drug B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

Amiodarone B-drug B-drug
or O O
Verapamil B-drug B-drug
: O O
The O O
risk O O
of O O
myopathy/rhabdomyolysis O O
is O O
increased O O
when O O
either O O
amiodarone B-drug B-drug
or O O
verapamil B-drug B-drug
is O O
used O O
concomitantly O O
with O O
a O O
closely O O
related O O
member O O
of O O
the O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitor I-group I-group
class I-group I-group
( O O
see O O
WARNINGS O O
, O O
Myopathy/Rhabdomyolysis O O
) O O
. O O

Lithium B-drug B-drug
: O O
Diclofenac B-drug B-drug
decreases O O
lithium B-drug B-drug
renal O O
clearance O O
and O O
increases O O
lithium B-drug B-drug
plasma O O
levels O O
. O O

- O O
Probenecid B-drug B-drug
: O O
Pretreatment O O
with O O
probenecid B-drug B-drug
reduces O O
both O O
the O O
natriuresis O O
and O O
hyperreninemia O O
produced O O
by O O
bumetanide B-drug B-drug
. O O

The O O
interaction O O
was O O
pharmacodynamic O O
; O O

Dose O O
of O O
AED B-group B-group
( O O
mg/day O O
) O O

Concomitantly O O
administered O O
iron-fortified B-drug_n B-drug_n
infant O O
formula O O
( O O
2.2 O O
mg O O
elemental O O
iron/6 B-drug_n B-drug_n
oz O O
) O O
has O O
no O O
significant O O
effect O O
on O O
cefdinir B-drug B-drug
pharmacokinetics O O
. O O

No O O
dosage O O
adjustment O O
is O O
required O O
for O O
Fluvoxamine B-drug B-drug
Tablets O O
. O O

Coadministration O O
of O O
Itraconazole B-drug B-drug
and O O
drugs O O
primarily O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
3A4 O O
enzyme O O
system O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
the O O
drugs O O
that O O
could O O
increase O O
or O O
prolong O O
both O O
therapeutic O O
and O O
adverse O O
effects O O
. O O

Buforin B-drug_n B-drug_n
II I-drug_n I-drug_n
may O O
be O O
active O O
in O O
inhibiting O O
Cryptosporidium O O
parvum O O
growth O O
in O O
vitro O O
upon O O
combination O O
with O O
either O O
azithromycin B-drug B-drug
or O O
minocycline B-drug B-drug
. O O

Lovastatin B-drug B-drug
is O O
metabolized O O
by O O
CYP3A4 O O
but O O
has O O
no O O
CYP3A4 O O
inhibitory O O
activity O O
; O O

The O O
effects O O
of O O
chlordiazepoxide B-drug B-drug
, O O
amphetamine B-drug B-drug
and O O
cocaine B-drug B-drug
on O O
bar-press O O
behavior O O
in O O
normal O O
and O O
genetically O O
nervous O O
dogs O O
. O O

Hydrocodone B-drug B-drug
: O O
Coadministration O O
of O O
Neurontin B-brand B-brand
( O O
125 O O
to O O
500 O O
mg O O
; O O

There O O
are O O
a O O
number O O
of O O
steps O O
physicians O O
can O O
take O O
to O O
ensure O O
that O O
their O O
patients O O
are O O
not O O
being O O
undertreated O O
. O O

Digitalis B-group B-group
: O O
Thyroid B-group B-group
preparations I-group I-group
may O O
potentiate O O
the O O
toxic O O
effects O O
of O O
digitalis B-group B-group
. O O

Studies O O
with O O
ACE B-group B-group
inhibitors I-group I-group
in O O
combination O O
with O O
diuretics B-group B-group
indicate O O
that O O
the O O
dose O O
of O O
the O O
ACE B-group B-group
inhibitor I-group I-group
can O O
be O O
reduced O O
when O O
it O O
is O O
given O O
with O O
a O O
diuretic B-group B-group
. O O

Monitoring O O
of O O
liver O O
enzymes O O
is O O
recommended O O
when O O
SUSTIVA B-brand B-brand
is O O
used O O
in O O
combination O O
with O O
ritonavir B-drug B-drug
. O O

Severe O O
allergic O O
reactions O O
including O O
anaphylaxis O O
have O O
been O O
reported O O
in O O
patients O O
exposed O O
to O O
a O O
variety O O
of O O
allergens O O
either O O
by O O
repeated O O
challenge O O
, O O
or O O
accidental O O
contact O O
, O O
and O O
with O O
diagnostic O O
or O O
therapeutic O O
agents O O
while O O
receiving O O
beta-blockers B-group B-group
. O O

Ketoconazole B-drug B-drug
: O O
Sensipar B-brand B-brand
is O O
metabolized O O
in O O
part O O
by O O
CYP3A4 O O
. O O

Erythromycin B-drug B-drug
( O O
500 O O
mg O O
every O O
8 O O
hrs O O
) O O

In O O
the O O
present O O
study O O
, O O
evoked O O
potentials O O
were O O
recorded O O
at O O
5 O O
, O O
20 O O
, O O
and O O
40 O O
min O O
following O O
IP O O
injections O O
of O O
saline O O
, O O
ethanol B-drug B-drug
( O O
2.0 O O
g/kg O O
) O O
, O O
physostigmine B-drug B-drug
( O O
0.6 O O
mg/kg O O
) O O
or O O
atropine B-drug B-drug
( O O
15.0 O O
mg/kg O O
) O O
on O O
separate O O
days O O
. O O

There O O
is O O
little O O
if O O
any O O
clinically O O
significant O O
interaction O O
between O O
Acarbose B-drug B-drug
and O O
metformin B-drug B-drug
. O O

Edema O O
has O O
been O O
reported O O
in O O
patients O O
concomitantly O O
receiving O O
Itraconazole B-drug B-drug
and O O
dihydropyridine B-group B-group
calcium I-group I-group
channel I-group I-group
blockers I-group I-group
. O O

Thyroid O O
hormonal O O
replacement O O
increases O O
metabolic O O
rate O O
, O O
which O O
requires O O
an O O
increase O O
in O O
digitalis B-group B-group
dosage O O
. O O

No O O
dose O O
adjustment O O
is O O
necessary O O
. O O

Antihypertensives B-group B-group
: O O
Amphetamines B-group B-group
may O O
antagonize O O
the O O
hypotensive O O
effects O O
of O O
antihypertensives B-group B-group
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

Caution O O
should O O
be O O
exercised O O
if O O
LEUSTATIN B-brand B-brand
Injection O O
is O O
administered O O
before O O
, O O
after O O
, O O
or O O
in O O
conjunction O O
with O O
other O O
drugs O O
known O O
to O O
cause O O
immunosuppression O O
or O O
myelosuppression O O
. O O

As O O
a O O
false-negative O O
result O O
may O O
occur O O
in O O
the O O
ferricyanide O O
test O O
, O O
it O O
is O O
recommended O O
that O O
either O O
the O O
glucose O O
oxidase O O
or O O
hexokinase O O
method O O
be O O
used O O
to O O
determine O O
blood/plasma O O
glucose O O
levels O O
in O O
patients O O
receiving O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
. O O

No O O
significant O O
interactions O O
with O O
digoxin B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
hydralazine B-drug B-drug
, O O
sulfinpyrazone B-drug B-drug
, O O
oral O O
contraceptives B-group B-group
, O O
tolbutamide B-drug B-drug
, O O
or O O
warfarin B-drug B-drug
have O O
been O O
observed O O
. O O

The O O
high O O
acquisition O O
cost O O
of O O
olanzapine B-drug B-drug
is O O
offset O O
by O O
reductions O O
in O O
other O O
treatment O O
costs O O
( O O
inpatient O O
and/or O O
outpatient O O
services O O
) O O
of O O
schizophrenia O O
. O O

The O O
daily O O
dose O O
of O O
ENABLEX B-brand B-brand
should O O
not O O
exceed O O
7.5 O O
mg O O
when O O
coadministered O O
with O O
potent O O
CYP3A4 O O
inhibitors O O
( O O
e.g. O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
clarithromycin B-drug B-drug
and O O
nefazadone O O
) O O
. O O

Treatment O O
of O O
the O O
glands O O
with O O
cytochalasin B-drug_n B-drug_n
D I-drug_n I-drug_n
redistributed O O
type O O
3 O O
inositol O O
1,4,5-trisphosphate O O
receptor O O
( O O
the O O
major O O
subtype O O
in O O
the O O
parietal O O
cell O O
) O O
from O O
the O O
fraction O O
containing O O
membranes O O
of O O
large O O
size O O
to O O
the O O
microsomal O O
fraction O O
, O O
suggesting O O
a O O
dissociation O O
of O O
the O O
store O O
from O O
the O O
plasma O O
membrane O O
. O O

diuretics* B-group B-group
; O O

It O O
is O O
presently O O
not O O
known O O
whether O O
these O O
same O O
drug O O
interactions O O
occur O O
with O O
dirithromycin B-drug B-drug
. O O

Doxazosin B-drug B-drug
mesylate I-drug I-drug
has O O
been O O
administered O O
without O O
any O O
evidence O O
of O O
an O O
adverse O O
drug O O
interaction O O
to O O
patients O O
receiving O O
thiazide B-group B-group
diuretics I-group I-group
, O O
beta-blocking B-group B-group
agents O I-group
, O O
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
. O O

Viable O O
counts O O
for O O
type O O
culture O O
E O O
. O O

The O O
concurrent O O
use O O
of O O
drugs O O
from O O
these O O
groups O O
is O O
decreasing O O
according O O
to O O
a O O
survey O O
of O O
200 O O
hospital O O
medical O O
records O O
. O O

Nephrotoxicity O O
associated O O
with O O
cyclosporine B-drug B-drug
may O O
also O O
be O O
enhanced O O
. O O

Pretreatment O O
of O O
megakaryocytes O O
with O O
extracellular O O
RR B-drug_n B-drug_n
( O O
50 O O
microM O O
) O O
also O O
inhibited O O
InsP B-drug_n B-drug_n
( I-drug_n I-drug_n
3 I-drug_n I-drug_n
) I-drug_n I-drug_n
-induced O O
responses O O
. O O

Dopamine B-group B-group
Antagonists I-group I-group
: O O
Since O O
apomorphine B-drug B-drug
is O O
a O O
dopamine B-group B-group
agonist I-group I-group
, O O
it O O
is O O
possible O O
that O O
dopamine B-group B-group
antagonists I-group I-group
, O O
such O O
as O O
the O O
neuroleptics B-group B-group
( O O
phenothiazines B-group B-group
, O O
butyrophenones B-group B-group
, O O
thioxanthenes B-group B-group
) O O
or O O
metoclopramide B-drug B-drug
, O O
may O O
diminish O O
the O O
effectiveness O O
of O O
APOKYN B-brand B-brand
. O O

If O O
such O O
drugs O O
are O O
needed O O
, O O
their O O
dose O O
should O O
be O O
reassessed O O
and O O
, O O
where O O
appropriate O O
, O O
plasma O O
concentration O O
measured O O
. O O

The O O
AUC O O
of O O
midazolam B-drug B-drug
on O O
Day O O
15 O O
was O O
similar O O
to O O
that O O
observed O O
at O O
baseline O O
. O O

5 O O
. O O

Appropriate O O
doses O O
for O O
this O O
combination O O
arenot O O
established O O
, O O
but O O
an O O
increase O O
in O O
thedosage O O
of O O
indinavir B-drug B-drug
may O O
be O O
required O O
. O O

They O O
are O O
part O O
of O O
the O O
treatment O O
of O O
patients O O
with O O
organ O O
transplants O O
, O O
malignancy O O
, O O
and O O
increasingly O O
those O O
with O O
conditions O O
such O O
as O O
psoriasis O O
, O O
rheumatoid O O
arthritis O O
, O O
and O O
liver O O
and O O
bowel O O
disease O O
in O O
which O O
inflammation O O
is O O
an O O
aetiological O O
factor O O
. O O

Phenytoin B-drug B-drug
: O O
Etodolac B-drug B-drug
has O O
no O O
apparent O O
pharmacokinetic O O
interaction O O
when O O
administered O O
with O O
phenytoin B-drug B-drug
. O O

Concomitant O O
use O O
of O O
HIVID B-drug B-drug
with O O
didanosine B-drug B-drug
is O O
not O O
recommended O O
. O O

Under O O
similar O O
conditions O O
, O O
bexarotene B-drug B-drug
concentrations O O
were O O
not O O
affected O O
by O O
concomitant O O
atorvastatin B-drug B-drug
administration O O
. O O

Increased O O
stability O O
of O O
nucleophosmin/B23 O O
in O O
anti-apoptotic O O
effect O O
of O O
ras O O
during O O
serum O O
deprivation O O
. O O

H2 B-group B-group
Receptor I-group I-group
Antagonists I-group I-group
: O O
Cimetidine B-drug B-drug
coadministration O O
leads O O
to O O
an O O
increased O O
peak O O
plasma O O
concentration O O
and O O
AUC O O
of O O
cisapride B-drug B-drug
, O O
there O O
is O O
no O O
effect O O
on O O
cisapride B-drug B-drug
absorption O O
when O O
it O O
is O O
coadministered O O
with O O
ranitidine B-drug B-drug
. O O

Pentamidine B-drug B-drug
may O O
cause O O
hypoglycemia O O
, O O
which O O
may O O
sometimes O O
be O O
followed O O
by O O
hyperglycemia O O
. O O

However O O
, O O
concomitant O O
administration O O
of O O
aspirin B-brand B-brand
with O O
CELEBREX B-brand B-brand
may O O
result O O
in O O
an O O
increased O O
rate O O
of O O
GI O O
ulceration O O
or O O
other O O
complications O O
, O O
compared O O
to O O
use O O
of O O
CELEBREX B-brand B-brand
alone O O
. O O

Another O O
investigator O O
found O O
no O O
increase O O
in O O
digoxin B-drug B-drug
levels O O
in O O
13 O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

If O O
additional O O
adrenergic B-group B-group
drugs I-group I-group
are O O
to O O
be O O
administered O O
by O O
any O O
route O O
, O O
they O O
should O O
be O O
used O O
with O O
caution O O
because O O
the O O
pharmacologically O O
predictable O O
sympathetic O O
effects O O
of O O
BROVANA B-brand B-brand
may O O
be O O
potentiated O O
. O O

Based O O
on O O
this O O
reported O O
activity O O
, O O
they O O
should O O
not O O
be O O
given O O
concomitantly O O
with O O
Coly-Mycin B-brand B-brand
M I-brand I-brand
Parenteral O O
except O O
with O O
the O O
greatest O O
caution O O
. O O

No O O
changes O O
were O O
observed O O
in O O
the O O
degree O O
of O O
anticoagulation O O
. O O

The O O
drugs O O
that O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
include O O
some O O
that O O
are O O
not O O
metabolized O O
by O O
the O O
enzyme O O
( O O
quinidine B-drug B-drug
; O O

However O O
, O O
because O O
higher O O
doses O O
( O O
up O O
to O O
360 O O
mg O O
QD O O
) O O
of O O
omeprazole B-drug B-drug
are O O
tolerated O O
in O O
Zollinger-Ellison O O
( O O
ZE O O
) O O
patients O O
, O O
no O O
dose O O
adjustment O O
for O O
omeprazole B-drug B-drug
is O O
recommended O O
at O O
current O O
doses O O
. O O

After O O
14 O O
days O O
of O O
co-administration O O
, O O
mean O O
trough O O
concentrations O O
of O O
clozapine B-drug B-drug
and O O
its O O
metabolites O O
, O O
N-desmethylclozapine B-drug_n B-drug_n
and O O
clozapine B-drug_n B-drug_n
N-oxide I-drug_n I-drug_n
, O O
were O O
elevated O O
with O O
fluvoxamine B-drug B-drug
by O O
about O O
three-fold O O
compared O O
to O O
baseline O O
concentrations O O
. O O

In O O
a O O
study O O
involving O O
healthy O O
subjects O O
receiving O O
TAMBOCOR B-brand B-brand
and O O
propranolol B-drug B-drug
concurrently O O
, O O
plasma O O
flecainide B-drug B-drug
levels O O
were O O
increased O O
about O O
20 O O
% O O
and O O
propranolol B-drug B-drug
levels O O
were O O
increased O O
about O O
30 O O
% O O
compared O O
to O O
control O O
values O O
. O O

Because O O
of O O
its O O
lack O O
of O O
anti-platelet O O
effect O O
valdecoxib B-drug B-drug
is O O
not O O
a O O
substitute O O
for O O
aspirin B-brand B-brand
for O O
cardiovascular O O
prophylaxis O O
. O O

The O O
management O O
of O O
infection O O
is O O
dealt O O
with O O
as O O
a O O
separate O O
section O O
. O O

diuretics* B-group B-group
; O O

Patients O O
should O O
be O O
advised O O
against O O
the O O
simultaneous O O
use O O
of O O
other O O
CNS B-group B-group
depressant I-group I-group
drugs I-group I-group
, O O
and O O
cautioned O O
that O O
the O O
effect O O
of O O
alcohol B-drug B-drug
may O O
be O O
increased O O
. O O

OTHER O O
CONCOMITANT O O
THERAPY O O
: O O
Although O O
specific O O
interaction O O
studies O O
were O O
not O O
performed O O
, O O
in O O
clinical O O
studies O O
, O O
cerivastatin B-drug B-drug
sodium I-drug I-drug
was O O
used O O
concomitantly O O
with O O
angiotensin- B-group B-group
converting I-group I-group
enzyme I-group I-group
( I-group I-group
ACE I-group I-group
) I-group I-group
inhibitors I-group I-group
, O O
betablockers B-group B-group
, O O
calcium-channel B-group B-group
blockers I-group I-group
, O O
diuretics B-group B-group
, O O
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
without O O
evidence O O
of O O
clinically O O
significant O O
adverse O O
interactions O O
. O O

Known O O
drug O O
interactions O O
include O O
barbiturates B-group B-group
, O O
tranquilizers B-group B-group
, O O
and O O
alcohol B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
drugs O O
possessing O O
nephrotoxic O O
( O O
e.g. O O
, O O
aminoglycosides B-group B-group
, O O
indomethacin B-drug B-drug
) O O
, O O
myelotoxic O O
( O O
e.g. O O
, O O
cytotoxic B-group O
chemotherapy O O
) O O
, O O
cardiotoxic O O
( O O
e.g. O O
, O O
doxorubicin B-drug B-drug
) O O
or O O
hepatotoxic O O
( O O
e.g. O O
, O O
methotrexate B-drug B-drug
, O O
asparaginase B-drug B-brand
) O O
effects O O
with O O
PROLEUKIN B-brand B-brand
may O O
increase O O
toxicity O O
in O O
these O O
organ O O
systems O O
. O O

PCP B-drug_n B-drug_n
produced O O
distinctive O O
effects O O
in O O
each O O
task O O
: O O
it O O
substituted O O
for O O
the O O
training O O
dose O O
in O O
PCP B-drug_n B-drug_n
discrimination O O
and O O
it O O
increased O O
the O O
number O O
of O O
responses O O
with O O
short O O
( O O
< O O
3 O O
s O O
) O O
interresponse O O
times O O
as O O
well O O
as O O
increasing O O
overall O O
response O O
rates O O
in O O
the O O
DRL O O
schedule O O
. O O

Eprosartan B-drug B-drug
( O O
up O O
to O O
400 O O
mg O O
b.i.d O O
. O O
or O O
800 O O
mg O O
q.d O O
. O O
) O O
doses O O
have O O
been O O
safely O O
used O O
concomitantly O O
with O O
a O O
thiazide B-group B-group
diuretic I-group I-group
( O O
hydrochlorothiazide B-drug B-drug
) O O
. O O

clinical O O
significance O O
unknown O O
. O O

Because O O
candesartan B-drug B-drug
is O O
not O O
significantly O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
and O O
at O O
therapeutic O O
concentrations O O
has O O
no O O
effects O O
on O O
P450 O O
enzymes O O
, O O
interactions O O
with O O
drugs O O
that O O
inhibit O O
or O O
are O O
metabolized O O
by O O
those O O
enzymes O O
would O O
not O O
be O O
expected O O
. O O

The O O
AUC O O
and O O
Cmax O O
of O O
descarboethoxyloratadine B-drug_n B-drug_n
, O O
an O O
active O O
metabolite O O
, O O
averaged O O
155 O O
% O O
( O O
27 O O
S.D O O
. O O
) O O
and O O
141 O O
% O O
( O O
35 O O
S.D O O
. O O
) O O
, O O
respectively O O
. O O

No O O
significant O O
difference O O
was O O
found O O
between O O
the O O
mean O O
values O O
of O O
the O O
volume O O
of O O
distribution O O
of O O
cloxacillin B-drug B-drug
with O O
and O O
without O O
probenecid B-drug B-drug
( O O
13.0 O O
and O O
12.6 O O
liters O O
, O O
respectively O O
) O O
. O O

Toxicity O O
of O O
cadmium O O
and O O
zinc B-drug B-drug
to O O
miracidia O O
of O O
Schistosoma O O
mansoni O O
. O O

Rifampicin B-drug B-drug
: O O
In O O
a O O
study O O
in O O
healthy O O
volunteers O O
, O O
a O O
six-day O O
course O O
of O O
rifampicin B-drug B-drug
at O O
600 O O
mg/day O O
followed O O
by O O
a O O
single O O
5 O O
mg O O
dose O O
of O O
isradipine B-drug B-drug
resulted O O
in O O
a O O
reduction O O
in O O
isradipine B-drug B-drug
levels O O
to O O
below O O
detectable O O
limits O O
. O O

and O O
, O O
rarely O O
, O O
euphoria O O
, O O
excitement O O
, O O
depression O O
, O O
hallucinations O O
, O O
paresthesia O O
, O O
muscle O O
pain O O
, O O
tinnitus O O
, O O
slurred O O
speech O O
, O O
coordination O O
disorder O O
, O O
tremor O O
, O O
rigidity O O
, O O
dystonia O O
, O O
ataxia O O
, O O
blurred O O
vision O O
, O O
nystagmus O O
, O O
strabismus O O
, O O
miosis O O
, O O
mydriasis O O
, O O
diplopia O O
, O O
dysarthria O O
, O O
epileptic O O
seizure O O
. O O

Cholecystokinin O O
octapeptide O O
is O O
a O O
necessary O O
factor O O
for O O
realization O O
of O O
this O O
action O O
of O O
neuroleptics B-group B-group
. O O

Menstrual O O
cycle O O
irregularities O O
were O O
accompanied O O
by O O
both O O
a O O
decrease O O
and O O
delay O O
in O O
the O O
peak O O
17b O O
-estradiol O O
and O O
progesterone O O
levels O O
following O O
administration O O
of O O
PEGASYS B-brand B-brand
to O O
female O O
monkeys O O
. O O

HMG-CoA B-group B-group
Reductase I-group I-group
Inhibitors I-group I-group
: O O
Inhibitors B-group B-group
of I-group I-group
HMG-CoA I-group I-group
reductase I-group I-group
may O O
cause O O
myopathy O O
, O O
which O O
is O O
manifested O O
as O O
muscle O O
pain O O
or O O
weakness O O
associated O O
with O O
elevated O O
levels O O
of O O
CPK O O
. O O

Although O O
the O O
clinical O O
significance O O
of O O
these O O
effects O O
is O O
not O O
known O O
, O O
caution O O
is O O
advised O O
in O O
the O O
co-administration O O
of O O
beta-agonists B-group B-group
with O O
non-potassium B-group B-group
sparing I-group I-group
diuretics I-group I-group
. O O

Since O O
animal O O
studies O O
suggest O O
that O O
the O O
action O O
of O O
barbiturates B-group B-group
may O O
be O O
prolonged O O
by O O
therapy O O
with O O
chlorpropamide B-drug B-drug
, O O
barbiturates B-group B-group
should O O
be O O
employed O O
with O O
caution O O
. O O

Antihistamines B-group B-group
may O O
have O O
additive O O
effects O O
with O O
alcohol B-drug B-drug
and O O
other O O
CNS B-group B-group
depressants I-group I-group
, O O
e.g. O O
, O O
hypnotics B-group B-group
, O O
sedatives B-group B-group
, O O
tranquilizers B-group B-group
, O O
antianxiety B-group B-group
agents I-group I-group
. O O

Upon O O
administration O O
of O O
10 O O
mg O O
of O O
Vardenafil B-drug B-drug
with O O
800 O O
mg O O
TID O O
indinavir B-drug B-drug
, O O
the O O
Cmax O O
and O O
AUC O O
of O O
indinavir B-drug B-drug
were O O
reduced O O
by O O
40 O O
% O O
and O O
30 O O
% O O
, O O
respectively O O
. O O

Interaction O O
of O O
clindamycin B-drug B-drug
and O O
gentamicin B-drug B-drug
in O O
vitro O O
. O O

Anafranil B-brand B-brand
should O O
not O O
be O O
used O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Respiratory O O
depression O O
, O O
hypotension O O
, O O
and O O
profound O O
sedation O O
or O O
coma O O
may O O
occur O O
. O O

Therefore O O
, O O
monitoring O O
of O O
theophylline B-drug B-drug
plasma O O
levels O O
should O O
be O O
considered O O
and O O
dosage O O
of O O
theophylline B-drug B-drug
adjusted O O
as O O
required O O
. O O

These O O
results O O
suggest O O
that O O
oral O O
administration O O
of O O
dmPGE2 B-drug_n B-drug_n
induces O O
a O O
more O O
pronounced O O
secretory O O
diarrhea O O
in O O
cecectomized O O
than O O
in O O
control O O
rats O O
, O O
probably O O
due O O
to O O
the O O
lack O O
of O O
the O O
reservoir O O
function O O
of O O
the O O
cecum O O
in O O
the O O
operated O O
animals O O
. O O

Caution O O
should O O
be O O
used O O
when O O
CYP3A4 B-drug O
inhibitors O O
are O O
co-administered O O
with O O
felodipine B-drug B-drug
. O O

The O O
actions O O
of O O
the O O
benzodiazepines B-group B-group
may O O
be O O
potentiated O O
by O O
barbiturates B-group B-group
, O O
narcotics B-group B-group
, O O
phenothiazines B-group B-group
, O O
monoamine B-group B-group
oxidase I-group I-group
inhibitors I-group I-group
or O O
other O O
antidepressants B-group B-group
. O O

Effects O O
of O O
Erythromycin B-drug B-drug
on O O
Felbatol B-brand B-brand
The O O
coadministration O O
of O O
erythromycin B-drug B-drug
( O O
1000 O O
mg/day O O
) O O
for O O
10 O O
days O O
did O O
not O O
alter O O
the O O
pharmacokinetic O O
parameters O O
of O O
Cmax O O
, O O
Cmin O O
, O O
AUC O O
, O O
CI/kg O O
or O O
tmax O O
at O O
felbamate B-drug B-drug
daily O O
doses O O
of O O
3000 O O
or O O
3600 O O
mg/day O O
in O O
10 O O
otherwise O O
healthy O O
subjects O O
with O O
epilepsy O O
. O O

Small O O
differences O O
in O O
sensitivity O O
to O O
chemotherapy O O
can O O
have O O
a O O
dramatic O O
effect O O
on O O
cure O O
rates O O
, O O
and O O
therefore O O
subtle O O
cell O O
type-specific O O
differences O O
may O O
be O O
important O O
determinants O O
of O O
drug O O
sensitivity O O
. O O

Potassium O B-group
sparing O I-group
agents O I-group
should O O
generally O O
not O O
be O O
used O O
in O O
patients O O
with O O
heart O O
failure O O
who O O
are O O
receiving O O
PRINIVIL B-brand B-brand
. O O

Methotrexate B-drug B-drug
: O O
Valdecoxib B-drug B-drug
10 I-drug O
mg I-drug O
BID O O
did O O
not O O
show O O
a O O
significant O O
effect O O
on O O
the O O
plasma O O
exposure O O
or O O
renal O O
clearance O O
of O O
methotrexate B-drug B-drug
. O O

Medications O O
that O O
interfere O O
with O O
your O O
bodys O O
ability O O
to O O
use O O
folate O O
may O O
also O O
increase O O
the O O
need O O
for O O
this O O
vitamin B-group O
. O O

Effect O O
of O O
estradiol B-drug B-drug
on O O
endotoxin-induced B-drug_n B-drug_n
changes O O
in O O
steroid O O
hormone O O
levels O O
and O O
lethality O O
in O O
male O O
rats O O
. O O

In O O
noradrenaline-precontracted B-drug B-drug
arteries O O
from O O
dietary-obese O O
rats O O
, O O
responses O O
to O O
resveratrol B-drug_n B-drug_n
were O O
not O O
attenuated O O
by O O
endothelial O O
denudation O O
, O O
indicating O O
an O O
action O O
independent O O
of O O
the O O
endothelium O O
. O O

Nelfinavir I-drug B-drug
M8 O O

Drug/Laboratory O O
Test O O
Interactions O O

d-amphetamine B-drug B-drug
with O O
desipramine B-drug B-drug
or O O
protriptyline B-drug B-drug
and O O
possibly O O
other O O
tricyclics B-group B-group
cause O O
striking O O
and O O
sustained O O
increases O O
in O O
the O O
concentration O O
of O O
d-amphetamine B-drug B-drug
in O O
the O O
brain O O
; O O

In O O
vitro O O
studies O O
were O O
conducted O O
to O O
investigate O O
the O O
potential O O
of O O
gabapentin B-drug B-drug
to O O
inhibit O O
the O O
major O O
cytochrome O O
P450 O O
enzymes O O
( O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
, O O
and O O
CYP3A4 O O
) O O
that O O
mediate O O
drug O O
and O O
xenobiotic O O
metabolism O O
using O O
isoform O O
selective O O
marker O O
substrates O O
and O O
human O O
liver O O
microsomal O O
preparations O O
. O O

Careful O O
supervision O O
of O O
diabetic O O
patients O O
under O O
treatment O O
with O O
Soriatane B-brand B-brand
is O O
recommended O O
. O O

The O O
potential O O
for O O
clinically O O
significant O O
drug-drug O O
interactions O O
posed O O
by O O
dolasetron B-drug B-drug
and O O
hydrodolasetron B-drug_n B-drug_n
appears O O
to O O
be O O
low O O
for O O
drugs O O
commonly O O
used O O
in O O
chemotherapy O O
or O O
surgery O O
, O O
because O O
hydrodolasetron B-drug_n B-drug_n
is O O
eliminated O O
by O O
multiple O O
routes O O
. O O

Aspirin B-brand B-brand
: O O
Concomitant O O
aspirin B-brand B-brand
may O O
decrease O O
the O O
metabolic O O
clearance O O
of O O
nicotinic B-drug B-drug
acid I-drug I-drug
. O O

During O O
clinical O O
trials O O
, O O
hypoglycemia O O
and O O
hyperglycemia O O
were O O
reported O O
in O O
diabetic O O
patients O O
receiving O O
oral O O
hypoglycemics B-group B-group
. O O

use O O
of O O
a O O
nonhormonal B-group B-group
contraceptive I-group I-group
product I-group I-group
is O O
recommended O O
. O O

Administration O O
of O O
a O O
5 O O
g O O
bolus O O
followed O O
by O O
1 O O
to O O
1.25 O O
g/hr O O
should O O
achieve O O
and O O
sustain O O
plasma O O
levels O O
of O O
0.13 O O
mg/mL O O
. O O

Dose O O
reduction O O
of O O
CRIXIVAN B-brand B-brand
to O O
600 O O
mg O O
every O O
8 O O
hours O O
should O O
be O O
considered O O
. O O

Therefore O O
, O O
a O O
starting O O
daily O O
dose O O
of O O
25 O O
mg O O
of O O
VIOXX B-brand B-brand
should O O
be O O
considered O O
for O O
the O O
treatment O O
of O O
osteoarthritis O O
when O O
VIOXX B-brand B-brand
is O O
co-administered O O
with O O
potent O O
inducers O O
of O O
hepatic O O
metabolism O O
. O O

Influence O O
of O O
Trileptal B-brand B-brand
on O O
AED B-group B-group
Concentration O O
( O O
Mean O O
change O O
, O O
90 O O
% O O
Confidence O O
Interval O O
) O O

Although O O
these O O
results O O
do O O
not O O
indicate O O
a O O
significant O O
interaction O O
between O O
TORADOL B-brand B-brand
and O O
warfarin B-drug B-drug
or O O
heparin B-drug B-drug
, O O
the O O
administration O O
of O O
TORADOL B-brand B-brand
to O O
patients O O
taking O O
anticoagulants B-group B-group
should O O
be O O
done O O
extremely O O
cautiously O O
, O O
and O O
patients O O
should O O
be O O
closely O O
monitored O O
. O O

The O O
decision O O
to O O
prescribe O O
this O O
agent O O
should O O
include O O
such O O
considerations O O
as O O
the O O
cost-risk-benefit O O
balance O O
, O O
patient O O
access O O
, O O
drug O O
distribution O O
pathways O O
, O O
and O O
prescription O O
drug O O
coverage O O
. O O

Aspirin/Acetaminophen B-brand B-brand
: O O
Pharmacokinetic O O
or O O
pharmacodynamic O O
drug-drug O O
interactions O O
have O O
not O O
been O O
demonstrated O O
between O O
Argatroban B-drug B-drug
and O O
concomitantly O O
administered O O
aspirin B-brand B-brand
( O O
162.5 O O
mg O O
orally O O
given O O
26 O O
and O O
2 O O
hours O O
prior O O
to O O
initiation O O
of O O
Argatroban B-drug B-drug
1 O O
g/kg/min O O
. O O
over O O
4 O O
hours O O
) O O
or O O
acetaminophen B-drug B-drug
( O O
1000 O O
mg O O
orally O O
given O O
12 O O
, O O
6 O O
and O O
0 O O
hours O O
prior O O
to O O
, O O
and O O
6 O O
and O O
12 O O
hours O O
subsequent O O
to O O
, O O
initiation O O
of O O
Argatroban B-drug B-drug
1.5 O O
g/kg/min O O
. O O
over O O
18 O O
hours O O
) O O
. O O

Pregnancy O O
Pregnancy O O
: O O
Category O O
C O O
PEGASYS B-brand B-brand
has O O
not O O
been O O
studied O O
for O O
its O O
teratogenic O O
effect O O
. O O

Intravenous O O
ranitidine B-drug B-drug
was O O
shown O O
to O O
double O O
the O O
bioavailability O O
of O O
oral O O
alendronate B-drug B-drug
. O O

Caution O O
is O O
advised O O
if O O
patients O O
receive O O
large O O
doses O O
of O O
ethchlorvynol B-drug B-drug
concurrently O O
. O O

Chlorprothixene B-drug B-drug
may O O
increase O O
the O O
plasma-level O O
of O O
concomitantly O O
given O O
lithium B-drug B-drug
. O O

Genetic O O
variation O O
in O O
metabolism O O
may O O
result O O
in O O
high O O
concentrations O O
of O O
drugs O O
and O O
an O O
increased O O
risk O O
of O O
adverse O O
effects O O
in O O
slow O O
metabolizers O O
, O O
which O O
is O O
important O O
when O O
using O O
for O O
example O O
antidepressants B-group B-group
or O O
chemotherapy O O
. O O

Ampicillin/Amoxicillin B-drug B-drug
: O O
An O O
increase O O
in O O
the O O
frequency O O
of O O
skin O O
rash O O
has O O
been O O
reported O O
among O O
patients O O
receiving O O
ampicillin B-drug B-drug
or O O
amoxicillin B-drug B-drug
concurrently O O
with O O
allopurinol B-drug B-drug
compared O O
to O O
patients O O
who O O
are O O
not O O
receiving O O
both O O
drugs O O
. O O

Hyperglycemia O O
has O O
also O O
been O O
reported O O
in O O
patients O O
receiving O O
CAMPTOSAR B-brand B-brand
. O O

Until O O
further O O
data O O
are O O
developed O O
regarding O O
drug O O
interactions O O
when O O
azithromycin B-drug B-drug
and O O
these O O
drugs O O
are O O
used O O
concomitantly O O
, O O
careful O O
monitoring O O
of O O
patients O O
is O O
advised O O
: O O
Digoxin B-drug B-drug
elevated O O
digoxin B-drug B-drug
concentrations O O
. O O

Oral O O
Contraceptives B-group B-group
Multiple O O
doses O O
of O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
, O O
the O O
estrogenic O O
component O O
in O O
most O O
oral O O
contraceptives B-group B-group
. O O

When O O
Bezalip B-brand B-brand
or O O
Bezalip B-brand B-brand
retard I-brand I-brand
is O O
used O O
at O O
the O O
same O O
time O O
as O O
other O O
medicines O O
or O O
substances O O
the O O
following O O
interactions O O
must O O
be O O
taken O O
into O O
account O O
: O O
- O O
Bezalip B-brand B-brand
and O O
Bezalip B-brand B-brand
retard I-brand I-brand
may O O
enhance O O
the O O
action O O
of O O
anticoagulants B-group B-group
of I-group I-group
the I-group I-group
coumarin I-group I-group
type I-group I-group
. O O

Oral O O
Contraceptives B-group B-group
: O O
The O O
effect O O
of O O
oral O O
contraceptives B-group B-group
on O O
the O O
pharmacokinetics O O
of O O
D.H.E B-brand B-brand
. I-brand I-brand
45 I-brand I-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
has O O
not O O
been O O
studied O O
. O O

Reduced O O
response O O
to O O
metyrapone O O
test O O
. O O

About O O
three O O
weeks O O
prior O O
to O O
admission O O
, O O
the O O
patient O O
was O O
started O O
on O O
clarithromycin B-drug B-drug
for O O
sinusitis O O
. O O

The O O
unrestricted O O
use O O
of O O
ascorbic B-drug B-drug
acid I-drug I-drug
for O O
these O O
purposes O O
can O O
not O O
be O O
advocated O O
on O O
the O O
basis O O
of O O
the O O
evidence O O
currently O O
available O O
. O O

cimetidine B-drug B-drug
) O O
and O O
many O O
that O O
are O O
substrates O O
for O O
P450 O O
2D6 O O
( O O
many O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
and O O
the O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
propafenone B-drug B-drug
and O O
flecainide B-drug B-drug
) O O
. O O

Nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group

Drugs O O
that O O
have O O
been O O
reported O O
to O O
diminish O O
oral O O
anticoagulant B-group B-group
response O O
, O O
ie O O
, O O
decreased O O
prothrom-bin O O
time O O
response O O
, O O
in O O
man O O
significantly O O
include O O
: O O
adrenocortical B-group B-group
steroids I-group I-group
; O O
alcohol* B-drug B-drug
; O O
antacids B-group B-group
; O O
antihistamines B-group B-group
; O O
barbiturates B-group B-group
; O O
carbamazepine B-drug B-drug
; O O
chloral B-drug B-drug
hydrate* O O
; O O
chlordiazepoxide B-drug B-drug
; O O
cholestyramine B-drug B-drug
; O O
diet O O
high O O
in O O
vitamin B-group B-group
K I-group I-group
; O O
diuretics* B-group B-group
; O O
ethchlorvynol B-drug B-drug
; O O
glutethimide B-drug B-drug
; O O
griseofulvin B-drug B-drug
; O O
haloperidol B-drug B-drug
; O O
meprobamate B-drug B-drug
; O O
oral O O
contraceptives B-group B-group
; O O
paraldehyde B-drug B-drug
; O O
primidone B-drug B-drug
; O O
ranitidine* B-drug B-drug
; O O
rifampin B-drug B-drug
; O O
unreliable O O
prothrombin O O
time O O
determinations O O
; O O
vitamin B-drug B-drug
C I-drug I-drug
; O O
warfarin B-drug B-drug
sodium I-drug I-drug
under-dosage O O
. O O

This O O
transient O O
hypotensive O O
response O O
is O O
not O O
a O O
contraindication O O
to O O
further O O
doses O O
which O O
can O O
be O O
given O O
without O O
difficulty O O
once O O
the O O
blood O O
pressure O O
has O O
increased O O
after O O
volume O O
expansion O O
. O O

Human O O
pharmacokinetics O O
data O O
indicate O O
that O O
oral O O
ketoconazole B-drug B-drug
potently O O
inhibits O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
resulting O O
in O O
an O O
eight-fold O O
increase O O
in O O
the O O
mean O O
AUC O O
of O O
cisapride B-drug B-drug
. O O

Increasing O O
the O O
felbamate B-drug B-drug
dose O O
to O O
1800 O O
mg/day O O
in O O
six O O
of O O
these O O
subjects O O
increased O O
the O O
steady-state O O
phenytoin B-drug B-drug
Cmin O O
to O O
25 O O
7 O O
micrograms/mL O O
. O O

Literature O O
reports O O
suggest O O
that O O
oral O O
calcium B-group B-group
antagonists I-group I-group
may O O
be O O
used O O
in O O
combination O O
with O O
beta-adrenergic B-group B-group
blocking I-group I-group
agents I-group I-group
when O O
heart O O
function O O
is O O
normal O O
, O O
but O O
should O O
be O O
avoided O O
in O O
patients O O
with O O
impaired O O
cardiac O O
function O O
. O O

The O O
effect O O
of O O
temperature O O
changes O O
on O O
the O O
number O O
of O O
microtubules O O
in O O
non-myelinated O O
axons O O
has O O
been O O
studied O O
in O O
cat O O
inferior O O
mesenteric O O
ganglion/hypogastric O O
nerve O O
preparations O O
incubated O O
at O O
various O O
temperatures O O
in O O
Eagles O O
minimal O O
essential O O
tissue O O
culture O O
medium O O
in O O
vitro O O
. O O

Administration O O
of O O
thiazide B-group B-group
diuretics I-group I-group
to O O
hypoparathyroid O O
patients O O
who O O
are O O
concurrently O O
being O O
treated O O
with O O
ergocalciferol B-drug B-drug
may O O
cause O O
hypercalcemia O O
. O O

Until O O
further O O
data O O
are O O
available O O
regarding O O
the O O
potential O O
interaction O O
of O O
dirithromycin B-drug B-drug
with O O
these O O
compounds O O
, O O
caution O O
should O O
be O O
used O O
during O O
coadministration O O
. O O

Restoration O O
of O O
vancomycin B-drug B-drug
susceptibility O O
in O O
Enterococcus O O
faecalis O O
by O O
antiresistance O O
determinant O O
gene O O
transfer O O
. O O

Other O O
common O O
adverse O O
reactions O O
are O O
dizziness O O
( O O
5-15 O O
% O O
) O O
, O O
weakness O O
( O O
5-15 O O
% O O
) O O
and O O
fatigue O O
( O O
2-4 O O
% O O
) O O
. O O

Interactions O O
with O O
other O O
drugs O O
metabolized O O
by O O
this O O
enzyme O O
could O O
potentially O O
occur O O
. O O

Further O O
, O O
designs O O
can O O
be O O
expressed O O
in O O
terms O O
of O O
proportionate O O
responses O O
associated O O
with O O
the O O
individual O O
compounds O O
rather O O
than O O
dose O O
levels O O
, O O
thereby O O
providing O O
for O O
results O O
that O O
are O O
applicable O O
across O O
compounds O O
. O O

therefore O O
, O O
the O O
disposition O O
of O O
zaleplon B-drug B-drug
is O O
not O O
expected O O
to O O
be O O
sensitive O O
to O O
alterations O O
in O O
protein O O
binding O O
. O O

The O O
potential O O
for O O
drug-drug O O
interaction O O
with O O
drugs O O
affected O O
by O O
cytochrome O O
P450 O O
enzymes O O
may O O
not O O
be O O
ruled O O
out O O
. O O

dermatitis O O

Lithium B-drug B-drug
: O O
In O O
a O O
study O O
conducted O O
in O O
healthy O O
subjects O O
, O O
mean O O
steady-state O O
lithium B-drug B-drug
plasma O O
levels O O
increased O O
approximately O O
17 O O
% O O
in O O
subjects O O
receiving O O
lithium B-drug B-drug
450 O O
mg O O
BID O O
with O O
CELEBREX B-brand B-brand
200 O O
mg O O
BID O O
as O O
compared O O
to O O
subjects O O
receiving O O
lithium B-drug B-drug
alone O O
. O O

In O O
situations O O
when O O
concurrent O O
therapy O O
is O O
necessary O O
, O O
careful O O
patient O O
monitoring O O
is O O
essential O O
. O O

Phosphate-Binding O O
Agents O O
: O O
Since O O
vitamin B-group B-group
D I-group I-group
also O O
has O O
an O O
effect O O
on O O
phosphate O O
transport O O
in O O
the O O
intestine O O
, O O
kidneys O O
and O O
bones O O
, O O
the O O
dosage O O
of O O
phosphate-binding O O
agents O O
must O O
be O O
adjusted O O
in O O
accordance O O
with O O
the O O
serum O O
phosphate O O
concentration O O
. O O

or O O
with O O
multivitamins B-group B-group
containing O O
zinc B-drug B-drug
may O O
substantially O O
interfere O O
with O O
drug O O
absorption O O
and O O
result O O
in O O
insufficient O O
plasma O O
and O O
tissue O O
quinolone B-group B-group
concentrations O O
. O O

Similarly O O
, O O
patients O O
receiving O O
the O O
drug O O
and O O
a O O
hydantoin B-group B-drug
, O O
sulfonamide B-group B-group
or O O
sulfonylurea B-group B-group
should O O
be O O
observed O O
for O O
signs O O
of O O
toxicity O O
to O O
these O O
drugs O O
. O O

Antipyrine B-drug B-drug
: O O
Antipyrine B-drug B-drug
pharmacokinetics O O
were O O
not O O
significantly O O
different O O
before O O
and O O
after O O
tiagabine B-drug B-drug
multiple-dose O O
regimens O O
. O O

Phenytoin B-drug B-drug
: O O
In O O
a O O
single O O
( O O
400 O O
mg O O
) O O
and O O
multiple O O
dose O O
( O O
400 O O
mg O O
TID O O
) O O
study O O
of O O
Neurontin B-brand B-brand
in O O
epileptic O O
patients O O
( O O
N=8 O O
) O O
maintained O O
on O O
phenytoin B-drug B-drug
monotherapy O O
for O O
at O O
least O O
2 O O
months O O
, O O
gabapentin B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
steady-state O O
trough O O
plasma O O
concentrations O O
of O O
phenytoin B-drug B-drug
and O O
phenytoin B-drug B-drug
had O O
no O O
effect O O
on O O
gabapentin B-drug B-drug
pharmacokinetics O O
. O O

Zidovudine B-drug B-drug
should O O
either O O
be O O
temporarily O O
discontinued O O
or O O
decreased O O
by O O
50 O O
% O O
when O O
coadministered O O
with O O
probenecid B-drug B-drug
on O O
the O O
day O O
of O O
VISTIDE B-brand B-brand
infusion O O
. O O

This O O
interaction O O
appears O O
to O O
be O O
related O O
both O O
to O O
pressor O O
activity O O
and O O
to O O
beta-adrenergic O O
stimulating O O
properties O O
of O O
these O O
catecholamines B-group O
and O O
may O O
produce O O
ventricular O O
arrhythmias O O
and O O
hypertension O O
. O O

Jacalin B-drug_n B-drug_n
: O O
an O O
IgA-binding O O
lectin O O
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCAplasma B-group B-group
levels O O
whenever O O
an O O
agent O O
of O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
class I-group I-group
including O O
Anafranil B-brand B-brand
is O O
going O O
to O O
be O O
co-administered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
( O O
and/or O O
P450 O O
1A2 O O
) O O
. O O

The O O
effect O O
of O O
cyclosporine B-drug B-drug
on O O
diltiazem B-drug B-drug
plasma O O
concentrations O O
has O O
not O O
been O O
evaluated O O
. O O

ERGAMISOL B-brand B-brand
( O O
levamisole B-drug B-drug
hydrochloride I-drug I-drug
) O O
has O O
been O O
reported O O
to O O
produce O O
ANTABUSE-like O O
side O O
effects O O
when O O
given O O
concomitantly O O
with O O
alcohol B-drug B-drug
. O O

During O O
the O O
above O O
experiments O O
we O O
noted O O
a O O
massive O O
precipitation O O
in O O
cell O O
cultures O O
stimulated O O
with O O
greater O O
than O O
or O O
equal O O
to O O
100 O O
micrograms O O
of O O
lectin O O
. O O

Other O O
drugs O O
metabolized O O
by O O
C.P.A O O
. O O

Cytochalasin B-drug_n B-drug_n
D I-drug_n I-drug_n
inhibited O O
the O O
carbachol-stimulated B-drug B-drug
intracellular O O
Ca O O
( O O
2+ O O
) O O
concentration O O
( O O
[ O O
Ca O O
( O O
2+ O O
) O O
] O O
( O O
i O O
) O O
) O O
increase O O
due O O
to O O
release O O
from O O
the O O
Ca O O
( O O
2+ O O
) O O
store O O
. O O

There O O
was O O
a O O
reduction O O
that O O
reached O O
borderline O O
statistical O O
significance O O
in O O
the O O
group O O
that O O
received O O
150 O O
mg/d O O
of O O
tolbutamide B-drug B-drug
. O O

Currently O O
, O O
there O O
are O O
no O O
safety O O
and O O
efficacy O O
data O O
available O O
from O O
the O O
use O O
of O O
this O O
combination O O
. O O

glutethimide B-drug B-drug
; O O

For O O
patients O O
receiving O O
both O O
therapies O O
, O O
standard O O
monitoring O O
of O O
tacrolimus B-drug B-drug
blood O O
concentrations O O
and O O
appropriate O O
tacrolimus B-drug B-drug
dosage O O
adjustments O O
are O O
recommended O O
. O O

Patients O O
on O O
rifampin B-drug B-drug
should O O
receive O O
70 O O
mg O O
of O O
CANCIDAS B-brand B-brand
daily O O
. O O

Sodium B-drug B-drug
Iodide I-drug I-drug
( O O
123I O O
and O O
131I O O
) O O
, O O
Sodium B-drug B-drug
Pertechnetate I-drug I-drug
Tc99m I-drug I-drug
: O O
Uptake O O
of O O
radiolabeled O O
ions O O
may O O
be O O
decreased O O
. O O

Nevirapine B-drug B-drug
is O O
principally O O
metabolized O O
by O O
the O O
liver O O
via O O
the O O
cytochrome O O
P450 O O
isoenzymes O O
, O O
3A4 O O
and O O
2B6 O O
. O O

CNS O O
Toxicity O O
Brain O O
hemorrhage O O
was O O
seen O O
in O O
a O O
female O O
dog O O
treated O O
for O O
3 O O
months O O
at O O
120 O O
mg/kg/day O O
. O O

This O O
allows O O
bitolterol B-drug B-drug
to O O
open O O
air O O
passages O O
, O O
increasing O O
the O O
effectiveness O O
of O O
the O O
steroid B-group B-group
. O O

It O O
is O O
known O O
that O O
CYP1A2 O O
is O O
inhibited O O
by O O
several O O
medicinal O O
products O O
, O O
including O O
fluvoxamine B-drug B-drug
, O O
and O O
such O O
medicinal O O
products O O
could O O
theoretically O O
adversely O O
influence O O
the O O
clearance O O
of O O
anagrelide B-drug B-drug
. O O

The O O
present O O
work O O
involved O O
the O O
administration O O
of O O
both O O
ethynyl B-drug B-drug
estradiol I-drug I-drug
and O O
levonorgestrel B-drug B-drug
to O O
groups O O
of O O
rats O O
, O O
followed O O
by O O
determination O O
of O O
the O O
homocysteine O O
excretion O O
rate O O
in O O
urine O O
. O O

Theoretically O O
, O O
the O O
naproxen B-drug B-drug
anion O O
itself O O
could O O
likewise O O
be O O
displaced O O
. O O

Indinavir B-drug B-drug
: O O
Coadministration O O
of O O
indinavir B-drug B-drug
with O O
VIRACEPT B-brand B-brand
resulted O O
in O O
an O O
83 O O
% O O
increase O O
in O O
nelfinavir B-drug B-drug
plasma O O
AUC O O
and O O
a O O
51 O O
% O O
increase O O
in O O
indinavir B-drug B-drug
plasma O O
A.C O O
. O O

Pharmacokinetics O O
of O O
calcium-entry B-group B-group
blockers I-group I-group
. O O

Coumarin-Type B-group B-group
Anticoagulants I-group I-group
: O O
Several O O
short-term O O
controlled O O
studies O O
failed O O
to O O
wshow O O
that O O
ibuprofen B-drug B-drug
significantly O O
affected O O
prothrombin O O
times O O
or O O
a O O
variety O O
of O O
other O O
clotting O O
factors O O
when O O
administered O O
to O O
individuals O O
on O O
coumarin-type B-group B-group
anticoagulants I-group I-group
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
glipizide B-drug B-drug
, O O
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
control O O
. O O

Flavoridin B-drug_n B-drug_n
alone O O
was O O
found O O
to O O
have O O
no O O
effect O O
on O O
CAS O O
, O O
but O O
can O O
completely O O
block O O
contortrostatin-induced B-drug_n O
phosphorylation O O
of O O
this O O
protein O O
in O O
MDA-MB-435 O O
cells O O
. O O

If O O
a O O
patient O O
is O O
truly O O
hypothyroid O O
, O O
it O O
is O O
likely O O
that O O
a O O
reduction O O
in O O
anticoagulant B-group B-group
dosage O O
will O O
be O O
required O O
. O O

Methenamine B-drug B-drug

Therefore O O
, O O
OMNICEF B-brand B-brand
for O O
Oral O O
Suspension O O
can O O
be O O
administered O O
with O O
iron-fortified B-drug_n B-drug_n
infant O O
formula O O
. O O

Both O O
CRIXIVAN B-brand B-brand
and O O
atazanavir B-drug B-drug
are O O
associated O O
with O O
indirect O O
( O O
unconjugated O O
) O O
hyperbilirubinemia O O
. O O

Alkalinizing O O
agents O O
: O O
Gastrointestinal O O
alkalinizing O O
agents O O
( O O
sodium B-drug B-drug
bicarbonate I-drug I-drug
, O O
etc O O
. O O
) O O
increase O O
absorption O O
of O O
amphetamines B-drug B-group
. O O

Patients O O
taking O O
REVIA B-brand B-brand
may O O
not O O
benefit O O
from O O
opioid B-group B-group
containing O O
medicines O O
, O O
such O O
as O O
cough O O
and O O
cold O O
preparations O O
, O O
antidiarrheal O O
preparations O O
, O O
and O O
opioid B-group B-group
analgesics I-group I-group
. O O

Hormonal B-group B-group
Contraceptives I-group I-group
, O O
Including O O
Oral O O
, O O
Injectable O O
, O O
Transdermal O O
, O O
and O O
Implantable O O
Contraceptives B-group B-group
: O O
An O O
interaction O O
study O O
demonstrated O O
that O O
co-administration O O
of O O
bosentan B-drug B-drug
and O O
the O O
oral O O
hormonal B-group B-group
contraceptive I-group I-group
Ortho-Novum B-brand B-brand
produced O O
average O O
decreases O O
of O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
levels O O
of O O
14 O O
% O O
and O O
31 O O
% O O
, O O
respectively O O
. O O

macrolide B-group B-group
antibiotics I-group I-group
e.g. O O
, O O
erythromycin B-drug B-drug
; O O

Radioligand O O
binding O O
experiments O O
using O O
the O O
uptake O O
inhibitor O O
hydrogen-3 O O
mazindol B-drug B-drug
revealed O O
a O O
significant O O
decrease O O
by O O
approximately O O
30 O O
% O O
in O O
norepinephrine B-drug B-drug
uptake-1 O O
carrier O O
density O O
in O O
functional O O
classes O O
II O O
to O O
III O O
and O O
IV O O
myocardium O O
versus O O
nonfailing O O
myocardium O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

However O O
, O O
the O O
pharmacodynamics O O
of O O
coadministration O O
of O O
zaleplon B-drug B-drug
and O O
promethazine B-drug B-drug
have O O
not O O
been O O
evaluated O O
. O O

AIM O O
AND O O
BACKGROUND O O
: O O
The O O
pharmacokinetic O O
interaction O O
between O O
sirolimus B-drug B-drug
, O O
a O O
macrolide B-group B-group
immunosuppressant I-group I-group
metabolized O O
by O O
CYP3A4 O O
, O O
and O O
the O O
calcium B-group B-group
channel I-group I-group
blocker I-group I-group
diltiazem B-drug B-drug
was O O
studied O O
in O O
18 O O
healthy O O
subjects O O
. O O

only O O
ibogaine B-drug_n B-drug_n
enhances O O
cocaine-induced B-drug B-drug
increases O O
in O O
accumbal O O
dopamine O O
. O O

Behavioral O O
mechanisms O O
underlying O O
the O O
link O O
between O O
smoking O O
and O O
drinking O O
. O O

John O O
s O O
wort O O
) O O
may O O
increase O O
the O O
formation O O
of O O
dapsone B-drug_n B-drug_n
hydroxylamine I-drug_n I-drug_n
, O O
a O O
metabolite O O
of O O
dapsone B-drug B-drug
associated O O
with O O
hemolysis O O
. O O

Like O O
ibogaine B-drug_n B-drug_n
( O O
40 O O
mg/kg O O
) O O
, O O
18-MC B-drug_n B-drug_n
( O O
40 O O
mg/kg O O
) O O
decreases O O
the O O
intravenous O O
self-administration O O
of O O
morphine B-drug B-drug
and O O
cocaine B-drug B-drug
and O O
the O O
oral O O
self-administration O O
of O O
ethanol B-drug B-drug
and O O
nicotine B-drug B-drug
in O O
rats O O
; O O

increased O O
plasminogen O O
antigen O O
and O O
activity O O
. O O

Permeation O O
studies O O
were O O
performed O O
on O O
guinea O O
pig O O
small O O
intestinal O O
mucosa O O
mounted O O
in O O
Ussing-type O O
chamber O O
. O O

Other O O
macrolide B-group B-group
antibiotics I-group I-group
, O O
such O O
as O O
erythromycin B-drug B-drug
, O O
have O O
not O O
been O O
studied O O
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
. O O

Compounds O O
tested O O
in O O
man O O
include O O
warfarin B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
aminopyrine B-drug B-drug
and O O
antipyrine B-drug B-drug
. O O

Reported O O
examples O O
include O O
the O O
following O O
: O O
Protease B-group B-group
Inhibitors I-group I-group
: O O
Protease B-group B-group
inhibitors I-group I-group
are O O
known O O
to O O
inhibit O O
CYP3A4 O O
to O O
varying O O
degrees O O
. O O

therefore O O
, O O
patients O O
who O O
may O O
be O O
adversely O O
affected O O
by O O
such O O
an O O
action O O
should O O
be O O
carefully O O
observed O O
. O O

In O O
patients O O
given O O
very O O
high O O
doses O O
( O O
3900 O O
mg O O
) O O
of O O
aspirin B-brand B-brand
daily O O
, O O
increases O O
in O O
serum O O
salicylate B-group O
levels O O
were O O
seen O O
when O O
nizatidine B-drug B-drug
, O O
150 O O
mg O O
b.i.d. O O
, O O
was O O
administered O O
concurrently O O
. O O

Nicotine B-drug B-drug
Transdermal O O
System O O
: O O
. O O

Rabbits O O
failed O O
to O O
maintain O O
pregnancy O O
when O O
dosed O O
with O O
1 O O
mg/kg/day O O
fulvestrant B-drug B-drug
IM O O
( O O
twice O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
during O O
the O O
period O O
of O O
organogenesis O O
. O O

- O O
Other O O
antihypertensive B-group B-group
drugs I-group I-group
: O O
Additive O O
effect O O
or O O
potentiation O O

The O O
physician O O
is O O
advised O O
to O O
monitor O O
the O O
plasma O O
concentrations O O
of O O
itraconazole B-drug B-drug
when O O
any O O
of O O
these O O
drugs O O
is O O
taken O O
concurrently O O
, O O
and O O
to O O
increase O O
the O O
dose O O
of O O
Itraconazole B-drug B-drug
if O O
necessary O O
. O O

The O O
concurrent O O
administration O O
of O O
CAMPTOSAR B-brand B-brand
with O O
irradiation O O
has O O
not O O
been O O
adequately O O
studied O O
and O O
is O O
not O O
recommended O O
. O O

Indomethacin B-drug B-drug
- O O
Concomitant O O
use O O
of O O
L-glutamine B-drug B-drug
and O O
indomethacin B-drug B-drug
may O O
ameliorate O O
increased O O
intestinal O O
permeability O O
caused O O
by O O
indomethacin B-drug B-drug
. O O

Prospective O O
studies O O
on O O
the O O
potential O O
for O O
hydroxyurea B-drug B-drug
to O O
interact O O
with O O
other O O
drugs O O
have O O
not O O
been O O
performed O O
. O O

There O O
is O O
, O O
however O O
, O O
currently O O
no O O
data O O
on O O
the O O
effect O O
of O O
combined O O
hyperglycaemia O O
and O O
hyperinsulinaemia O O
on O O
the O O
renal O O
and O O
ocular O O
blood O O
flow O O
seen O O
in O O
diabetic O O
patients O O
on O O
insulin O B-drug
therapy O O
. O O

Animals O O
dosed O O
with O O
1,3-difluoroacetone B-drug_n B-drug_n
did O O
not O O
display O O
the O O
2-3 O O
hour O O
lag O O
phase O O
in O O
either O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
synthesis O O
or O O
in O O
citrate O O
and O O
fluoride O O
accumulation O O
characteristic O O
of O O
animals O O
dosed O O
with O O
1,3-difluoro-2-propanol B-drug_n B-drug_n
. O O

In O O
clinical O O
trials O O
, O O
antacids B-group B-group
were O O
administered O O
concomitantly O O
with O O
lansoprazole B-drug B-drug
delayed-release O O
capsules O O
; O O

DISCUSSION O O
: O O
Clarithromycin B-drug B-drug
is O O
a O O
potent O O
inhibitor O O
of O O
CYP3A4 O O
, O O
the O O
major O O
enzyme O O
responsible O O
for O O
simvastatin B-drug B-drug
metabolism O O
. O O

Sodium B-drug B-drug
thiosulfate I-drug I-drug
is O O
a O O
neutralizing O O
agent O O
for O O
cisplatin B-drug B-drug
that O O
protects O O
against O O
renal O O
damage O O
. O O

Digitalis B-group B-group
glycosides I-group I-group
: O O
Patients O O
on O O
digitalis B-group B-group
glycosides I-group I-group
may O O
be O O
at O O
increased O O
risk O O
of O O
arrhythmias O O
due O O
to O O
hypokalemia O O
. O O

Phenytoin B-drug B-drug
: O O
Accutane B-brand B-brand
has O O
not O O
been O O
shown O O
to O O
alter O O
the O O
pharmacokinetics O O
of O O
phenytoin B-drug B-drug
in O O
a O O
study O O
in O O
seven O O
healthy O O
volunteers O O
. O O

The O O
average O O
increase O O
was O O
45 O O
% O O
. O O

There O O
was O O
an O O
increasing O O
incidence O O
of O O
transient O O
thrombocytopenia O O
( O O
or O O
=100 O O
x O O
10 O O
( O O
9 O O
) O O
/L O O
) O O
with O O
increasing O O
everolimus B-drug B-drug
AUC O O
( O O
P O O
= O O
.03 O O
) O O
. O O

MAO B-group B-group
Inhibitors I-group I-group
: O O
Serious O O
side O O
effects O O
and O O
even O O
death O O
have O O
been O O
reported O O
following O O
the O O
concomitant O O
use O O
of O O
certain O O
drugs O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

This O O
should O O
be O O
taken O O
into O O
account O O
when O O
evaluating O O
serum O O
amylase O O
levels O O
for O O
diagnosis O O
or O O
monitoring O O
of O O
pancreatitis O O
in O O
patients O O
using O O
EXTRANEAL B-brand B-brand
. O O

No O O
change O O
in O O
phase O O
was O O
detected O O
, O O
although O O
the O O
aerosol O O
particles O O
appeared O O
to O O
contain O O
residual O O
solvent B-group O
. O O

Sympathomimetic B-group B-group
amines I-group I-group
may O O
reduce O O
the O O
antihypertensive O O
effects O O
of O O
reserpine B-drug B-drug
, O O
veratrum B-group B-group
alkaloids I-group I-group
, O O
methyldopa B-drug B-drug
and O O
mecamylamine B-drug B-drug
. O O

CYP3A4 O O
and O O
-2C19 O O
Inhibitors O O
- O O
In O O
vitro O O
studies O O
indicated O O
that O O
CYP3A4 O O
and O O
-2C19 O O
are O O
the O O
primary O O
enzymes O O
involved O O
in O O
the O O
metabolism O O
of O O
escitalopram B-drug B-drug
. O O

this O O
can O O
cause O O
headaches O O
and O O
other O O
signs O O
of O O
hypertensive O O
crisis O O
. O O

Celecoxib B-drug B-drug
metabolism O O
is O O
predominantly O O
mediated O O
via O O
cytochrome O O
P450 O O
2C9 O O
in O O
the O O
liver O O
. O O

Digitalis B-group B-group
glycosides I-group I-group
: O O
amphotericin B-drug B-drug
B-induced O O
hypokalemia O O
may O O
potentiate O O
digitalis B-group B-group
toxicity O O
. O O

Potential O O
effect O O
on O O
anticoagulation O O
. O O

Androgens B-group B-group
may O O
increase O O
sensitivity O O
to O O
oral O O
anticoagulahts O O
. O O

SERUM O O
LEVELS O O
OF O O
PHENYTOIN B-drug B-drug
SHOULD O O
BE O O
DETERMINED O O
ON O O
DIFFERENT O O
DAYS O O
FOR O O
EVIDENCE O O
OF O O
AN O O
INCREASE O O
OR O O
FOR O O
A O O
CONTINUING O O
RISE O O
IN O O
LEVELS O O
. O O

Absorption O O
of O O
tetracyclines B-group B-group
is O O
impaired O O
by O O
antacids B-group B-group
containing O O
aluminum B-drug B-drug
, O O
calcium B-drug B-drug
, O O
or O O
magnesium B-drug B-drug
, O O
and O O
iron-containing B-drug B-drug
preparations O O
. O O

The O O
effects O O
of O O
adenosine B-drug B-drug
are O O
antagonized O O
by O O
methylxanthines B-group B-group
such O O
as O O
caffeine B-drug B-drug
and O O
theophylline B-drug B-drug
. O O

Oral O O
contraceptives B-group B-group
: O O
Aprepitant B-drug B-drug
, O O
when O O
given O O
once O O
daily O O
for O O
14 O O
days O O
as O O
a O O
100-mg O O
capsule O O
with O O
an O O
oral O O
contraceptive B-group B-group
containing O O
35 O O
mcg O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
1 O O
mg O O
of O O
norethindrone B-drug B-drug
, O O
decreased O O
the O O
AUC O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
by O O
43 O O
% O O
, O O
and O O
decreased O O
the O O
AUC O O
of O O
norethindrone B-drug B-drug
by O O
8 O O
% O O
; O O

Particular O O
caution O O
should O O
be O O
exercised O O
in O O
using O O
preparations O O
containing O O
sulfur B-drug B-drug
, O O
resorcinol B-drug B-drug
, O O
or O O
salicylic B-drug B-drug
acid I-drug I-drug
in O O
combination O O
with O O
DIFFERIN B-brand B-brand
Gel O O
. O O

Ketoconazole B-drug B-drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
40 O O
mg O O
) O O
and O O
ketoconazole B-drug B-drug
( O O
200 O O
mg O O
) O O
decreased O O
the O O
Cmax O O
and O O
AUC O O
of O O
ketoconazole B-drug B-drug
by O O
21 O O
% O O
and O O
10 O O
% O O
, O O
respectively O O
, O O
and O O
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
citalopram B-drug B-drug
. O O

Terfenadine B-drug B-drug
: O O
In O O
a O O
prospective O O
study O O
involving O O
six-healthy-male O O
volunteers O O
, O O
dirithromycin B-drug B-drug
did O O
not O O
affect O O
the O O
metabolism O O
of O O
terfenadine B-drug B-drug
. O O

The O O
existence O O
of O O
PI O O
was O O
related O O
to O O
the O O
number O O
of O O
drugs O O
prescribed O O
to O O
each O O
patient O O
( O O
p O O
< O O
0.01 O O
) O O
. O O

No O O
Information O O
Provided O O

. O O

Certain O O
other O O
antibiotics B-group B-group
( O O
aminoglycosides B-group B-group
and O O
polymyxin B-group B-group
) O O
have O O
also O O
been O O
reported O O
to O O
interfere O O
with O O
the O O
nerve O O
transmission O O
at O O
the O O
neuromuscular O O
junction O O
. O O

Likewise O O
, O O
gabapentin B-drug B-drug
pharmacokinetics O O
were O O
unaltered O O
by O O
carbamazepine B-drug B-drug
administration O O
. O O

atorvastatin I-drug B-drug
concentration O O

Controlled O O
and O O
uncontrolled O O
domestic O O
studies O O
suggest O O
that O O
concomitant O O
use O O
of O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
and O O
beta-blockers B-group B-group
is O O
usually O O
well O O
tolerated O O
, O O
but O O
available O O
data O O
are O O
not O O
sufficient O O
to O O
predict O O
the O O
effects O O
of O O
concomitant O O
treatment O O
in O O
patients O O
with O O
left O O
ventricular O O
dysfunction O O
or O O
cardiac O O
conduction O O
abnormalities O O
. O O

It O O
is O O
recommended O O
that O O
buspirone B-drug B-drug
hydrochloride I-drug I-drug
not O O
be O O
used O O
concomitantly O O
with O O
MAO B-group B-group
inhibitors I-group I-group
Because O O
the O O
effects O O
of O O
concomitant O O
administration O O
of O O
buspirone B-drug B-drug
HCl I-drug I-drug
with O O
most O O
other O O
psychotropic B-group B-group
drugs I-group I-group
have O O
not O O
been O O
studied O O
, O O
the O O
concomitant O O
use O O
of O O
buspirone B-drug B-drug
HCl I-drug I-drug
with O O
other O O
CNS-active O O
drugs O O
should O O
be O O
approached O O
with O O
caution O O
. O O

No O O
interaction O O
trials O O
have O O
been O O
conducted O O
with O O
MEPRON B-brand B-brand
and O O
rifabutin B-drug B-drug
. O O

Fluconazole B-drug B-drug
and O O
Ketoconazole B-drug B-drug
: O O
Ketoconazole B-drug B-drug
and O O
fluconazole B-drug B-drug
are O O
predominantly O O
CYP O O
3A4 O O
and O O
2C9 O O
inhibitors O O
, O O
respectively O O
. O O

These O O
observations O O
strongly O O
suggest O O
that O O
the O O
homodimeric O O
structure O O
of O O
contortrostatin B-drug_n B-drug_n
functionally O O
distinguishes O O
it O O
from O O
other O O
monomeric O O
members O O
of O O
the O O
disintegrin O O
family O O
. O O

- O O
Impaired O O
glucose O O
tolerance O O

If O O
a O O
diuretic B-group B-group
is O O
also O O
used O O
, O O
it O O
may O O
increase O O
the O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

The O O
most O O
significant O O
drug O O
interactions O O
following O O
administration O O
of O O
Cerebyx B-brand B-brand
are O O
expected O O
to O O
occur O O
with O O
drugs O O
that O O
interact O O
with O O
phenytoin B-drug B-drug
. O O

Corticosteroids B-group B-group
: O O
A O O
relationship O O
of O O
functional O O
antagonism O O
exists O O
between O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
, O O
which O O
promote O O
calcium O O
absorption O O
, O O
and O O
corticosteroids B-group B-group
, O O
which O O
inhibit O O
calcium O O
absorption O O
. O O

Keys O O
to O O
maximizing O O
benefit O O
while O O
avoiding O O
adverse O O
drug O O
effects O O
. O O

When O O
given O O
concurrently O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
thiazide B-group B-group
diuretics I-group I-group
. O O

Other O O
Drug O O
Interactions O O
: O O
No O O
pharmacokinetic O O
interactions O O
were O O
observed O O
between O O
vardenafil B-drug B-drug
and O O
the O O
following O O
drugs O O
: O O
glyburide B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
Maalox B-brand B-brand
, O O
and O O
ranitidine B-drug B-drug
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
Amphetamines B-group B-group
can O O
cause O O
a O O
significant O O
elevation O O
in O O
plasma O O
corticosteroid B-group B-group
levels O O
. O O

When O O
cocaine B-drug B-drug
is O O
the O O
primary O O
addiction O O
, O O
after O O
withdrawal O O
the O O
most O O
effective O O
treatment O O
is O O
group O O
therapy O O
with O O
other O O
recovering O O
cocaine O B-drug
abusers O O
. O O

Today O O
pharmacological O O
magnesium B-drug B-drug
therapy O O
mainly O O
concerns O O
the O O
obstetrical O O
, O O
cardiological O O
and O O
anaesthesiological O O
fields O O
. O O

Compared O O
with O O
conventional B-group B-group
antipsychotics I-group I-group
, O O
it O O
has O O
greater O O
affinity O O
for O O
serotonin O O
5-HT2A O O
than O O
for O O
dopamine O O
D2 O O
receptors O O
. O O

Due O O
to O O
a O O
theoretical O O
risk O O
of O O
a O O
pharmacodynamic O O
interaction O O
, O O
use O O
of O O
ergotamine-containing B-drug B-drug
or O O
ergot-type B-group B-group
medications I-group I-group
( O O
like O O
dihydroergotamine B-drug B-drug
or O O
methysergide B-drug B-drug
) O O
and O O
FROVA B-brand B-brand
within O O
24 O O
hours O O
of O O
each O O
other O O
should O O
be O O
avoided O O
( O O
see O O
a O O
href= O O
frova_od.htm O O
# O O
CI O O
CONTRAINDICATIONS O O
) O O
. O O

Drug O O
Name O O

The O O
following O O
similar O O
changes O O
may O O
be O O
expected O O
with O O
larger O O
doses O O
of O O
estrogen B-group B-group
: O O
Increased O O
sulfobromophthalein O O
retention O O
; O O

Due O O
to O O
high O O
inter-patient O O
variability O O
and O O
limited O O
sampling O O
, O O
the O O
extent O O
of O O
the O O
increase O O
in O O
SN38 B-drug_n B-drug_n
levels O O
in O O
patients O O
receiving O O
concurrent O O
irinotecan B-drug B-drug
and O O
AVASTIN B-brand B-brand
is O O
uncertain O O
. O O

Hypoglycemics B-group B-group

http O O
: O O
//www.rxlist.com/cgi/generic3/guanethidine_od.htm O O

The O O
authors O O
examined O O
the O O
effect O O
of O O
the O O
cyclooxygenase-2 O O
( O O
COX-2 O O
) O O
inhibitor O O
, O O
rofecoxib B-drug B-drug
, O O
at O O
steady O O
state O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
following O O
a O O
single O O
dose O O
in O O
healthy O O
subjects O O
. O O

WelChol B-brand B-brand
was O O
found O O
to O O
have O O
no O O
significant O O
effect O O
on O O
the O O
bioavailability O O
of O O
digoxin B-drug B-drug
, O O
lovastatin B-drug B-drug
, O O
metoprolol B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
valproic B-drug B-drug
acid I-drug I-drug
, O O
and O O
warfarin B-drug B-drug
. O O

Such O O
interactions O O
might O O
be O O
manifested O O
by O O
increased O O
susceptibility O O
to O O
bruising O O
, O O
nosebleeds O O
, O O
hemoptysis O O
, O O
hematemesis O O
, O O
hematuria O O
and O O
blood O O
in O O
the O O
stool O O
. O O

There O O
is O O
a O O
single O O
case O O
report O O
, O O
which O O
suggests O O
that O O
sucralfate B-drug B-drug
may O O
interfere O O
with O O
anagrelide B-drug B-drug
absorption O O
. O O

Spontaneous O O
reports O O
of O O
serotonin O O
syndrome O O
associated O O
with O O
co-administration O O
of O O
ZYVOX B-brand B-brand
and O O
serotonergic B-group B-group
agents I-group I-group
, O O
including O O
antidepressants B-group B-group
such O O
as O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
have O O
been O O
reported O O
. O O

Therefore O O
, O O
4 O O
to O O
5 O O
hours O O
should O O
elapse O O
between O O
administration O O
of O O
cholestyramine B-drug B-drug
and O O
thyroid B-group B-group
hormones I-group I-group
. O O

It O O
is O O
not O O
known O O
whether O O
alosetron B-drug B-drug
might O O
induce O O
other O O
enzymes O O
. O O

The O O
use O O
of O O
ROMAZICON B-brand B-brand
is O O
not O O
recommended O O
in O O
epileptic O O
patients O O
who O O
have O O
been O O
receiving O O
benzodiazepine O B-group
treatment O O
for O O
a O O
prolonged O O
period O O
. O O

Caution O O
should O O
be O O
used O O
when O O
administering O O
or O O
taking O O
TARCEVA B-brand B-brand
with O O
ketoconazole B-drug B-drug
and O O
other O O
strong O O
CYP3A4 O O
inhibitors O O
such O O
as O O
, O O
but O O
not O O
limited O O
to O O
, O O
atazanavir B-drug B-drug
, O O
clarithromycin B-drug B-drug
, O O
indinavir B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
nefazodone B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
ritonavir B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
telithromycin B-drug B-drug
, O O
troleandomycin B-drug B-drug
( O O
TAO B-drug B-drug
) O O
, O O
and O O
voriconazole B-drug B-drug
. O O

The O O
clinical O O
significance O O
, O O
if O O
any O O
, O O
of O O
these O O
observations O O
is O O
unknown O O
. O O

Oral O O
Anticoagulants B-group B-group
: O O
Thyroid B-group B-group
hormones I-group I-group
appear O O
to O O
increase O O
catabolism O O
of O O
vitamin O O
K-dependent O O
clotting O O
factors O O
. O O

Medroxyprogesterone B-drug B-drug
Acetate I-drug I-drug
- O O
L-histidine B-drug B-drug
was O O
observed O O
to O O
enhance O O
( O O
in O O
tissue O O
culture O O
) O O
the O O
effect O O
of O O
medroxyprogesterone B-drug B-drug
acetate I-drug I-drug
in O O
reducing O O
the O O
number O O
of O O
human O O
breast O O
cancer O O
cells O O
that O O
were O O
in O O
the O O
S O O
phase O O
. O O

Other O O
Drugs O O
: O O
Based O O
on O O
the O O
results O O
of O O
drug O O
interaction O O
studies O O
, O O
no O O
dosage O O
adjustment O O
is O O
recommended O O
when O O
SUSTIVA B-brand B-brand
( O O
efavirenz B-drug B-drug
) O O
is O O
given O O
with O O
the O O
following O O
: O O
aluminum/magnesium B-group B-drug
hydroxide I-group B-group
antacids I-group I-group
, O O
azithromycin B-drug B-drug
, O O
cetirizine B-drug B-drug
, O O
famotidine B-drug B-drug
, O O
fluconazole B-drug B-drug
, O O
lamivudine B-drug B-drug
, O O
lorazepam B-drug B-drug
, O O
nelfinavir B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
and O O
zidovudine B-drug B-drug
. O O

The O O
concurrent O O
use O O
of O O
intravenously O O
or O O
orally O O
administered O O
methylxanthines B-group B-group
( O O
e.g. O O
, O O
aminophylline B-drug B-drug
, O O
theophylline B-drug B-drug
) O O
by O O
patients O O
receiving O O
BROVANA B-brand B-brand
has O O
not O O
been O O
completely O O
evaluated O O
. O O

74.1 O O
% O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
9.3 O O
) O O
of O O
the O O
total O O
PICR O O
could O O
be O O
avoided O O
by O O
simple O O
recommendations O O
; O O

The O O
data O O
do O O
not O O
suggest O O
the O O
need O O
for O O
dose O O
adjustment O O
of O O
either O O
HUMIRA B-brand B-brand
or O O
MTX B-drug B-drug
. O O

Diphenhydramine B-drug B-drug
hydrochloride I-drug I-drug
has O O
additive O O
effects O O
with O O
alcohol B-drug B-drug
and O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
hypnotics B-group B-group
, O O
sedatives B-group B-group
, O O
tranquilizers B-group B-group
, O O
etc O O
) O O
. O O

g/mL O O
; O O

If O O
the O O
treatment O O
is O O
continued O O
, O O
these O O
patients O O
should O O
be O O
particularly O O
carefully O O
monitored O O
for O O
adverse O O
effects O O
, O O
especially O O
conduction O O
disturbances O O
and O O
exacerbation O O
of O O
tachyarrhythmias O O
, O O
as O O
amiodarone B-drug B-drug
is O O
continued O O
. O O

Probenecid B-drug B-drug
Prolonged O O
action O O
of O O
etomidate B-drug B-drug

The O O
first O O
phase O O
of O O
this O O
sequence O O
, O O
initiation O O
, O O
is O O
considered O O
to O O
result O O
from O O
at O O
least O O
one O O
event O O
in O O
the O O
genetic O O
apparatus O O
. O O

Concomitant O O
use O O
of O O
prophylactic O O
low O O
dose O O
heparin B-drug B-drug
did O O
not O O
appear O O
to O O
affect O O
safety O O
, O O
however O O
, O O
its O O
effects O O
on O O
the O O
efficacy O O
of O O
Xigris B-brand B-brand
have O O
not O O
been O O
evaluated O O
in O O
an O O
adequate O O
and O O
well-controlled O O
clinical O O
trial O O
. O O

Amphotericin B-drug B-drug
B I-drug I-drug
or O O
potassium-depleting B-group B-group
diuretics I-group I-group
( O O
benzothiadiazines B-group B-group
and O O
related O O
drugs O O
, O O
ethacrynic B-drug B-drug
acid I-drug I-drug
and O O
furosemide B-drug B-drug
) O O
enhanced O O
hypokalemia O O
. O O

Aspirin B-brand B-brand
: O O
As O O
with O O
other O O
NSAIDs B-group B-group
, O O
concomitant O O
administration O O
of O O
Ponstel B-brand B-brand
and O O
aspirin B-brand B-brand
is O O
not O O
generally O O
recommended O O
because O O
of O O
the O O
potential O O
of O O
increased O O
adverse O O
effects O O
. O O

Calcium B-group B-group
Antagonists O I-group
: O O
After O O
repeated O O
co-administration O O
of O O
Trileptal B-brand B-brand
, O O
the O O
AUC O O
of O O
felodipine B-drug B-drug
was O O
lowered O O
by O O
28 O O
% O O
[ O O
90 O O
% O O
CI O O
: O O
20-33 O O
] O O
. O O

Patients O O
with O O
Crohn O O
s O O
disease O O
who O O
received O O
immunosuppressants B-group B-group
tended O O
to O O
experience O O
fewer O O
infusion O O
reactions O O
compared O O
to O O
patients O O
on O O
no O O
immunosuppressants B-group B-group
. O O

There O O
have O O
been O O
a O O
number O O
of O O
reports O O
in O O
the O O
post-marketing O O
experience O O
of O O
coma O O
and O O
death O O
associated O O
with O O
the O O
concomitant O O
intravenous O O
misuse O O
of O O
buprenorphine B-drug B-drug
and O O
benzodiazepines B-drug B-group
by O O
addicts O O
. O O

The O O
regulation O O
of O O
the O O
level O O
of O O
the O O
glucocorticoid-induced O O
gene O O
expression O O
by O O
the O O
antioxidative O O
gallates O O
is O O
of O O
great O O
interest O O
from O O
a O O
therapeutic O O
point O O
of O O
view O O
. O O

If O O
concomitant O O
treatment O O
with O O
frovatriptan B-drug B-drug
and O O
an O O
SSRI B-group B-group
is O O
clinically O O
warranted O O
, O O
appropriate O O
observation O O
of O O
the O O
patient O O
is O O
advised O O
. O O

Quinolones B-group B-group
form O O
chelates O O
with O O
alkaline O O
earth O O
and O O
transition O O
metals O O
. O O

Beta-adrenergic B-group B-group
Blocking I-group I-group
Agents I-group I-group
: O O
Experience O O
in O O
over O O
1400 O O
patients O O
in O O
a O O
non-comparative O O
clinical O O
trial O O
has O O
shown O O
that O O
concomitant O O
administration O O
of O O
nifedipine B-drug B-drug
and O O
beta-blocking B-group B-group
agents I-group I-group
is O O
usually O O
well O O
tolerated O O
, O O
but O O
there O O
have O O
been O O
occasional O O
literature O O
reports O O
suggesting O O
that O O
the O O
combination O O
may O O
increase O O
the O O
likelihood O O
of O O
congestive O O
heart O O
failure O O
, O O
severe O O
hypotension O O
or O O
exacerbation O O
of O O
angina O O
. O O

Moreover O O
, O O
as O O
noted O O
with O O
alprazolam B-drug B-drug
, O O
the O O
effect O O
of O O
fluvoxamine B-drug B-drug
may O O
even O O
be O O
more O O
pronounced O O
when O O
it O O
is O O
administered O O
at O O
higher O O
doses O O
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
ertapenem B-drug B-drug
does O O
not O O
inhibit O O
P-glycoprotein-mediated O O
transport O O
of O O
digoxin B-drug B-drug
or O O
vinblastine B-drug B-drug
and O O
that O O
ertapenem B-drug B-drug
is O O
not O O
a O O
substrate O O
for O O
P-glycoprotein-mediated O O
transport O O
. O O

Concurrent O O
administration O O
of O O
vasopressor B-group B-group
drugs I-group I-group
( O O
for O O
the O O
treatment O O
of O O
hypotension O O
related O O
to O O
obstetric O O
blocks O O
) O O
and O O
ergot-type B-group B-group
oxytocic I-group I-group
drugs I-group I-group
may O O
cause O O
severe O O
, O O
persistent O O
hypertension O O
or O O
cerebrovascular O O
accidents O O
. O O

Thus O O
, O O
when O O
NSAIDs B-group B-group
and O O
lithium B-drug B-drug
are O O
administered O O
concurrently O O
, O O
subjects O O
should O O
be O O
observed O O
carefully O O
for O O
signs O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

( O O
Read O O
circulars O O
for O O
lithium B-drug B-drug
preparation O O
before O O
use O O
of O O
such O O
concurrent O O
therapy O O
) O O
. O O

When O O
atropine B-drug B-drug
and O O
pralidoxime B-drug B-drug
are O O
used O O
together O O
, O O
the O O
signs O O
of O O
atropinization O O
( O O
flushing O O
, O O
mydriasis O O
, O O
tachycardia O O
, O O
dryness O O
of O O
the O O
mouth O O
and O O
nose O O
) O O
may O O
occur O O
earlier O O
than O O
might O O
be O O
expected O O
than O O
when O O
atropine B-drug B-drug
is O O
used O O
alone O O
because O O
pralidoxime B-drug B-drug
may O O
potentiate O O
the O O
effect O O
of O O
atropine B-drug B-drug
. O O

Diuretic B-group B-group
agents I-group I-group
may O O
decrease O O
vascular O O
response O O
to O O
pressor O O
drugs O O
such O O
as O O
epinephrine B-drug B-drug
. O O

- O O
Nitrofurantoin B-drug B-drug
( O O
e.g. O O
, O O
Furadantin B-brand B-brand
) O O
or O O

Effect O O
of O O
AEDs B-group B-group
in O O
Pediatric O O
Patients O O
There O O
was O O
about O O
a O O
22 O O
% O O
increase O O
of O O
apparent O O
total O O
body O O
clearance O O
of O O
levetiracetam B-drug B-drug
when O O
it O O
was O O
co-administered O O
with O O
enzyme-inducing O O
AEDs B-group B-group
. O O

Disulfiram B-drug B-drug
appears O O
to O O
decrease O O
the O O
rate O O
at O O
which O O
certain O O
drugs O O
are O O
metabolized O O
and O O
therefore O O
may O O
increase O O
the O O
blood O O
levels O O
and O O
the O O
possibility O O
of O O
clinical O O
toxicity O O
of O O
drugs O O
given O O
concomitantly O O
. O O

Coadministration O O
of O O
thioridazine B-drug B-drug
has O O
been O O
reported O O
to O O
worsen O O
the O O
tremor O O
in O O
elderly O O
patients O O
with O O
Parkinsons O O
disease O O
; O O

Antihistamines B-group B-group
: O O
Amphetamines B-group B-group
may O O
counteract O O
the O O
sedative O O
effect O O
of O O
antihistamines B-group B-group
. O O

Changes O O
in O O
urinary O O
homocysteine O O
following O O
synthetic B-group B-group
steroidal I-group I-group
estrogen I-group I-group
and O O
progestogen O O
administration O O
to O O
rats O O
. O O

Plasma O O
concentrations O O
of O O
azole B-group B-group
antifungal I-group I-group
agents I-group I-group
are O O
reduced O O
when O O
given O O
concurrently O O
with O O
isoniazid B-drug B-drug
. O O

Hitherto O O
unrecognized O O
interactions O O
between O O
homopolyribonucleotides O O
and O O
complexes O O
thereof O O
are O O
suggested O O
by O O
interferon O O
induction O O
data O O
obtained O O
in O O
a O O
highly O O
sensitive O O
assay O O
system O O
of O O
primary O O
rabbit O O
kidney O O
cell O O
cultures O O
superinduced O O
by O O
metabolic O O
inhibitors O O
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reaction O O
. O O

Isoflurane B-drug B-drug
potentiates O O
the O O
muscle O O
relaxant O O
effect O O
of O O
all O O
muscle B-group B-group
relaxants I-group I-group
, O O
most O O
notably O O
nondepolarizing B-group B-group
muscle I-group I-group
relaxants I-group I-group
, O O
and O O
MAC O O
( O O
minimum O O
alveolar O O
concentration O O
) O O
is O O
reduced O O
by O O
concomitant O O
administration O O
of O O
N O O
2O O O
. O O

Concurrent O O
administration O O
of O O
etanercept B-drug B-drug
( O O
another O O
TNF O O
-blocking O O
agent O O
) O O
and O O
anakinra B-drug B-drug
( O O
an O O
interleukin-1 B-group B-group
antagonist I-group I-group
) O O
has O O
been O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
serious O O
infections O O
, O O
and O O
increased O O
risk O O
of O O
neutropenia O O
and O O
no O O
additional O O
benefit O O
compared O O
to O O
these O O
medicinal O O
products O O
alone O O
. O O

The O O
conversion O O
of O O
6-deoxy B-drug_n B-drug_n
penciclovir I-drug_n I-drug_n
to O O
penciclovir B-drug B-drug
is O O
catalyzed O O
by O O
aldehyde O O
oxidase O O
. O O

In O O
patients O O
receiving O O
coumarin-type B-group B-group
anticoagulants I-group I-group
, O O
the O O
addition O O
of O O
Nalfon B-brand B-brand
to O O
therapy O O
could O O
prolong O O
the O O
prothrombin O O
time O O
. O O

5 O O
. O O

. O O

Caution O O
is O O
advised O O
in O O
patients O O
receiving O O
concomitant O O
high-dose O O
aspirin B-brand B-brand
and O O
carbonic B-group B-group
anhydrase I-group I-group
inhibitors I-group I-group
, O O
as O O
anorexia O O
, O O
tachypnea O O
, O O
lethargy O O
and O O
coma O O
have O O
been O O
rarely O O
reported O O
due O O
to O O
a O O
possible O O
drug O O
interaction O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
may O O
block O O
the O O
antihypertensive O O
action O O
of O O
guanethidine B-drug B-drug
and O O
similarly O O
acting O O
compounds O O
. O O

The O O
rats O O
treated O O
with O O
the O O
highest O O
dose O O
of O O
TML B-drug_n B-drug_n
manifested O O
significantly O O
longer O O
latencies O O
to O O
lose O O
the O O
righting O O
reflex O O
and O O
shorter O O
durations O O
of O O
sleep O O
than O O
did O O
controls O O
. O O

High-dose O O
cyclosporin B-drug B-drug
A I-drug O
resulting O O
in O O
concentrations O O
above O O
2000 O O
ng/mL O O
administered O O
with O O
oral O O
etoposide B-drug B-drug
has O O
led O O
to O O
an O O
80 O O
% O O
increase O O
in O O
etoposide B-drug B-drug
exposure O O
with O O
a O O
38 O O
% O O
decrease O O
in O O
total O O
body O O
clearance O O
of O O
etoposide B-drug B-drug
compared O O
to O O
etoposide B-drug B-drug
alone O O
. O O

Since O O
a O O
clinically O O
significant O O
interaction O O
may O O
be O O
anticipated O O
, O O
alternative O O
antihypertensive B-drug B-group
therapy O O
should O O
be O O
considered O O
in O O
these O O
patients O O
. O O

The O O
clinical O O
significance O O
of O O
these O O
changes O O
has O O
not O O
been O O
adequately O O
studied O O
. O O

It O O
is O O
suggested O O
that O O
there O O
is O O
a O O
minor O O
contribution O O
of O O
adenosine O O
receptors O O
to O O
these O O
effects O O
, O O
although O O
theophylline-induced B-drug B-drug
anxiogenic O O
effects O O
were O O
antagonized O O
by O O
an O O
A2 O O
receptor O O
agonist O O
. O O

Drug/ O O
Laboratory O O
Test O O
Interactions O O
: O O
It O O
is O O
not O O
known O O
if O O
MEPRON B-brand B-brand
interferes O O
with O O
clinical O O
laboratory O O
test O O
or O O
assay O O
results O O
. O O

These O O
levels O O
then O O
remained O O
stable O O
for O O
up O O
to O O
1 O O
year O O
of O O
therapy O O
. O O

Indomethacin B-drug B-drug
may O O
also O O
affect O O
plasma O O
renin O O
levels O O
, O O
aldosterone O O
excretion O O
, O O
and O O
renin O O
profile O O
evaluation O O
. O O

The O O
extent O O
of O O
interaction O O
depends O O
on O O
the O O
variability O O
of O O
effect O O
on O O
CYP2D6 O O
. O O

Drugs O O
that O O
Inhibit O O
Drug O O
Transport O O
Systems O O
Lapatinib B-drug B-drug
is O O
a O O
substrate O O
of O O
the O O
efflux O O
transporter O O
P-glycoprotein O O
( O O
Pgp O O
, O O
ABCB1 O O
) O O
. O O

Ultimately O O
however O O
, O O
up O O
to O O
80 O O
% O O
of O O
type O O
2 O O
diabetics O O
die O O
from O O
macrovascular O O
cardiovascular O O
disease O O
. O O

Furthermore O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
combining O O
digoxin B-drug B-drug
with O O
any O O
drug O O
that O O
may O O
cause O O
a O O
significant O O
deterioration O O
in O O
renal O O
function O O
, O O
since O O
a O O
decline O O
in O O
glomerular O O
filtration O O
or O O
tubular O O
secretion O O
may O O
impair O O
the O O
excretion O O
of O O
digoxin B-drug B-drug
. O O

Effect O O

CONCLUSION O O
: O O
Cisapride B-drug B-drug
can O O
be O O
administered O O
safely O O
to O O
patients O O
receiving O O
low O O
therapeutic O O
dosages O O
of O O
fluoxetine B-drug B-drug
. O O

The O O
optimal O O
dose O O
of O O
indinavir B-drug B-drug
, O O
when O O
given O O
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
, O O
is O O
not O O
known O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Cephalosporins B-group B-group
, O O
including O O
cefotaxime B-drug B-drug
sodium I-drug I-drug
, O O
are O O
known O O
to O O
occasionally O O
induce O O
a O O
positive O O
direct O O
Coombs O O
test O O
. O O

OBJECTIVES O O
. O O

Metoclopramide B-drug B-drug
: O O
Bioavailability O O
is O O
mildly O O
reduced O O
( O O
approximately O O
10 O O
% O O
) O O
when O O
zalcitabine B-drug B-drug
and O O
metoclopramide B-drug B-drug
are O O
coadministered O O
. O O

In O O
our O O
laboratory O O
, O O
preliminary O O
whole-cell O O
, O O
tight O O
seal O O
recordings O O
of O O
rat O O
spinal O O
substantia O O
gelatinosa O O
neurons O O
including O O
biocytin O O
in O O
the O O
patch O O
pipette O O
yielded O O
a O O
significantly O O
smaller O O
proportion O O
of O O
neurons O O
hyperpolarized O O
by O O
selective B-group B-group
opioid I-group I-group
agonists I-group I-group
compared O O
with O O
recordings O O
without O O
biocytin O O
. O O

Nonetheless O O
, O O
the O O
range O O
of O O
individual O O
Simulect B-brand B-brand
clearance O O
values O O
in O O
the O O
presence O O
of O O
azathioprine B-drug B-drug
( O O
12-57 O O
mL/h O O
) O O
or O O
mycophenolate B-drug B-drug
mofetil I-drug I-drug
( O O
7-54 O O
mL/h O O
) O O
did O O
not O O
extend O O
outside O O
the O O
range O O
observed O O
with O O
dual O O
therapy O O
( O O
10-78 O O
mL/h O O
) O O
. O O

In O O
vivo O O
interaction O O
studies O O
in O O
humans O O
have O O
demonstrated O O
that O O
digoxin B-drug B-drug
and O O
warfarin B-drug B-drug
do O O
not O O
affect O O
the O O
PK O O
properties O O
of O O
anagrelide B-drug B-drug
, O O
nor O O
does O O
anagrelide B-drug B-drug
affect O O
the O O
PK O O
properties O O
of O O
digoxin B-drug B-drug
or O O
warfarin B-drug B-drug
. O O

Diltiazem B-drug B-drug
plasma O O
levels O O
were O O
not O O
significantly O O
affected O O
by O O
lovastatin B-drug B-drug
or O O
pravastatin B-drug B-drug
. O O

Metabolism O O
of O O
dasatinib B-drug B-drug
is O O
mainly O O
hepatic O O
. O O

Cimetidine B-drug B-drug
, O O
Ranitidine B-drug B-drug
: O O
In O O
normal O O
volunteers O O
( O O
n=9 O O
) O O
, O O
pretreatment O O
with O O
cimetidine B-drug B-drug
or O O
ranitidine B-drug B-drug
did O O
not O O
affect O O
flurbiprofen B-drug B-drug
pharmacokinetics O O
except O O
that O O
a O O
small O O
( O O
13 O O
% O O
) O O
but O O
statistically O O
significant O O
increase O O
in O O
the O O
area O O
under O O
the O O
serum O O
concentration O O
curve O O
of O O
flurbiprofen B-drug B-drug
resulted O O
with O O
cimetidine B-drug B-drug
. O O

Using O O
in O O
situ O O
hybridization O O
, O O
we O O
observed O O
that O O
METH B-drug B-drug
caused O O
a O O
rapid O O
and O O
transient O O
dose-dependent O O
increase O O
in O O
arc O O
mRNA O O
level O O
in O O
the O O
striatum O O
and O O
cortex O O
that O O
was O O
abolished O O
by O O
pretreatment O O
with O O
the O O
specific O O
dopamine O O
D1 O O
receptor O O
antagonist O O
SCH-23390 B-drug_n B-drug_n
but O O
not O O
by O O
an O O
atypical B-group B-group
neuroleptic I-group I-group
clozapine B-drug B-drug
. O O

Consider O O
additive O O
sedative O O
effects O O
and O O
confusional O O
states O O
to O O
emerge O O
, O O
if O O
chlorprothixene B-drug B-drug
is O O
given O O
with O O
benzodiazepines B-group B-group
or O O
barbituates B-group B-group
. O O

Aminophylline B-drug B-drug
Etomidate I-drug I-drug
antagonism O O

Coumarin B-group B-group
Anticoagulants O I-group
: O O
In O O
a O O
small O O
clinical O O
trial O O
in O O
which O O
lovastatin B-drug B-drug
was O O
administered O O
to O O
warfarin B-drug B-drug
treated O O
patients O O
, O O
no O O
effect O O
on O O
prothrombin O O
time O O
was O O
detected O O
. O O

Coadministration O O
of O O
single O O
, O O
oral O O
doses O O
of O O
zaleplon B-drug B-drug
with O O
erythromycin B-drug B-drug
( O O
10 O O
mg O O
and O O
800 O O
mg O O
, O O
respectively O O
) O O
, O O
a O O
strong O O
, O O
selective O O
CYP3A4 O O
inhibitor O O
produced O O
a O O
34 O O
% O O
increase O O
in O O
zaleplons B-drug B-drug
maximal O O
plasma O O
concentrations O O
and O O
a O O
20 O O
% O O
increase O O
in O O
the O O
area O O
under O O
the O O
plasma O O
concentration-time O O
curve O O
. O O

Other O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
( O O
e.g. O O
, O O
aspirin B-brand B-brand
) O O
may O O
also O O
have O O
this O O
effect O O
. O O

iii O O
. O O

The O O
clinical O O
relevance O O
is O O
unclear O O
. O O

alcohol* B-drug B-drug
; O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
fenoprofen B-drug B-drug
, O O
because O O
of O O
its O O
affinity O O
for O O
albumin O O
, O O
may O O
displace O O
from O O
their O O
binding O O
sites O O
other O O
drugs O O
that O O
are O O
also O O
albumin O O
bound O O
, O O
and O O
this O O
may O O
lead O O
to O O
drug O O
interaction O O
. O O

[ O O
A O O
pharmacological O O
analysis O O
of O O
the O O
effect O O
of O O
angiotensin B-drug_n B-drug_n
on O O
stimulated O O
gastric O O
secretion O O
] O O
Chronic O O
experiments O O
on O O
dogs O O
with O O
gastric O O
fistulas O O
were O O
carried O O
out O O
to O O
study O O
the O O
influence O O
of O O
angiotensin B-drug_n B-drug_n
1 I-drug_n I-drug_n
and O O
angiotensin B-drug_n B-drug_n
2 I-drug_n I-drug_n
on O O
pentagastrin- B-drug B-drug
and O O
histamine-induced B-drug B-drug
gastric O O
acid O O
secretion O O
. O O

changes O O
in O O
cervical O O
mucus O O
, O O
the O O
endometrium O O
, O O
and O O
the O O
fallopian O O
tubes O O
; O O

Anticoagulants B-group B-group
including O O
coumarin O B-group
derivatives O I-group
, O O
indandione O O
derivatives O O
, O O
and O O
platelet B-group B-group
aggregation I-group I-group
inhibitors I-group I-group
such O O
as O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
, O O
and O O
aspirin B-brand B-brand
may O O
increase O O
the O O
risk O O
of O O
bleeding O O
when O O
administered O O
concomitantly O O
with O O
ardeparin B-drug B-drug
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
( O O
10 O O
mg O O
BID O O
for O O
7 O O
days O O
) O O
with O O
glyburide B-drug B-drug
( O O
5 O O
mg O O
QD O O
or O O
10 O O
mg O O
BID O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
( O O
exposure O O
) O O
of O O
glyburide B-drug B-drug
. O O

Protein O O
Binding O O
In O O
vitro O O
, O O
diclofenac B-drug B-drug
interferes O O
minimally O O
or O O
not O O
at O O
all O O
with O O
the O O
protein O O
binding O O
of O O
salicylic B-drug B-drug
acid I-drug I-drug
( O O
20 O O
% O O
decrease O O
in O O
binding O O
) O O
, O O
tolbutamide B-drug B-drug
, O O
prednisolone B-drug B-drug
( O O
10 O O
% O O
decrease O O
in O O
binding O O
) O O
, O O
or O O
warfarin B-drug B-drug
. O O

injection O O
of O O
phencyclidine B-drug_n B-drug_n
( O O
PCP B-drug_n B-drug_n
) O O
were O O
observed O O
by O O
measuring O O
locomotor O O
activity O O
and O O
stereotyped O O
behavior O O
. O O

Thus O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
on O O
one O O
of O O
the O O
agents O O
in O O
this O O
category O O
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
treatment O O
with O O
EQUETROTM B-brand B-brand
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
adjustment O O
may O O
be O O
necessary O O
. O O

Repeated O O
injection O O
of O O
PCP B-drug_n B-drug_n
for O O
20 O O
days O O
into O O
mice O O
induced O O
lower O O
locomotor O O
activity O O
than O O
that O O
in O O
acutely O O
injected O O
mice O O
. O O

Ibogaine B-drug_n B-drug_n
, O O
but O O
not O O
18-MC B-drug_n B-drug_n
, O O
decreases O O
heart O O
rate O O
at O O
high O O
doses O O
. O O

Similar O O
effects O O
would O O
be O O
expected O O
with O O
other O O
potent O O
CYP2D6 O O
inhibitors O O
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
quinidine B-drug B-drug
) O O
. O O

The O O
following O O
medications O O
have O O
been O O
administered O O
in O O
clinical O O
trials O O
with O O
Simulect B-brand B-brand
with O O
no O O
increase O O
in O O
adverse O O
reactions O O
: O O
ATG/ALG O O
, O O
azathioprine B-drug B-drug
, O O
corticosteroids B-group B-group
, O O
cyclosporine B-drug B-drug
, O O
mycophenolate B-drug B-drug
mofetil I-drug I-drug
, O O
and O O
muromonab-CD3 B-drug B-drug
. O O

Therefore O O
, O O
it O O
is O O
recommended O O
that O O
Fluvoxamine B-drug B-drug
Tablets O O
not O O
be O O
used O O
in O O
combination O O
with O O
MAOIs B-group B-group
, O O
or O O
within O O
14 O O
days O O
of O O
discontinuing O O
treatment O O
with O O
a O O
MAOI B-group B-group
. O O

Midazolam B-drug B-drug
used O O
at O O
doses O O
of O O
1.25 O O
mg/kg O O
and O O
2.5 O O
mg/kg O O
decreased O O
the O O
antinociceptive O O
effect O O
of O O
morphine B-drug B-drug
, O O
metamizol B-drug B-drug
( O O
only O O
in O O
the O O
tail-flick O O
test O O
) O O
and O O
indomethacin B-drug B-drug
. O O

Oral O O
Contraceptives B-group B-group
Rofecoxib B-drug B-drug
did O O
not O O
have O O
any O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
norethindrone B-drug B-drug
. O O

The O O
continued O O
need O O
for O O
the O O
other O O
antiarrhythmic B-drug B-group
agent O I-group
should O O
be O O
reviewed O O
after O O
the O O
effects O O
of O O
amiodarone B-drug B-drug
have O O
been O O
established O O
, O O
and O O
discontinuation O O
ordinarily O O
should O O
be O O
attempted O O
. O O

Drug-lab O O
interactions O O
: O O
implications O O
for O O
nutrition O O
support O O
. O O

However O O
, O O
careful O O
attention O O
must O O
be O O
directed O O
to B-group O
cross O O
toxicity O O
and O O
possible O O
pharmacokinetic O O
interactions O O
between O O
antiretroviral O B-group
and O O
antineoplastic B-group B-group
drugs I-group I-group
. O O

Effect O O
of O O
other O O
agents O O
on O O
the O O
pharmacokinefics O O
of O O
aprepitant B-drug B-drug

Patients O O
who O O
require O O
the O O
use O O
of O O
one O O
of O O
these O O
drugs O O
with O O
HIVID B-drug B-drug
should O O
have O O
frequent O O
clinical O O
and O O
laboratory O O
monitoring O O
with O O
dosage O O
adjustment O O
for O O
any O O
significant O O
change O O
in O O
renal O O
function O O
. O O

however O O
, O O
150 O O
mg O O
of O O
ranitidine B-drug B-drug
q12h O O
for O O
3 O O
days O O
increased O O
the O O
ceftibuten B-drug B-drug
C O O
max O O
by O O
23 O O
% O O
and O O
ceftibuten B-drug B-drug
AUC O O
by O O
16 O O
% O O
. O O

Antacid B-group B-group
( O O
Maalox B-brand B-brand
) O O
: O O
Maalox B-brand B-brand
reduced O O
the O O
bioavailability O O
of O O
gabapentin B-drug B-drug
( O O
N=16 O O
) O O
by O O
about O O
20 O O
% O O
. O O

The O O
intensity O O
, O O
uniformity O O
and O O
time O O
course O O
of O O
anticoagulant B-group B-group
interference O O
by O O
phenobarbital B-drug B-drug
, O O
secobarbital B-drug B-drug
, O O
glutethimide B-drug B-drug
, O O
chloral B-drug B-drug
hydrate I-drug I-drug
and O O
methaqualone B-drug B-drug
were O O
systematically O O
investigated O O
in O O
16 O O
patients O O
receiving O O
coumarin B-group B-group
therapy O O
. O O

Warfarin-Vitamin B-drug B-drug
K B-group I-drug
can O O
antagonize O O
the O O
effect O O
of O O
warfarin B-drug B-drug

If O O
a O O
patient O O
has O O
been O O
treated O O
with O O
cyclophosphamide B-drug B-drug
within O O
10 O O
days O O
of O O
general O O
anesthesia O O
, O O
the O O
anesthesiologist O O
should O O
be O O
alerted O O
. O O

The O O
effect O O
of O O
alosetron B-drug B-drug
on O O
monoamine O O
oxidases O O
and O O
on O O
intestinal O O
first O O
pass O O
secondary O O
to O O
high O O
intraluminal O O
concentrations O O
have O O
not O O
been O O
examined O O
. O O

2 O O
. O O

Clinical O O
implications O O
of O O
warfarin B-drug B-drug
interactions O O
with O O
five O O
sedatives B-group B-group
. O O

Table O O
5a O O
: O O
Drugs O O
That O O
Should O O
Not O O
Be O O
Coadministered O O
With O O
SUSTIVA B-brand B-brand

Clonidine B-drug B-drug
: O O
Concomitant O O
administration O O
of O O
clonidine B-drug B-drug
with O O
agents B-group O
with I-group O
b-blocking I-group B-group
properties I-group I-group
may O O
potentiate O O
blood-pressure- O O
and O O
heart-rate-lowering O O
effects O O
. O O

Steady O O
state O O
plasma O O
digitoxin B-drug B-drug
concentrations O O
did O O
not O O
appear O O
to O O
change O O
. O O

CFUs O O
were O O
maintained O O
at O O
low O O
levels O O
( O O
10 O O
( O O
3 O O
) O O
CFU O O
mL O O
( O O
-1 O O
) O O
) O O
for O O
24 O O
h O O
by O O
vancomycin/flavone B-drug B-drug
combinations O O
. O O

Appropriate O O
doses O O
for O O
this O O
combination O O
are O O
not O O
established O O
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
other O O
drugs O O
is O O
withdrawn O O
from O O
cotherapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
may O O
be O O
required O O
. O O

Olanzapine B-drug B-drug
treatment O O
improves O O
quality O O
of O O
life O O
in O O
patients O O
with O O
schizophrenia O O
and O O
related O O
psychoses O O
to O O
a O O
greater O O
extent O O
than O O
haloperidol B-drug B-drug
, O O
and O O
to O O
broadly O O
the O O
same O O
extent O O
as O O
risperidone B-drug B-drug
. O O

Since O O
PLETAL B-brand B-brand
is O O
extensively O O
metabolized O O
by O O
cytochrome O O
P-450 O O
isoenzymes O O
, O O
caution O O
should O O
be O O
exercised O O
when O O
PLETAL B-brand B-brand
is O O
coadministered O O
with O O
inhibitors O O
of O O
C.P.A O O
. O O
such O O
as O O
ketoconazole B-drug B-drug
and O O
erythromycin B-drug B-drug
or O O
inhibitors O O
of O O
CYP2C19 O O
such O O
as O O
omeprazole B-drug B-drug
. O O

On O O
the O O
average O O
for O O
the O O
group O O
, O O
the O O
dose O O
of O O
cyclosporine B-drug B-drug
was O O
reduced O O
about O O
20 O O
% O O
in O O
these O O
patients O O
. O O

In O O
vitro O O
studies O O
evaluating O O
the O O
minimum O O
inhibitory O O
concentration O O
( O O
MIC O O
) O O
of O O
vancomycin B-drug B-drug
, O O
cefazolin B-drug B-drug
, O O
ampicillin B-drug B-drug
, O O
ampicillin/flucoxacillin B-drug B-drug
, O O
ceftazidime B-drug B-drug
, O O
gentamicin B-drug B-drug
, O O
and O O
amphotericin B-drug B-drug
demonstrated O O
no O O
evidence O O
of O O
incompatibility O O
of O O
these O O
antibiotics B-group B-group
with O O
EXTRANEAL B-brand B-brand
. O O

Fulminant O O
rhabdomyolysis O O
has O O
been O O
seen O O
as O O
early O O
as O O
three O O
weeks O O
after O O
initiation O O
of O O
combined O O
therapy O O
with O O
another O O
fibrate B-group B-group
and O O
lovastatin B-drug B-drug
but O O
may O O
be O O
seen O O
after O O
several O O
months O O
. O O

Although O O
it O O
has O O
not O O
been O O
definitively O O
demonstrated O O
that O O
fluvoxamine B-drug B-drug
is O O
a O O
potent O O
IIIA4 O O
inhibitor O O
, O O
it O O
is O O
likely O O
to O O
be O O
, O O
given O O
the O O
substantial O O
interaction O O
of O O
fluvoxamine B-drug B-drug
with O O
alprazolam B-drug B-drug
. O O

Although O O
the O O
clinical O O
significance O O
is O O
not O O
known O O
, O O
it O O
is O O
not O O
recommended O O
that O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
be O O
taken O O
concomitantly O O
with O O
H2 B-group B-group
receptor I-group I-group
antagonists I-group I-group
. O O

The O O
administration O O
of O O
guanfacine B-drug B-drug
concomitantly O O
with O O
known O O
microsomal O O
enzyme O O
inducer O O
( O O
phenobarbital B-drug B-drug
or O O
phenytoin B-drug B-drug
) O O
to O O
two O O
patients O O
with O O
renal O O
impairment O O
reportedly O O
resulted O O
in O O
significant O O
reductions O O
in O O
elimination O O
half-life O O
and O O
plasma O O
concentration O O
. O O

These O O
antibiotics B-group B-group
should O O
be O O
used O O
in O O
the O O
myasthenic O O
patient O O
only O O
where O O
definitely O O
indicated O O
, O O
and O O
then O O
careful O O
adjustment O O
should O O
be O O
made O O
of O O
adjunctive O O
anticholinesterase B-group B-group
dosage O O
. O O

Both O O
18-MC B-drug_n B-drug_n
and O O
ibogaine B-drug_n B-drug_n
are O O
sequestered O O
in O O
fat O O
and O O
, O O
like O O
ibogaine B-drug_n B-drug_n
, O O
18-MC B-drug_n B-drug_n
probably O O
has O O
an O O
active O O
metabolite O O
. O O

Theophylline B-drug B-drug
- O O
Combined O O
administration O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
40 O O
mg/day O O
for O O
21 O O
days O O
) O O
and O O
the O O
CYP1A2 O O
substrate O O
theophylline B-drug B-drug
( O O
single O O
dose O O
of O O
300 O O
mg O O
) O O
did O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
theophylline B-drug B-drug
. O O

Digitalis B-group B-group
Glycosides I-group I-group
: O O
Therapeutic O O
effects O O
of O O
digitalis B-group B-group
glycosides I-group I-group
may O O
be O O
reduced O O
. O O

However O O
, O O
other O O
published O O
reports O O
describe O O
modest O O
elevations O O
( O O
less O O
than O O
two-fold O O
) O O
of O O
clozapine B-drug B-drug
and O O
metabolite O O
concentrations O O
when O O
clozapine B-drug B-drug
was O O
taken O O
with O O
paroxetine B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
and O O
sertraline B-drug B-drug
. O O

These O O
results O O
suggest O O
that O O
D1 O O
receptors O O
are O O
coupled O O
to O O
activation O O
of O O
arc O O
gene O O
, O O
which O O
may O O
be O O
involved O O
in O O
functional O O
or O O
structural O O
alterations O O
underlying O O
neural O O
plasticity O O
triggered O O
by O O
METH B-drug B-drug
. O O

. O O

Close O O
monitoring O O
allows O O
physicians O O
to O O
minimize O O
risks O O
, O O
maximize O O
benefits O O
, O O
and O O
get O O
the O O
most O O
out O O
of O O
what O O
modern O O
medications O O
can O O
do O O
to O O
help O O
older O O
patients O O
. O O

Because O O
ritonavir B-drug B-drug
is O O
coadministered O O
, O O
prescribers O O
should O O
also O O
refer O O
to O O
the O O
prescribing O O
information O O
for O O
ritonavir B-drug B-drug
regarding O O
drug O O
interactions O O
associated O O
with O O
this O O
agent O O
. O O

Exogenous O O
estradiol B-drug B-drug
also O O
appeared O O
to O O
influence O O
the O O
percentage O O
of O O
endotoxin-induced B-drug_n B-drug_n
deaths O O
in O O
a O O
dose-dependent O O
manner O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
used O O
when O O
administering O O
MEPRON B-brand B-brand
concurrently O O
with O O
other O O
highly O O
plasma O O
protein- O O
bound O O
drugs O O
with O O
narrow O O
therapeutic O O
indices O O
, O O
as O O
competition O O
for O O
binding O O
sites O O
may O O
occur O O
. O O

Therefore O O
, O O
the O O
potential O O
for O O
such O O
drug O O
interaction O O
should O O
be O O
considered O O
in O O
patients O O
receiving O O
AZOPT B-brand B-brand
( O O
brinzolamide B-drug B-drug
ophthalmic O O
suspension O O
) O O
1 O O
% O O
. O O

When O O
administered O O
concurrently O O
, O O
the O O
following O O
drugs O O
may O O
interact O O
with O O
adrenal B-group B-group
corticosteroids I-group I-group
. O O

forms O O
of O O
memory O O
. O O

Warfarin B-drug B-drug
, O O
Digoxin B-drug B-drug
, O O
Salicylate B-group B-group
, O O
and O O
Heparin B-drug B-drug
The O O
in O O
vitro O O
binding O O
of O O
warfarin B-drug B-drug
to O O
plasma O O
proteins O O
is O O
only O O
slightly O O
reduced O O
by O O
ketorolac B-drug B-drug
tromethamine I-drug I-drug
( O O
99.5 O O
% O O
control O O
vs O O
99.3 O O
% O O
) O O
when O O
ketorolac B-drug B-drug
plasma O O
concentrations O O
reach O O
5 O O
to10 O O
m O O
g/mL O O
. O O

Conversely O O
, O O
at O O
exposure O O
levels O O
close O O
to O O
the O O
" O O
limit O O
values O O
" O O

Reduced O O
response O O
to O O
metyrapone O O
test O O
. O O

Subjects O O
treated O O
with O O
200 O O
mg O O
of O O
dideoxyinosine B-drug B-drug
twice O O
daily O O
for O O
21 O O
days O O
received O O
1200 O O
mg O O
of O O
azithromycin B-drug B-drug
or O O
an O O
equivalent O O
amount O O
of O O
placebo/day O O
for O O
Days O O
8 O O
to O O
21 O O
. O O

Therefore O O
, O O
caution O O
should O O
be O O
used O O
in O O
concomitant O O
administration O O
. O O

Use O O
of O O
barrier O O
form O O
of O O
contraception O O
is O O
suggested O O
while O O
on O O
griseofulvin B-drug B-drug
therapy O O
. O O

With O O
drugs O O
inhibiting O O
CYP3A O O
to O O
a O O
lesser O O
, O O
but O O
still O O
significant O O
degree O O
, O O
estazolam B-drug B-drug
should O O
be O O
used O O
only O O
with O O
caution O O
and O O
consideration O O
of O O
appropriate O O
dosage O O
reduction O O
. O O

However O O
, O O
because O O
some O O
quinolones B-group B-group
have O O
been O O
reported O O
to O O
enhance O O
the O O
anticoagulant O O
effects O O
of O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
in O O
patients O O
, O O
the O O
prothrombin O O
time O O
or O O
other O O
suitable O O
coagulation O O
test O O
should O O
be O O
closely O O
monitored O O
if O O
a O O
quinolone B-group B-group
antimicrobial I-group I-group
is O O
administered O O
concomitantly O O
with O O
warfarin B-drug B-drug
or O O
its O O
derivatives O O
. O O

Clinically O O
meaningful O O
drug O O
interactions O O
have O O
occurred O O
with O O
concomitant O O
medications O O
and O O
include O O
, O O
but O O
are O O
not O O
limited O O
to O O
the O O
following O O
: O O
Agents O O
Highly O O
Bound O O
to O O
Plasma O O
Protein O O
Carbamazepine B-drug B-drug
is O O
not O O
highly O O
bound O O
to O O
plasma O O
proteins O O
; O O

Clinical O O
Laboratory O O

Geriatric O O
Use O O
When O O
tumor O O
response O O
was O O
considered O O
by O O
age O O
, O O
objective O O
responses O O
were O O
seen O O
in O O
24 O O
% O O
and O O
22 O O
% O O
of O O
patients O O
under O O
65 O O
years O O
of O O
age O O
and O O
in O O
16 O O
% O O
and O O
11 O O
% O O
of O O
patients O O
65 O O
years O O
of O O
age O O
and O O
older O O
, O O
who O O
were O O
treated O O
with O O
FASLODEX B-brand B-brand
in O O
the O O
European O O
and O O
North O O
American O O
trials O O
, O O
respectively O O
. O O

Therefore O O
, O O
etodolac B-drug B-drug
can O O
generally O O
be O O
given O O
without O O
the O O
need O O
for O O
dosage O O
modifications O O
in O O
special O O
populations O O
such O O
as O O
uncompromised O O
elderly O O
patients O O
, O O
those O O
with O O
moderate O O
renal O O
impairment O O
, O O
and O O
patients O O
with O O
stable O O
hepatic O O
disease O O
. O O

Studies O O
of O O
the O O
effect O O
of O O
food O O
on O O
the O O
pharmacokinetics O O
of O O
fluvastatin B-drug B-drug
have O O
demonstrated O O
marked O O
reductions O O
in O O
the O O
rate O O
of O O
bioavailability O O
-- O O
from O O
40 O O
% O O
to O O
60 O O
% O O
; O O

In O O
a O O
patient O O
with O O
a O O
nonfunctioning O O
thyroid O O
gland O O
who O O
is O O
receiving O O
thyroid O O
replacement O O
therapy O O
, O O
free O O
levothyroxine B-drug B-drug
may O O
be O O
decreased O O
when O O
estrogens B-group B-group
are O O
started O O
thus O O
increasing O O
thyroid B-group O
requirements O O
. O O

In O O
patients O O
receiving O O
Nalfon B-brand B-brand
and O O
a O O
steroid B-group B-group
concomitantly O O
, O O
any O O
reduction O O
in O O
steroid B-group B-group
dosage O O
should O O
be O O
gradual O O
in O O
order O O
to O O
avoid O O
the O O
possible O O
complications O O
of O O
sudden O O
steroid B-group O
withdrawal O O
. O O

The O O
effect O O
of O O
foods O O
highly O O
fortified O O
with O O
elemental O O
iron B-drug_n B-drug_n
( O O
primarily O O
iron-fortified B-drug_n B-drug_n
breakfast O O
cereals O O
) O O
on O O
cefdinir B-drug B-drug
absorption O O
has O O
not O O
been O O
studied O O
. O O

As O O
plasma O O
protein O O
binding O O
of O O
decitabine B-drug B-drug
is O O
negligible O O
( O O
1 O O
% O O
) O O
, O O
interactions O O
due O O
to O O
displacement O O
of O O
more O O
highly O O
protein O O
bound O O
drugs O O
from O O
plasma O O
proteins O O
are O O
not O O
expected O O
. O O

Although O O
specific O O
drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
ALPHAGAN B-brand B-brand
P I-brand I-brand
, O O
the O O
possibility O O
of O O
an O O
additive O O
or O O
potentiating O O
effect O O
with O O
CNS B-group B-group
depressants I-group I-group
( O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
opiates B-group B-group
, O O
sedatives B-group B-group
, O O
or O O
anesthetics B-group B-group
) O O
should O O
be O O
considered O O
. O O

Gabapentin B-drug B-drug
pharmacokinetic O O
parameters O O
without O O
and O O
with O O
probenecid B-drug B-drug
were O O
comparable O O
. O O

and O O
, O O
rarely O O
, O O
dry O O
mouth O O
, O O
anorexia O O
, O O
taste O O
disorder O O
, O O
abdominal O O
pain O O
, O O
vomiting O O
, O O
diarrhea O O
, O O
and O O
positive O O
test O O
for O O
occult O O
blood O O
in O O
stool O O
. O O

Plasma O O
levels O O
of O O
anticonvulsant B-group B-group
agents I-group I-group
may O O
become O O
subtherapeutic O O
during O O
cisplatin B-drug B-drug
therapy O O
. O O

Cardiovascular O O
agents O O
( O O
e.g. O O
, O O
atenolol B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
propranolol B-drug B-drug
) O O
. O O

+164 O O
% O O

vi O O
. O O

A O O
possible O O
interaction O O
between O O
glyburide B-drug B-drug
and O O
ciprofloxacin B-drug B-drug
, O O
a O O
fluoroquinolone B-group B-group
antibiotic I-group I-group
, O O
has O O
been O O
reported O O
, O O
resulting O O
in O O
a O O
potentiation O O
of O O
the O O
hypoglycemic O O
action O O
of O O
glyburide B-drug B-drug
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reaction O O
. O O

These O O
above O O
findings O O
are O O
summarized O O
in O O
TABLE O O
1 O O
. O O

In O O
vitro O O
studies O O
have O O
shown O O
that O O
, O O
because O O
of O O
its O O
affinity O O
for O O
protein O O
, O O
6MNA B-drug_n B-drug_n
may O O
displace O O
other O O
protein-bound O O
drugs O O
from O O
their O O
binding O O
site O O
. O O

The O O
effects O O
of O O
PEGASYS B-brand B-brand
on O O
male O O
fertility O O
have O O
not O O
been O O
studied O O
. O O

The O O
pressor O O
effects O O
of O O
catecholamines B-group O
such O O
as O O
dopamine B-drug B-drug
or O O
norepinephrine B-drug B-drug
are O O
enhanced O O
by O O
Bretylium B-drug B-drug
Tosylate I-drug I-drug
. O O

Because O O
dexfenfluramine B-drug B-drug
is O O
a O O
serotonin O O
releaser O O
and O O
reuptake O O
inhibitor O O
, O O
dexfenfluramine B-drug B-drug
should O O
not O O
be O O
used O O
concomitantly O O
with O O
a O O
MAO B-group B-group
inhibitor I-group I-group
. O O

CONCLUSIONS/INTERPRETATION O O
: O O
Glucose B-drug B-drug
and O O
insulin B-drug B-drug
can O O
exert O O
additive O O
vasodilator O O
properties O O
on O O
renal O O
and O O
ocular O O
circulation O O
. O O

Dexamethasone B-drug B-drug
at O O
10 O O
( O O
-10 O O
) O O
M O O
or O O
retinyl B-drug B-drug
acetate I-drug I-drug
at O O
about O O
3 O O
X O O
10 O O
( O O
-9 O O
) O O
M O O
inhibits O O
proliferation O O
stimulated O O
by O O
EGF B-drug_n B-drug_n
. O O

Therefore O O
, O O
concurrent O O
administration O O
of O O
drugs O O
that O O
induce O O
or O O
inhibit O O
this O O
enzyme O O
may O O
affect O O
quetiapine B-drug B-drug
pharmacokinetics O O
. O O

Our O O
results O O
indicate O O
important O O
relationships O O
among O O
ras O O
, O O
nucleophosmin/B23 O O
, O O
activation O O
of O O
caspase-3 O O
, O O
and O O
induction O O
of O O
apoptosis O O
. O O

Plasma O O
concentrations O O
increased O O
by O O
SUSTIVA B-brand B-brand
( O O
efavirenz B-drug B-drug
) O O
; O O

Coadministration O O
of O O
terfenadine B-drug B-drug
with O O
Itraconazole B-drug B-drug
has O O
led O O
to O O
elevated O O
plasma O O
concentrations O O
of O O
terfenadine B-drug B-drug
, O O
resulting O O
in O O
rare O O
instances O O
of O O
life- O O
threatening O O
cardiac O O
dysrhythmias O O
and O O
one O O
death O O
. O O

Agents O O
that O O
are O O
CYP O O
inducers O O
that O O
have O O
been O O
found O O
, O O
or O O
are O O
expected O O
, O O
to O O
decrease O O
plasma O O
levels O O
of O O
EQUETROTM B-brand B-brand
are O O
the O O
following O O
: O O
Cisplatin B-drug B-drug
, O O
doxorubicin B-drug B-drug
HCL I-drug I-drug
, O O
felbamate B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
Phenytoin B-drug B-drug
( O O
2 O O
) O O
, O O
primidone B-drug B-drug
, O O
methsuximide B-drug B-drug
, O O
and O O
theophylline B-drug B-drug
Thus O O
, O O
if O O
a O O
patient O O
has O O
been O O
titrated O O
to O O
a O O
stable O O
dosage O O
on O O
EQUETROTM B-brand B-brand
, O O
and O O
then O O
begins O O
a O O
course O O
of O O
treatment O O
with O O
one O O
of O O
these O O
CYP3A4 O O
inducers O O
, O O
it O O
is O O
reasonable O O
to O O
expect O O
that O O
a O O
dose O O
increase O O
for O O
EQUETROTM B-brand B-brand
may O O
be O O
necessary O O
. O O

The O O
Cmax O O
of O O
norethindrone B-drug B-drug
was O O
13 O O
% O O
higher O O
when O O
it O O
was O O
coadministered O O
with O O
gabapentin B-drug B-drug
; O O

The O O
effectiveness O O
of O O
norepinephrine B-drug B-drug
in O O
increasing O O
the O O
force O O
of O O
contraction O O
was O O
decreased O O
in O O
relation O O
to O O
the O O
degree O O
of O O
heart O O
failure O O
. O O

Cholestyramine B-drug B-drug
resin B-group B-group
may O O
delay O O
or O O
reduce O O
the O O
absorption O O
of O O
concomitant O O
oral O O
medication O O
such O O
as O O
phenylbutazone B-group B-drug
, O O
warfarin B-drug B-drug
, O O
thiazide B-group B-group
diuretics I-group I-group
( O O
acidic O O
) O O
or O O
propranolol B-drug B-drug
( O O
basic O O
) O O
, O O
as O O
well O O
as O O
tetracycline B-drug B-drug
penicillin I-drug I-drug
G I-drug I-drug
, O O
phenobarbital B-drug B-drug
, O O
thyroid O O
and O O
thyroxine B-drug B-group
preparations O I-group
, O O
estrogens B-group B-group
and O O
progestins B-group B-group
, O O
and O O
digitalis B-group B-group
. O O

- O O
Changes O O
in O O
TBg O O
concentration O O
should O O
be O O
taken O O
into O O
consideration O O
in O O
the O O
interpretation O O
of O O
T4 O O
and O O
T3 O O
values O O
. O O

14-OH O O
metabolite O O
concentration O O

No O O
data O O
from O O
prospective O O
clinical O O
trials O O
currently O O
exist O O
comparing O O
the O O
3 O O
approved O O
agents O O
( O O
efavirenz B-drug B-drug
, O O
nevirapine B-drug B-drug
or O O
delavirdine B-drug B-drug
) O O
. O O

A O O
false-positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
. O O

Intracellular O O
and O O
extracellular O O
application O O
of O O
RR B-drug_n B-drug_n
reduced O O
ADP-induced O O
increases O O
in O O
[ O O
Ca O O
( O O
2+ O O
) O O
] O O
( O O
i O O
) O O
. O O

Imipramine B-drug B-drug
: O O
Coadministration O O
of O O
single O O
doses O O
of O O
Sonata B-brand B-brand
20 O O
mg O O
and O O
imipramine B-drug B-drug
75 O O
mg O O
produced O O
additive O O
effects O O
on O O
decreased O O
alertness O O
and O O
impaired O O
psychomotor O O
performance O O
for O O
2 O O
to O O
4 O O
hours O O
after O O
administration O O
. O O

Total O O
body O O
clearance O O
of O O
Simulect B-brand B-brand
was O O
reduced O O
by O O
an O O
average O O
22 O O
% O O
and O O
51 O O
% O O
when O O
azathioprine B-drug B-drug
and O O
mycophenolate B-drug B-drug
mofetil I-drug I-drug
, O O
respectively O O
, O O
were O O
added O O
to O O
a O O
regimen O O
consisting O O
of O O
cyclosporine B-drug B-drug
, O O
USP O O
( O O
MODIFIED O O
) O O
and O O
corticosteroids B-group B-group
. O O

Of O O
the O O
1357 O O
patients O O
who O O
received O O
AMEVIVE B-brand B-brand
in O O
clinical O O
trials O O
, O O
a O O
total O O
of O O
100 O O
patients O O
were O O

Ibandronate B-drug B-drug
should O O
be O O
taken O O
at O O
least O O
60 O O
minutes O O
before O O
any O O
oral O O
medications O O
containing O O
multivalent O O
cations O O
( O O
including O O
antacids B-group B-group
, O O
supplements O O
or O O
vitamins B-group B-group
) O O
. O O

Frequent O O
prothrombin O O
determinations O O
are O O
advisable O O
until O O
it O O
has O O
been O O
determined O O
definitely O O
that O O
the O O
prothrombin O O
level O O
has O O
been O O
stabilized O O
. O O

The O O
risk O O
of O O
a O O
potential O O
interaction O O
between O O
NovoSeven B-brand B-brand
and O O
coagulation B-group B-group
factor I-group I-group
concentrates O I-group
has O O
not O O
been O O
adequately O O
evaluated O O
in O O
preclinical O O
or O O
clinical O O
studies O O
. O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
slows O O
the O O
renal O O
elimination O O
of O O
lome-floxacin O B-drug
. O O

Among O O
the O O
polyene B-group B-group
antibiotics I-group I-group
, O O
many O O
, O O
like O O
filipin B-drug_n B-drug_n
, O O
can O O
not O O
be O O
used O O
clinically O O
because O O
they O O
are O O
toxic O O
; O O

Patients O O
' O O
mean O O
age O O
was O O
69.1 O O
( O O
95 O O
% O O
CI O O
, O O
+/- O O
1.2 O O
) O O
. O O

Plasma O O
valproate B-drug B-drug
concentration O O
should O O
be O O
monitored O O
when O O
isoniazid B-drug B-drug
and O O
valproate B-drug B-drug
are O O
co O O
administered O O
, O O
and O O
appropriate O O
dosage O O
adjustments O O
of O O
valproate B-drug B-drug
should O O
be O O
made O O
. O O

Effective O O
use O O
of O O
drugs O O
in O O
therapy O O
depends O O
not O O
only O O
on O O
clinical O O
acumen O O
but O O
also O O
on O O
the O O
availability O O
of O O
relevant O O
pharmacokinetic O O
and O O
pharmacodynamic O O
data O O
. O O

Drug O O
Interactions O O
. O O

salicylates B-group B-group
; O O
sulfinpyrazone B-drug B-drug
; O O

No O O
adverse O O
effects O O
on O O
female O O
fertility O O
and O O
embryonic O O
survival O O
were O O
evident O O
in O O
female O O
animals O O
dosed O O
at O O
0.001 O O
mg/kg/day O O
( O O
approximately O O
one-thousandth O O
of O O
the O O
human O O
dose O O
based O O
on O O
BSA O O
) O O
. O O

These O O
agents O O
have O O
also O O
been O O
shown O O
to O O
decrease O O
platelet O O
nucleotide O O
release O O
and O O
thromboxane O O
A2 O O
generation O O
. O O

Do O O
not O O
start O O
or O O
stop O O
any O O
medicine O O
without O O
doctor O O
or O O
pharmacist O O
approval O O
. O O

Psychoactive B-group B-group
Drugs I-group I-group
: O O
Hallucinations O O
have O O
been O O
reported O O
when O O
TORADOL B-brand B-brand
was O O
used O O
in O O
patients O O
taking O O
psychoactive B-group B-group
drugs I-group I-group
( O O
fluoxetine B-drug B-drug
, O O
thiothixene B-drug B-drug
, O O
alprazolam B-drug B-drug
) O O
. O O

Use O O
caution O O
when O O
giving O O
these O O
drugs O O
together O O
, O O
especially O O
in O O
patients O O
with O O
hepatic O O
or O O
cardiac O O
disease O O
. O O

In O O
addition O O
, O O
Fondaparinux B-drug B-drug
neither O O
influenced O O
the O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
, O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
piroxicam B-drug B-drug
, O O
and O O
digoxin B-drug B-drug
, O O
nor O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
at O O
steady O O
state O O
. O O

Cypermethrin-induced B-drug B-drug
oxidative O O
stress O O
in O O
rat O O
brain O O
and O O
liver O O
is O O
prevented O O
by O O
vitamin B-drug B-drug
E I-drug I-drug
or O O
allopurinol B-drug B-drug
. O O

In O O
patients O O
taking O O
diclofenac B-drug B-drug
and O O
lithium B-drug B-drug
concomitantly O O
, O O
lithium B-drug B-drug
toxicity O O
may O O
develop O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
atypical B-group B-group
antipsychotic I-group I-group
clozapine B-drug B-drug
was O O
tested O O
in O O
combination O O
with O O
an O O
active O O
dose O O
of O O
PCP B-drug_n B-drug_n
in O O
two-lever O O
drug O O
discrimination O O
and O O
mixed O O
signalled-unsignalled O O
differential-reinforcement-of-low-rates O O
( O O
DRL O O
) O O
procedures O O
. O O

The O O
vasodilating O O
effects O O
of O O
isosorbide B-drug B-drug
mononitrate I-drug I-drug
may O O
be O O
additive O O
with O O
those O O
of O O
other O O
vasodilators B-group B-group
. O O

In O O
vitro O O
, O O
buspirone B-drug B-drug
does O O
not O O
displace O O
tightly O O
bound O O
drugs O O
like O O
phenytoin B-drug B-drug
, O O
propranolol B-drug B-drug
, O O
and O O
warfarin B-drug B-drug
from O O
serum O O
proteins O O
. O O

No O O
evidence O O
of O O
fetal O O
toxicity O O
including O O
adverse O O
effects O O
on O O
immune O O
system O O
development O O
was O O
observed O O
in O O
any O O
of O O
these O O
animals O O
. O O

Efavirenz B-drug B-drug
has O O
demonstrated O O
superiority O O
over O O
nelfinavir B-drug B-drug
in O O
nucleoside-experienced O O
patients O O
, O O
although O O
combining O O
these O O
2 O O
agents O O
may O O
represent O O
the O O
best O O
approach O O
in O O
these O O
circumstances O O
. O O

Gold B-group B-drug
is O O
excreted O O
slowly O O
from O O
the O O
body O O
. O O

When O O
ertapenem B-drug B-drug
is O O
co-administered O O
with O O
probenecid B-drug B-drug
( O O
500 O O
mg O O
p.o O O
. O O
every O O
6 O O
hours O O
) O O
, O O
probenecid B-drug B-drug
competes O O
for O O
active O O
tubular O O
secretion O O
and O O
reduces O O
the O O
renal O O
clearance O O
of O O
ertapenem B-drug B-drug
. O O

METHODS O O
: O O
All O O
patients O O
were O O
enrolled O O
in O O
two O O
sequential O O
trials O O
performed O O
at O O
the O O
Aviano O O
Cancer O O
Center O O
, O O
Italy O O
, O O
from O O
April O O
1988 O O
to O O
December O O
1998 O O
. O O

There O O
was O O
no O O
effect O O
on O O
bleeding O O
time O O
, O O
PT O O
or O O
aPTT O O
. O O

The O O
potential O O
for O O
drug O O
interactions O O
with O O
EMTRIVA B-brand B-brand
has O O
been O O
studied O O
in O O
combination O O
with O O
indinavir B-drug B-drug
, O O
stavudine B-drug B-drug
, O O
famciclovir B-drug B-drug
, O O
and O O
tenofovir B-drug B-drug
disoproxil I-drug I-drug
fumarate I-drug I-drug
. O O

therefore O O
, O O
administration O O
of O O
these O O
agents O O
should O O
precede O O
lomefloxacin B-drug B-drug
dosing O O
by O O
4 O O
hours O O
or O O
follow O O
lomefloxacin B-drug B-drug
dosing O O
by O O
at O O
least O O
2 O O
hours O O
. O O

As O O
a O O
moderate O O
inhibitor O O
of O O
CYP3A4 O O
, O O
aprepitant B-drug B-drug
can O O
increase O O
plasma O O
concentrations O O
of O O
coadministered O O
medicinal O O
products O O
that O O
are O O
metabolized O O
through O O
CYP3A4 O O
. O O

Medications O O
can O O
interfere O O
with O O
folate O O
utilization O O
, O O
including O O
: O O
anticonvulsant B-group B-group
medications I-group I-group
( O O
such O O
as O O
phenytoin B-drug B-drug
, O O
and O O
primidone B-drug B-drug
) O O
metformin B-drug B-drug
( O O
sometimes O O
prescribed O O
to O O
control O O
blood O O
sugar O O
in O O
type O O
2 O O
diabetes O O
) O O
sulfasalazine B-drug B-drug
( O O
used O O
to O O
control O O
inflammation O O
associated O O
with O O
Crohns O O
disease O O
and O O
ulcerative O O
colitis O O
) O O
triamterene B-drug B-drug
( O O
a O O
diuretic B-group B-group
) O O
Methotrexate B-drug B-drug
There O O
has O O
been O O
concern O O
about O O
the O O
interaction O O
between O O
vitamin B-drug B-drug
B12 I-drug I-drug
and O O
folic B-drug B-drug
acid I-drug I-drug
. O O

Digoxin B-drug B-drug
: O O
Some O O
calcium B-group B-group
blockers I-group I-group
may O O
increase O O
the O O
concentration O O
of O O
digitalis B-group B-group
preparations I-group I-group
in O O
the O O
blood O O
. O O

The O O
mechanism O O
of O O
the O O
action O O
of O O
PTX B-drug_n B-drug_n
was O O
discussed O O
in O O
the O O
relation O O
with O O
Na O O
, O O
K-ATPase O O
. O O

Pregnancy O O
estrogens B-group B-group
and O O
estrogen-containing B-group B-group
oral O O
contraceptives B-group B-group
increase O O
TBg O O
concentrations O O
. O O

Reformed O O
microtubules O O
appeared O O
to O O
function O O
normally O O
with O O
respect O O
to O O
their O O
possible O O
role O O
in O O
the O O
transport O O
of O O
noradrenaline O O
storage O O
vesicles O O
along O O
the O O
axons O O
. O O

Free O O
hormone O O
concentrations O O
may O O
be O O
decreased O O
. O O

Exposed O O
histidines O O
on O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
are O O
available O O
for O O
zinc B-drug B-drug
chelation O O
, O O
and O O
these O O
have O O
been O O
exploited O O
in O O
the O O
development O O
of O O
a O O
novel O O
purification O O
protocol O O
for O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
using O O
zinc-chelating B-drug B-drug
chromatography O O
. O O

However O O
, O O
it O O
was O O
observed O O
that O O
the O O
pharmacokinetics O O
of O O
ENBREL B-brand B-brand
was O O
unaltered O O
by O O
concomitant O O
methotrexate B-drug B-drug
in O O
rheumatoid O O
arthritis O O
patients O O
. O O

Ketamine B-drug B-drug
: O O
When O O
administered O O
to O O
patients O O
on O O
a O O
thyroid B-group O
preparation I-group O
, O O
this O O
parenteral O O
anesthetic B-group B-group
may O O
cause O O
hypertension O O
and O O
tachycardia O O
. O O

Acetaminophen B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
and O O
valproic B-drug B-drug
acid I-drug I-drug
were O O
added O O
to O O
pooled O O
human O O
serum O O
at O O
therapeutic O O
concentrations O O
. O O

Metformin B-drug B-drug
: O O
In O O
healthy O O
subjects O O
given O O
single O O
500 O O
mg O O
doses O O
of O O
cephalexin B-drug B-drug
and O O
metformin B-drug B-drug
, O O
plasma O O
metformin B-drug B-drug
mean O O
cmax O O
and O O
AUC O O
increased O O
by O O
an O O
average O O
of O O
34 O O
% O O
and O O
24 O O
% O O
, O O
respectively O O
, O O
and O O
metformin B-drug B-drug
mean O O
renal O O
clearance O O
decreased O O
by O O
14 O O
% O O
. O O

Therefore O O
, O O
a O O
possible O O
lack O O
of O O
desired O O
effect O O
of O O
treatment O O
should O O
be O O
taken O O
into O O
consideration O O
before O O
such O O
drugs O O
are O O
given O O
concomitantly O O
with O O
lactulose B-drug B-drug
. O O

Nevertheless O O
, O O
clinical O O
studies O O
, O O
as O O
well O O
as O O
postmarketing O O
observations O O
have O O
shown O O
that O O
Lodine B-brand B-brand
can O O
reduce O O
the O O
natriuretic O O
effect O O
of O O
furosemide B-drug B-drug
and O O
thiazides B-group B-group
in O O
some O O
patients O O
. O O

MAO B-group B-group
inhibitors I-group I-group
, O O
narcotic B-group B-group
analgesics I-group I-group
( O O
e.g. O O
, O O
meperidine B-drug B-drug
) O O
, O O
nitrates B-group B-group
and O O
nitrites B-group B-group
, O O
sympathomimetic B-group B-group
agents I-group I-group
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
and O O
other O O
drugs O O
having O O
anticholinergic O O
activity O O
. O O

consequently O O
, O O
caution O O
is O O
advised O O
if O O
dexfenfluramine B-drug B-drug
and O O
such O O
drugs O O
are O O
prescribed O O
concurrently O O
. O O

( O O
Effects O O
may O O
be O O
potentiated O O
when O O
used O O
concurrently O O
with O O
thiazide B-group B-group
diuretics I-group I-group
; O O

The O O
effectiveness O O
of O O
progestin-only B-group B-group
pills O O
is O O
reduced O O
by O O
hepatic O O
enzyme-inducing O O
drugs O O
such O O
as O O
the O O
anticonvulsants B-group B-group
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
and O O
barbiturates B-group B-group
, O O
and O O
the O O
antituberculosis B-group B-group
drug I-group I-group
rifampin B-drug B-drug
. O O

Concurrent O O
administration O O
of O O
indinavir B-drug B-drug
and O O
didanosine B-drug B-drug
significantly O O
reduces O O
the O O
level O O
of O O
exposure O O
to O O
indinavir B-drug B-drug
, O O
but O O
it O O
is O O
unclear O O
how O O
soon O O
after O O
didanosine B-drug B-drug
administration O O
indinavir B-drug B-drug
may O O
be O O
given O O
safely O O
. O O

When O O
such O O
drugs O O
are O O
administered O O
to O O
a O O
patient O O
receiving O O
DIABINESE B-brand B-brand
, O O
the O O
patient O O
should O O
be O O
closely O O
observed O O
for O O
loss O O
of O O
control O O
. O O

Drug O O
interaction O O
studies O O
with O O
Xigris B-brand B-brand
have O O
not O O
been O O
performed O O
in O O
patients O O
with O O
severe O O
sepsis O O
. O O

Phenytoin B-drug B-drug
, O O
nicotine B-drug B-drug
, O O
and O O
rifampin B-drug B-drug
may O O
decrease O O
Clozapine B-drug B-drug
plasma O O
levels O O
, O O
resulting O O
in O O
a O O
decrease O O
in O O
effectiveness O O
of O O
a O O
previously O O
effective O O
Clozapine B-drug B-drug
dose O O
. O O

Concomitant O O
treatment O O
of O O
four O O
patients O O
in O O
the O O
United O O
Kingdom O O
with O O
FOSCAVIR B-brand B-brand
and O O
intravenous O O
pentamidine B-drug B-drug
may O O
have O O
caused O O
hypocalcemia O O
; O O

Tablets O O
Simultaneous O O
administration O O
of O O
sucralfate B-drug B-drug
and O O
furosemide B-drug B-drug
tablets O O
may O O
reduce O O
the O O
natriuretic O O
and O O
antihypertensive O O
effects O O
of O O
furosemide B-drug B-drug
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
( O O
40 O O
mg O O
BID O O
( O O
day O O
1 O O
) O O
and O O
40 O O
mg O O
QD O O
( O O
days O O
2-7 O O
) O O
) O O
with O O
glyburide B-drug B-drug
( O O
5 O O
mg O O
QD O O
) O O
did O O
not O O
affect O O
either O O
the O O
pharmacokinetics O O
( O O
exposure O O
) O O
or O O
the O O
pharmacodynamics O O
( O O
blood O O
glucose O O
and O O
insulin O O
levels O O
) O O
of O O
glyburide B-drug B-drug
. O O

No O O
significant O O
effects O O
on O O
cisapride B-drug B-drug
metabolism O O
or O O
QT O O
interval O O
were O O
noted O O
. O O

This O O
study O O
demonstrates O O
that O O
concurrent O O
administration O O
of O O
thiosulfate B-drug B-drug
permits O O
at O O
least O O
a O O
twofold O O
increase O O
in O O
dose O O
and O O
total O O
exposure O O
to O O
cisplatin B-drug B-drug
. O O

Therefore O O
, O O
such O O
combined O O
treatment O O
should O O
be O O
approached O O
with O O
caution O O
and O O
patients O O
should O O
be O O
monitored O O
closely O O
when O O
Clozapine B-drug B-drug
is O O
combined O O
with O O
these O O
drugs O O
, O O
particularly O O
with O O
fluvoxamine B-drug B-drug
. O O

In O O
the O O
long-term O O
safety O O
studies O O
, O O
guanfacine B-drug B-drug
was O O
given O O
concomitantly O O
with O O
many O O
drugs O O
without O O
evidence O O
of O O
any O O
interactions O O
. O O

The O O
concurrent O O
use O O
of O O
Robinul B-brand B-brand
Injection O O
with O O
other O O
anticholinergics B-group B-group
or O O
medications O O
with O O
anticholinergic O O
activity O O
, O O
such O O
as O O
phenothiazines B-group B-group
, O O
antiparkinson B-group B-group
drugs I-group I-group
, O O
or O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
may O O
intensify O O
the O O
antimuscarinic O O
effects O O
and O O
may O O
result O O
in O O
an O O
increase O O
in O O
anticholinergic O O
side O O
effects O O
. O O

They O O
are O O
weak O O
inhibitors O O
of O O
CYP2C19 O O
and O O
CYP2A6 O O
, O O
and O O
mild-to-moderate O O
inhibitors O O
of O O
CYP2C9 O O
at O O
therapeutic O O
concentrations O O
. O O

Because O O
fluvoxamine B-drug B-drug
reduces O O
the O O
clearance O O
of O O
both O O
diazepam B-drug B-drug
and O O
its O O
active O O
metabolite O O
, O O
N-desmethyldiazepam B-drug_n B-drug_n
, O O
there O O
is O O
a O O
strong O O
likelihood O O
of O O
substantial O O
accumulation O O
of O O
both O O
species O O
during O O
chronic O O
co-administration O O
. O O

Antibiotics B-group B-group
: O O
No O O
human O O
drug O O
interaction O O
studies O O
with O O
antibiotics B-group B-group
were O O
conducted O O
. O O

There O O
have O O
been O O
greater O O
than O O
two-fold O O
increases O O
of O O
previously O O
stable O O
plasma O O
levels O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
when O O
fluoxetine B-drug B-drug
has O O
been O O
administered O O
in O O
combination O O
with O O
these O O
agents O O
. O O

No O O
formal O O
drug/laboratory O O
test O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
CLOLAR B-brand B-brand
. O O

In O O
patients O O
where O O
rifampin B-drug B-drug
or O O
other O O
CYP3A4 O O
inducers O O
are O O
indicated O O
, O O
alternative O O
therapeutic O O
agents O O
with O O
less O O
enzyme O O
induction O O
potential O O
should O O
be O O
considered O O
. O O

As O O
with O O
all O O
drugs O O
, O O
the O O
potential O O
exists O O
for O O
interaction O O
with O O
other O O
drugs O O
by O O
a O O
variety O O
of O O
mechanisms O O
. O O

The O O
amount O O
of O O
metformin B-drug B-drug
absorbed O O
while O O
taking O O
Acarbose B-drug B-drug
was O O
bioequivalent O O
to O O
the O O
amount O O
absorbed O O
when O O
taking O O
placebo O O
, O O
as O O
indicated O O
by O O
the O O
plasma O O
AUC O O
values O O
. O O

All O O
the O O
animals O O
were O O
killed O O
at O O
the O O
end O O
of O O
the O O
9th O O
week O O
of O O
the O O
experiment O O
. O O

The O O
pharmacokinetics O O
of O O
etodolac B-drug B-drug
in O O
healthy O O
normal O O
volunteers O O
has O O
been O O
extensively O O
studied O O
and O O
is O O
well O O
described O O
. O O

Patients O O
on O O
lithium B-drug B-drug
treatment O O
should O O
be O O
closely O O
monitored O O
when O O
CELEBREX B-brand B-brand
is O O
introduced O O
or O O
withdrawn O O
. O O

In O O
addition O O
, O O
administration O O
to O O
a O O
patient O O
population O O
with O O
hepatic O O
insufficiency O O
resulted O O
in O O
a O O
2.5-fold O O
increase O O
in O O
both O O
the O O
rate O O
and O O
extent O O
of O O
bioavailability O O
relative O O
to O O
controls O O
. O O

Hydrocodone B-drug B-drug
increases O O
gabapentin B-drug B-drug
AUC O O
values O O
by O O
14 O O
% O O
. O O

Therefore O O
, O O
Clozapine B-drug B-drug
should O O
not O O
be O O
used O O
with O O
other O O
agents O O
having O O
a O O
well-known O O
potential O O
to O O
suppress O O
bone O O
marrow O O
function O O
. O O

We O O
could O O
observe O O
that O O
ginsenosides B-drug_n B-drug_n
inhibited O O
high O O
threshold O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
currents O O
in O O
a O O
dose-dependent O O
manner O O
. O O

Selegiline B-drug B-drug
- O O
L-phenylalanine B-drug B-drug
and O O
the O O
selective B-group B-group
MAO I-group I-group
inhibitor I-group I-group
selegiline B-drug B-drug
may O O
have O O
synergistic O O
antidepressant O O
activity O O
if O O
used O O
concomitantly O O
. O O

As O O
the O O
primary O O
effect O O
of O O
adenosine B-drug B-drug
is O O
to O O
decrease O O
conduction O O
through O O
the O O
A-V O O
node O O
, O O
higher O O
degrees O O
of O O
heart O O
block O O
may O O
be O O
produced O O
in O O
the O O
presence O O
of O O
carbamazepine B-drug B-drug
. O O

The O O
effect O O
of O O
these O O
interactions O O
on O O
mean O O
AUCs O O
and O O
Cmin O O
are O O
summarized O O
in O O
Table O O
2 O O
: O O
Table O O
2 O O
: O O
Summary O O
of O O
AED O O
interactions O O
with O O
Trileptal B-brand B-brand

Drugs O O
and O O
other O O
substances O O
demonstrated O O
to O O
be O O
CYP O O
3A O O
inhibitors O O
on O O
the O O
basis O O
of O O
clinical O O
studies O O
involving O O
benzodiazepines B-group B-group
metabolized O O
similarly O O
to O O
alprazolam B-drug B-drug
or O O
on O O
the O O
basis O O
of O O
in O O
vitro O O
studies O O
with O O
alprazolam B-drug B-drug
or O O
other O O
benzodiazepines B-group B-group
( O O
caution O O
is O O
recommended O O
during O O
coadministration O O
with O O
alprazolam B-drug B-drug
) O O
: O O
Available O O
data O O
from O O
clinical O O
studies O O
of O O
benzodiazepines B-group B-group
other O O
than O O
alprazolam B-drug B-drug
suggest O O
a O O
possible O O
drug O O
interaction O O
with O O
alprazolam B-drug B-drug
for O O
the O O
following O O
: O O
diltiazem B-drug B-drug
, O O
isoniazid B-drug B-drug
, O O
macrolide B-group B-group
antibiotics I-group I-group
such O O
as O O
erythromycin B-drug B-drug
and O O
clarithromycin B-drug B-drug
, O O
and O O
grapefruit O O
juice O O
. O O

Ketorolac B-drug B-drug
does O O
not O O
alter O O
digoxin B-drug B-drug
protein O O
binding O O
. O O

Tricyclic B-group B-group
antidepressants I-group I-group
may O O
enhance O O
the O O
seizure O O
risk O O
in O O
patients O O
taking O O
tramadol B-drug B-drug

Since O O
the O O
therapeutic O O
range O O
of O O
theophylline B-drug B-drug
is O O
narrow O O
theophylline B-drug B-drug
serum O O
levels O O
should O O
be O O
monitored O O
closely O O
, O O
and O O
appropriate O O
dosage O O
adjustments O O
of O O
theophylline B-drug B-drug
should O O
be O O
made O O
. O O

Combination O O
was O O
associated O O
with O O
a O O
higher O O
frequency O O
of O O
adverse O O
clinical O O
experiences O O
( O O
eg O O
, O O
dizziness O O
, O O
nausea O O
, O O
paresthesia O O
) O O
and O O
laboratory O O
abnormalities O O
( O O
elevated O O
liver O O
enzymes O O
) O O
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
has O O
been O O
demonstrated O O
to O O
interfere O O
with O O
the O O
elimination O O
of O O
other O O
quinolones B-group B-group
. O O

Antipyrine B-drug B-drug
: O O
Because O O
atorvastatin B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
antipyrine B-drug B-drug
, O O
interactions O O
with O O
other O O
drugs B-drug O
metabolized O O
via O O
the O O
same O O
cytochrome O O
isozymes O O
are O O
not O O
expected O O
. O O

Because O O
a O O
similar O O
interaction O O
is O O
likely O O
, O O
VIRACEPT B-brand B-brand
should O O
also O O
not O O
be O O
administered O O
concurrently O O
with O O
astemizole B-drug B-drug
. O O

Calcium B-group B-group
channel I-group I-group
blocking I-group I-group
agents I-group I-group
: O O
Coadministration O O
of O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
did O O
not O O
have O O
any O O
effect O O
on O O
either O O
the O O
safety O O
or O O
efficacy O O
of O O
ibutilide B-drug B-drug
in O O
the O O
clinical O O
trials O O
. O O

Anticoagulants B-drug B-group
: O O
Potentiation O O
of O O
warfarin-type B-drug B-drug
( O O
CYP2C9 B-drug O
and O O
CYP3A4 B-drug O
substrate O O
) O O
anticoagulant B-drug B-group
response O O
is O O
almost O O
always O O
seen O O
in O O
patients O O
receiving O O
amiodarone B-drug B-drug
and O O
can O O
result O O
in O O
serious O O
or O O
fatal O O
bleeding O O
. O O

The O O
use O O
of O O
MAO B-group B-group
inhibitors I-group I-group
or O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
hydrocodone B-drug B-drug
preparations O O
may O O
increase O O
the O O
effect O O
of O O
either O O
the O O
antidepressant B-group B-group
or O O
hydrocodone B-drug B-drug
. O O

It O O
has O O
recently O O
been O O
demonstrated O O
that O O
toxin B-drug_n B-drug_n
A I-drug_n I-drug_n
exerts O O
its O O
cytotoxic O O
effect O O
by O O
the O O
glucosylation O O
of O O
the O O
small O O
GTP-binding O O
proteins O O
of O O
the O O
Rho O O
family O O
. O O

Potentiation O O
occurs O O
with O O
ganglionic B-group B-group
peripheral I-group I-group
adrenergic I-group I-group
blocking I-group I-group
drugs I-group I-group
. O O

Also O O
, O O
in O O
vitro O O
experiments O O
demonstrated O O
a O O
lack O O
of O O
interaction O O
between O O
dirithromycin B-drug B-drug
and O O
terfenadine B-drug B-drug
. O O

The O O
clinical O O
significance O O
of O O
this O O
finding O O
is O O
unknown O O
. O O

The O O
main O O
indications O O
are O O
eclampsia O O
, O O
some O O
dysrhythmias O O
( O O
torsades O O
de O O
pointe O O
particularly O O
) O O
and O O
myocardial O O
ischaemias O O
. O O

Also O O
, O O
there O O
were O O
no O O
clinically O O
significant O O
differences O O
in O O
adverse O O
events O O
when O O
loratadine B-drug B-drug
was O O
administered O O
with O O
or O O
without O O
ketoconazole B-drug B-drug
. O O

To O O
determine O O
whether O O
injection O O
of O O
thiosulfate B-drug B-drug
would O O
permit O O
larger O O
doses O O
of O O
cisplatin B-drug B-drug
to O O
be O O
administered O O
, O O
a O O
fixed O O
9.9-g/m2 O O
dose O O
of O O
thiosulfate B-drug B-drug
was O O
given O O
intravenously O O
over O O
three O O
hours O O
concurrently O O
with O O
escalating O O
doses O O
of O O
cisplatin B-drug B-drug
. O O

Cytochalasin B-drug_n B-drug_n
D I-drug_n I-drug_n
at O O
10 O O
microM O O
preferentially O O
blocked O O
the O O
secretory O O
effect O O
of O O
carbachol B-drug B-drug
and O O
its O O
synergism O O
with O O
cAMP O O
, O O
whereas O O
it O O
had O O
no O O
effect O O
on O O
histamine- O O
or O O
cAMP-stimulated O O
acid O O
secretion O O
within O O
15 O O
min O O
. O O

Omeprazole B-drug B-drug
: O O
No O O
clinically O O
significant O O
changes O O
in O O
lomefloxacin B-drug B-drug
pharmacokinetics O O
( O O
AUC O O
, O O
C O O
max O O
, O O
or O O
T O O
max O O
) O O
were O O
observed O O
when O O
a O O
single O O
dose O O
of O O
lomefloxacin B-drug B-drug
400 O O
mg O O
was O O
given O O
after O O
multiple O O
doses O O
of O O
omeprazole B-drug B-drug
( O O
20 O O
mg O O
qd O O
) O O
in O O
13 O O
healthy O O
volunteers O O
. O O

Caution O O
is O O
indicated O O
when O O
piperacillin B-drug B-drug
is O O
used O O
perioperatively O O
. O O

In O O
the O O
presence O O
of O O
phentolamine B-drug B-drug
( O O
10 O O
( O O
-6 O O
) O O
M O O
) O O
, O O
the O O
second O O
contraction O O
was O O
inhibited O O
selectively O O
. O O

Heparin B-drug B-drug
Sodium I-drug I-drug
Injection O O
should O O
not O O
be O O
mixed O O
with O O
doxorubicin B-drug B-drug
, O O
droperidol B-drug B-drug
, O O
ciprofloxacin B-drug B-drug
, O O
or O O
mitoxantrone B-drug B-drug
, O O
since O O
it O O
has O O
been O O
reported O O
that O O
these O O
drugs O O
are O O
incompatible O O
with O O
heparin B-drug B-drug
and O O
a O O
precipitate O O
may O O
form O O
. O O

The O O
intestinal O O
absorption O O
of O O
arsenate B-drug_n B-drug_n
( O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
) I-drug_n I-drug_n
has O O
been O O
investigated O O
in O O
the O O
chick O O
by O O
means O O
of O O
the O O
in O O
situ O O
ligated O O
duodenal O O
loop O O
technique O O
. O O

If O O
leprosy-associated O O
inflammatory O O
reactions O O
develop O O
in O O
patients O O
being O O
treated O O
with O O
dapsone B-drug B-drug
and O O
clofazimine B-drug B-drug
, O O
it O O
is O O
still O O
advisable O O
to O O
continue O O
treatment O O
with O O
both O O
drugs O O
. O O

Fexofenadine B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
either O O
erythromycin B-drug B-drug
or O O
ketoconazole B-drug B-drug
. O O

Dofetilide B-drug B-drug
is O O
metabolized O O
to O O
a O O
small O O
extent O O
by O O
the O O
CYP3A4 O O
isoenzyme O O
of O O
the O O
cytochrome O O
P450 O O
system O O
. O O

Because O O
the O O
risk O O
to O O
the O O
development O O
of O O
the O O
fetal O O
immune O O
system O O
and O O
postnatal O O
immune O O
function O O
in O O
humans O O
is O O
unknown O O
, O O
AMEVIVE B-brand B-brand
should O O
be O O
used O O
during O O
pregnancy O O
only O O
if O O
clearly O O
needed O O
. O O

Significant O O
pharmacokinetic O O
interactions O O
mediated O O
by O O
inhibition O O
of O O
CYP O O
isoenzymes O O
therefore O O
appear O O
unlikely O O
. O O

Tiagabine B-drug B-drug
has O O
shown O O
no O O
clinically O O
important O O
potentiation O O
of O O
the O O
pharmacodynamic O O
effects O O
of O O
triazo O O
lam O O
or O O
alcohol B-drug B-drug
. O O

metabolizers O O
. O O

Population O O
pharmacokinetic O O
analyses O O
were O O
conducted O O
on O O
plasma O O
concentration O O
data O O
from O O
1445 O O
patients O O
in O O
clinical O O
trials O O
to O O
examine O O
the O O
effects O O
of O O
concomitant O O
medications O O
on O O
clearance O O
or O O
volume O O
of O O
distribution O O
of O O
dofetilide B-drug B-drug
. O O

Isoproterenol B-drug B-drug
hydrochloride I-drug I-drug
injection O O
and O O
epinephrine B-drug B-drug
should O O
not O O
be O O
administered O O
simultaneously O O
because O O
both O O
drugs O O
are O O
direct O O
cardiac O O
stimulants O O
and O O
their O O
combined O O
effects O O
may O O
induce O O
serious O O
arrhythmias O O
. O O

Compared O O
with O O
lean O O
rats O O
, O O
arteries O O
from O O
dietary-obese O O
rats O O
showed O O
significant O O
( O O
P O O
< O O
0.001 O O
) O O
endothelial O O
dysfunction O O
, O O
as O O
indicated O O
by O O
a O O
decrease O O
( O O
> O O
20 O O
% O O
) O O
in O O
maximal O O
acetylcholine-induced O O
vasorelaxation O O
. O O

Suppression O O
by O O
verapamil B-drug B-drug
of O O
bombesin-enhanced B-drug_n B-drug_n
peritoneal O O
metastasis O O
of O O
intestinal O O
adenocarcinomas O O
induced O O
by O O
azoxymethane B-drug_n B-drug_n
in O O
wistar O O
rats O O
. O O

Glyburide B-drug B-drug
: O O
In O O
a O O
randomized O O
, O O
multiple-dose O O
crossover O O
study O O
, O O
patients O O
with O O
Type O O
2 O O
diabetes O O
were O O
administered O O
120 O O
mg O O
Starlix B-brand B-brand
three O O
times O O
a O O
day O O
before O O
meals O O
for O O
1 O O
day O O
in O O
combination O O
with O O
glyburide B-drug B-drug
10 O O
mg O O
daily O O
. O O

This O O
might O O
increase O O
the O O
risk O O
of O O
methotrexate B-drug B-drug
toxic O O
reactions O O
. O O

Since O O
the O O
arrival O O
of O O
oral O O
erection-supporting B-group B-group
medication I-group I-group
, O O
patients O O
want O O
to O O
know O O
how O O
safe O O
sexual O O
activity O O
is O O
in O O
cardiovascular O O
disease O O
in O O
general O O
and O O
during O O
use O O
of O O
erection-supporting B-group B-group
medication I-group I-group
in O O
particular O O
. O O

Bile B-group B-group
acid I-group I-group
sequestrants I-group I-group
have O O
been O O
shown O O
to O O
bind O O
other O O
drugs O O
given O O
concurrently O O
. O O

Allopurinol B-drug B-drug
: O O
In O O
a O O
study O O
of O O
healthy O O
male O O
volunteers O O
no O O
significant O O
pharmacokinetic O O
interaction O O
occurred O O
when O O
captopril B-drug B-drug
and O O
allopurinol B-drug B-drug
were O O
administered O O
concomitantly O O
for O O
6 O O
days O O
. O O

See O O
CLINICAL O O
PHARMACOLOGY O O
. O O

Inhibitory O O
effects O O
of O O
ruthenium B-drug_n B-drug_n
red I-drug_n O
on O O
inositol O O
1,4 O O
, O O
5-trisphosphate-induced O O
responses O O
in O O
rat O O
megakaryocytes O O
. O O

Drugs O O
That O O
Inhibit O O
Both O O
Aldehyde O O
Oxidase O O
and O O
CYP3A4 O O
Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
inhibits O O
both O O
aldehyde O O
oxidase O O
( O O
in O O
vitro O O
) O O
and O O
CYP3A4 O O
( O O
in O O
vitro O O
and O O
in O O
vivo O O
) O O
, O O
the O O
primary O O
and O O
secondary O O
enzymes O O
, O O
respectively O O
, O O
responsible O O
for O O
zaleplon B-drug B-drug
metabolism O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
No O O
laboratory O O
test O O
abnormalities O O
related O O
to O O
the O O
use O O
of O O
guanfacine B-drug B-drug
have O O
been O O
identified O O
. O O

These O O
increases O O
in O O
concentration O O
may O O
lead O O
to O O
increased O O
effects O O
, O O
( O O
lower O O
blood O O
pressure O O
and O O
increased O O
heart O O
rate O O
) O O
. O O

There O O
have O O
been O O
postmarketing O O
reports O O
of O O
drug O O
interactions O O
when O O
erythromycin B-drug B-drug
is O O
coadministered O O
with O O
cisapride B-drug B-drug
, O O
resulting O O
in O O
QT O O
prolongation O O
, O O
cardiac O O
arrythmias O O
, O O
ventricular O O
tachycardia O O
, O O
ventricular O O
fibrulation O O
, O O
and O O
torsades O O
de O O
pointes O O
, O O
most O O
like O O
due O O
to O O
inhibition O O
of O O
hepatic O O
metabolism O O
of O O
cisapride B-drug B-drug
by O O
erythromycin B-drug B-drug
. O O

There O O
are O O
3 O O
types O O
of O O
indications O O
: O O
specific O O
( O O
for O O
the O O
treatment O O
of O O
some O O
forms O O
of O O
magnesium B-drug B-drug
deficit O O
i.e O O
. O O
acute O O
) O O
, O O
pharmacological O O
( O O
i.e O O
. O O
without O O
alterations O O
of O O
magnesium B-drug B-drug
status O O
) O O
and O O
mixed O O
-- O O
pharmacological O O
and O O
aetiopathogenic O O
-- O O
( O O
for O O
example O O
complications O O
of O O
chronic O O
alcoholism O O
) O O
. O O

decreased O O
antithrombin O B-drug
3 O I-drug
; O O

Two O O
percent O O
of O O
patients O O
treated O O
concurrently O O
with O O
ENBREL B-brand B-brand
and O O
anakinra B-drug B-drug
developed O O
neutropenia O O
( O O
ANC O O
1 O O
x O O
109/L O O
) O O
. O O

Reported O O
examples O O
of O O
this O O
interaction O O
include O O
the O O
following O O
: O O
Antibiotics B-drug B-group
: O O
Rifampin B-drug B-drug
is O O
a O O
potent O O
inducer O O
of O O
CYP3A4 B-drug O
. O O

The O O
resulting O O
increase O O
in O O
free O O
drug O O
concentration O O
may O O
lead O O
to O O
enhanced O O
drug O O
effect O O
in O O
vivo O O
. O O

The O O
results O O
raise O O
the O O
possibility O O
that O O
the O O
ethanolysis O O
reaction O O
may O O
occur O O
in O O
the O O
stomach O O
of O O
people O O
who O O
consume O O
alcohol B-drug B-drug
and O O
3-hydroxy-1,4-benzodiazepine B-group B-drug_n
on O O
a O O
regular O O
basis O O
. O O

Patients O O
should O O
be O O
warned O O
of O O
the O O
potential O O
danger O O
of O O
the O O
intravenous O O
self-administration O O
of O O
benzodiazepines B-group B-group
while O O
under O O
treatment O O
with O O
SUBOXONE B-brand B-brand
or O O
SUBUTEX B-brand B-brand
. O O

In O O
vitro O O
studies O O
also O O
indicate O O
that O O
celecoxib B-drug B-drug
, O O
although O O
not O O
a O O
substrate O O
, O O
is O O
an O O
inhibitor O O
of O O
cytochrome O O
P450 O O
2D6 O O
. O O

Acute O O
symptoms O O
should O O
be O O
treated O O
with O O
a O O
short-acting O O
, O O
inhaled O O
beta2-agonist B-group B-group
such O O
as O O
salbutamol B-drug B-drug
( O O
the O O
physician O O
should O O
provide O O
the O O
patient O O
with O O
such O O
medication O O
and O O
instruct O O
the O O
patient O O
in O O
how O O
it O O
should O O
be O O
used O O
) O O
. O O

Drug O O
interaction O O
studies O O
of O O
mefenamic B-drug B-drug
acid I-drug I-drug
and O O
these O O
compounds O O
have O O
not O O
been O O
conducted O O
. O O

Cimetidine B-drug B-drug
is O O
reported O O
to O O
reduce O O
hepatic O O
metabolism O O
of O O
certain O O
tricyclic B-drug B-group
antidepressants I-drug I-group
, O O
thereby O O
delaying O O
elimination O O
and O O
increasing O O
steady-state O O
concentrations O O
of O O
these O O
drugs B-drug O
. O O

This O O
indicates O O
that O O
gabapentin B-drug B-drug
does O O
not O O
undergo O O
renal O O
tubular O O
secretion O O
by O O
the O O
pathway O O
that O O
is O O
blocked O O
by O O
probenecid B-drug B-drug
. O O

Induction O O
of O O
such O O
tumors O O
is O O
consistent O O
with O O
the O O
pharmacology-related O O
endocrine O O
feedback O O
alterations O O
in O O
gonadotropin O O
levels O O
caused O O
by O O
an O O
antiestrogen B-group B-group
. O O

Acid-catalyzed O O
ethanolysis O O
of O O
temazepam B-drug B-drug
in O O
anhydrous O O
and O O
aqueous O O
ethanol B-drug B-drug
solutions O O
. O O

Concomitant O O
use O O
of O O
calcium B-drug B-drug
supplements O O
and O O
L-lysine B-drug B-drug
may O O
increase O O
calcium B-drug B-drug
absorption O O

Monitor O O
serum O O
potassium O O
levels O O
; O O

Digoxin B-drug B-drug
: O O
In O O
a O O
study O O
in O O
12 O O
patients O O
with O O
congestive O O
heart O O
failure O O
where O O
ketoprofen B-drug B-drug
and O O
digoxin B-drug B-drug
were O O
concomitantly O O
administered O O
, O O
ketoprofen B-drug B-drug
did O O
not O O
alter O O
the O O
serum O O
levels O O
of O O
digoxin B-drug B-drug
. O O

Valproate B-drug B-drug
Keppra B-brand B-brand
( O O
1500 O O
mg O O
twice O O
daily O O
) O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
valproate B-drug B-drug
in O O
healthy O O
volunteers O O
. O O

If O O
you O O
are O O
50 O O
years O O
of O O
age O O
or O O
older O O
, O O
ask O O
your O O
physician O O
to O O
check O O
your O O
B12 O O
status O O
before O O
you O O
take O O
a O O
supplement O O
that O O
contains O O
folic B-drug B-drug
acid I-drug I-drug
. O O

Vancomycin O O
resistance O O
reversal O O
in O O
enterococci O O
by O O
flavonoids O O
. O O

route O O
. O O

Jacalin B-drug_n B-drug_n
is O O
a O O
D-Gal O O
binding O O
lectin O O
and O O
should O O
be O O
a O O
useful O O
tool O O
for O O
studying O O
of O O
serum O O
and O O
secretory O O
IgA O O
. O O

The O O
increase O O
of O O
phenobarbital B-drug B-drug
level O O
, O O
however O O
, O O
is O O
small O O
( O O
15 O O
% O O
) O O
when O O
given O O
with O O
Trileptal B-brand B-brand
. O O

therefore O O
, O O
periodic O O
liver O O
function O O
testing O O
( O O
transaminases O O
, O O
bilirubin O O
, O O
and O O
alkaline O O
phosphatase O O
) O O
should O O
be O O
considered O O
. O O

Until O O
specific O O
compatibility O O
data O O
are O O
available O O
, O O
it O O
is O O
not O O
recommended O O
that O O
DOXIL B-brand B-brand
be O O
mixed O O
with O O
other O O
drugs O O
. O O

Anticonvulsants B-group B-group

Pharmacokinetic-related O O
Interactions O O
: O O
Clozapine B-drug B-drug
is O O
a O O
substrate O O
for O O
many O O
CYP O O
450 O O
isozymes O O
, O O
in O O
particular O O
1A2 O O
, O O
2D6 O O
, O O
and O O
3A4 O O
. O O

Concomitant O O
use O O
of O O
Isocarboxazid B-drug B-drug
and O O
other O O
psychotropic B-group B-group
agents I-group I-group
is O O
generally O O
not O O
recommended O O
because O O
of O O
possible O O
potentiating O O
effects O O
. O O

Methadone B-drug B-drug

Table O O
9 O O

The O O
majority O O
of O O
adverse O O
events O O
with O O
NNRTIs B-group B-group
occur O O
within O O
the O O
first O O
month O O
, O O
and O O
are O O
predictable O O
and O O
manageable O O
without O O
therapy O O
interruption O O
. O O

administration O O
1 O O
hour O O
before O O
or O O
4 O O
hours O O
after O O
colestipol B-drug B-drug
is O O
recommended O O
. O O
) O O

Failure O O
of O O
neomycin B-drug B-drug
to O O
modify O O
ACTH B-group B-group
induced O O
hypertension O O
in O O
sheep O O
. O O

PATIENTS O O
: O O
Random O O
sample O O
of O O
626 O O
MAC O O
out O O
of O O
a O O
total O O
of O O
1306 O O
. O O

Monitor O O
for O O
symptoms O O
of O O
hyperglycemia O O
; O O

At O O
higher O O
than O O
recommended O O
doses O O
, O O
VIOXX B-brand B-brand
75 O O
mg O O
administered O O
once O O
daily O O
for O O
10 O O
days O O
increased O O
plasma O O
concentrations O O
by O O
23 O O
% O O
as O O
measured O O
by O O
AUC0-24hr O O
in O O
patients O O
receiving O O
methotrexate B-drug B-drug
7.5 O O
to O O
15 O O
mg/week O O
for O O
rheumatoid O O
arthritis O O
. O O

Acitretin B-drug B-drug
: O O
Interferes O O
with O O
the O O
contraceptive O O
effect O O
of O O
microdosed O O
progestin-containing B-group O
minipill O O
preparations O O
. O O

Co-administration O O
of O O
CYP3A4 O O
inhibitors O O
( O O
eg O O
, O O
ketoconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
erythromycin B-drug B-drug
, O O
grapefruit O O
juice O O
, O O
cimetidine B-drug B-drug
) O O
with O O
felodipine B-drug B-drug
may O O
lead O O
to O O
several- O O
fold O O
increases O O
in O O
the O O
plasma O O
levels O O
of O O
felodipine B-drug B-drug
, O O
either O O
due O O
to O O
an O O
increase O O
in O O
bioavailability O O
or O O
due O O
to O O
a O O
decrease O O
in O O
metabolism O O
. O O

Differences O O
can O O
occur O O
in O O
therapeutic O O
effect O O
and O O
in O O
adverse O O
events O O
. O O

Conversely O O
, O O
adverse O O
effects O O
may O O
result O O
from O O
displacement O O
of O O
protein-bound O O
Anafranil B-brand B-brand
by O O
other O O
highly O O
bound O O
drugs O O
. O O

The O O
recommended O O
dosage O O
( O O
one O O
or O O
two O O
capsules O O
twice O O
daily O O
, O O
morning O O
and O O
evening O O
) O O
should O O
not O O
be O O
exceeded O O
. O O

Increases O O
in O O
sertraline B-drug B-drug
dose O O
should O O
be O O
guided O O
by O O
clinical O O
response O O
. O O

Pharmacokinetic O O
studies O O
have O O
demonstrated O O
that O O
omeprazole B-drug B-drug
and O O
erythromycin B-drug B-drug
significantly O O
increased O O
the O O
systemic O O
exposure O O
of O O
cilostazol B-drug B-drug
and/or O O
its O O
major O O
metabolites O O
. O O

Brain O O
hemorrhage O O
and O O
optic O O
nerve O O
vacuolation O O
were O O
seen O O
in O O
another O O
female O O
dog O O
that O O
was O O
sacrificed O O
in O O
moribund O O
condition O O
after O O
11 O O
weeks O O
of O O
escalating O O
doses O O
up O O
to O O
280 O O
mg/kg/day O O
. O O

Warning O O
signs O O
, O O
irrespective O O
of O O
cause O O
, O O
are O O
: O O
dryness O O
of O O
mouth O O
, O O
thirst O O
, O O
weakness O O
, O O
lethargy O O
, O O
drowsiness O O
, O O
restlessness O O
, O O
muscle O O
pains O O
or O O
cramps O O
, O O
muscular O O
fatigue O O
, O O
hypotension O O
, O O
oliguria O O
, O O
tachycardia O O
, O O
and O O
gastrointestinal O O
disturbances O O
such O O
as O O
nausea O O
and O O
vomiting O O
. O O

In O O
studies O O
in O O
normal O O
volunteers O O
, O O
there O O
was O O
no O O
pharmacodynamic O O
interaction O O
between O O
intravenous O O
iloprost B-drug B-drug
and O O
either O O
nifedipine B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
or O O
captopril B-drug B-drug
. O O

Expected O O
to O O
substantially O O
decrease O O
plasma O O
levels O O
of O O
efavirenz B-drug B-drug
; O O
has O O
not O O
been O O
studied O O
in O O
combination O O
with O O
SUSTIVA B-brand B-brand
. O O

As O O
with O O
some O O
other O O
nondepolarizing B-group B-group
neuromuscular I-group I-group
blocking I-group I-group
agents I-group I-group
, O O
the O O
time O O
of O O
onset O O
of O O
neuromuscular O O
block O O
induced O O
by O O
NUROMAX B-brand B-brand
is O O
lengthened O O
and O O
the O O
duration O O
of O O
block O O
is O O
shortened O O
in O O
patients O O
receiving O O
phenytoin B-drug B-drug
or O O
carbamazepine B-drug B-drug
. O O

Uricosuric B-group B-group
drugs I-group I-group
, O O
such O O
as O O
probenecid B-drug B-drug
and O O
sulfinpyrazone B-drug B-drug
, O O
can O O
inhibit O O
renal O O
tubular O O
secretion O O
of O O
nitrofurantoin B-drug B-drug
. O O

Potential O O
for O O
ABILIFY B-brand B-brand
to O O
Affect O O
Other O O
Drugs O O
Aripiprazole B-drug B-drug
is O O
unlikely O O
to O O
cause O O
clinically O O
important O O
pharmacokinetic O O
interactions O O
with O O
drugs O O
metabolized O O
by O O
cytochrome O O
P450 O O
enzymes O O
. O O

Antifungals B-group B-group
: O O
In O O
vitro O O
and/or O O
in O O
vivo O O
data O O
indicate O O
that O O
fluconazole B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
and O O
oral O O
ketoconazole B-drug B-drug
markedly O O
inhibit O O
the O O
metabolism O O
of O O
cisapride B-drug B-drug
, O O
which O O
can O O
result O O
in O O
an O O
increase O O
in O O
plasma O O
cisapride B-drug B-drug
levels O O
and O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

This O O
medicine O O
should O O
not O O
be O O
taken O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Drugs O O
that O O
inhibit O O
cytochrome O O
P450IID6 O O
, O O
such O O
as O O
quinidine B-drug B-drug
, O O
might O O
increase O O
the O O
plasma O O
concentrations O O
of O O
flecainide B-drug B-drug
in O O
patients O O
that O O
are O O
on O O
chronic O O
flecainide B-drug B-drug
therapy O O
; O O

Methotrexate B-drug B-drug
VIOXX B-brand B-brand
12.5 O O
, O O
25 O O
, O O
and O O
50 O O
mg O O
, O O
each O O
dose O O
administered O O
once O O
daily O O
for O O
7 O O
days O O
, O O
had O O
no O O
effect O O
on O O
the O O
plasma O O
concentration O O
of O O
methotrexate B-drug B-drug
as O O
measured O O
by O O
AUC0-24hr O O
in O O
patients O O
receiving O O
single O O
weekly O O
methotrexate B-drug B-drug
doses O O
of O O
7.5 O O
to O O
20 O O
mg O O
for O O
rheumatoid O O
arthritis O O
. O O

Antacids I-group B-group
: O O
Administration O O
of O O
flurbiprofen B-drug B-drug
to O O
volunteers O O
under O O
fasting O O
conditions O O
, O O
or O O
with O O
antacid B-group B-group
suspension O O
yielded O O
similar O O
serum O O
flurbiprofen B-drug B-drug
time O O
profiles O O
in O O
young O O
subjects O O
( O O
n=12 O O
) O O
. O O

Effects O O
on O O
the O O
absorption O O
of O O
other O O
beta-blockers B-group B-group
have O O
not O O
been O O
determined O O
. O O

Therefore O O
, O O
EXTREME O O
CAUTION O O
should O O
be O O
exercised O O
when O O
administering O O
dopamine B-drug B-drug
HCl I-drug I-drug
to O O
patients O O
receiving O O
cyclopropane B-drug B-drug
or O O
halogenated B-group B-group
hydrocarbon I-group I-group
anesthetics I-group I-group
. O O

Another O O
investigator O O
found O O
no O O
increase O O
in O O
digoxin B-drug B-drug
levels O O
in O O
12 O O
patients O O
with O O
coronary O O
artery O O
disease O O
. O O

PEGASYS B-brand B-brand
is O O
to O O
be O O
used O O
during O O
pregnancy O O
only O O
if O O
the O O
potential O O
benefit O O
justifies O O
the O O
potential O O
risk O O
to O O
the O O
fetus O O
. O O

In O O
hematologic O O
studies O O
or O O
in O O
transfusion O O
cross-matching O O
procedures O O
when O O
anti-globulin O O
tests O O
are O O
performed O O
on O O
the O O
minor O O
side O O
or O O
in O O
Coombs O O
testing O O
of O O
newborns O O
whose O O
mothers O O
have O O
received O O
cephalosporin B-group B-group
antibiotics I-group I-group
before O O
parturition O O
, O O
it O O
should O O
be O O
recognized O O
that O O
a O O
positive O O
Coombs O O
test O O
may O O
be O O
due O O
to O O
the O O
drug O O
. O O

Anticoagulants B-group B-group
. O O

Tolbutamide B-drug B-drug
: O O
In O O
diabetic O O
patients O O
receiving O O
diflunisal B-drug B-drug
and O O
tolbutamide B-drug B-drug
, O O
no O O
significant O O
effects O O
were O O
seen O O
on O O
tolbutamide B-drug B-drug
plasma O O
levels O O
or O O
fasting O O
blood O O
glucose O O
. O O

There O O
is O O
limited O O
experience O O
with O O
concomitant O O
antihypertensive B-group B-group
agents I-group I-group
such O O
as O O
alpha-blockers B-group B-group
, O O
calcium B-group B-group
channel-blockers I-group I-group
, O O
ACE B-group B-group
inhibitors I-group I-group
, O O
and O O
diuretics B-group B-group
( O O
both O O
thiazide-like B-group B-group
and O O
loop O O
) O O
. O O

No O O
drug O O
, O O
nutritional O O
supplement O O
, O O
food O O
or O O
herb O O
interactions O O
have O O
yet O O
been O O
reported O O
. O O

Note O O
: O O
dissolution O O
of O O
aerosol O O
particles O O
of O O
budesonide B-drug B-drug
in O O
Survanta B-brand B-brand
, O O
a O O
model O O
lung B-group B-group
surfactant I-group I-group
. O O

If O O
TYKERB B-brand B-brand
is O O
administered O O
with O O
drugs O O
that O O
are O O
substrates O O
of O O
Pgp O O
, O O
increased O O
concentrations O O
of O O
the O O
substrate O O
drug O O
are O O
likely O O
, O O
and O O
caution O O
should O O
be O O
exercised O O
. O O

ETHANOL B-drug B-drug
/ O O
NUTRITION O O
/ O O
HERB O O
INTERACTIONS O O
: O O
Food O O
: O O
CNS O O
effects O O
of O O
caffeine B-drug B-drug
may O O
be O O
enhanced O O
if O O
combination B-group B-group
hormonal I-group I-group
contraceptives I-group I-group
are O O
used O O
concurrently O O
with O O
caffeine B-drug B-drug
. O O

If O O
antacids B-group B-group
are O O
required O O
during O O
OMNICEF B-brand B-brand
therapy O O
, O O
OMNICEF B-brand B-brand
should O O
be O O
taken O O
at O O
least O O
2 O O
hours O O
before O O
or O O
after O O
the O O
antacid B-group B-group
. O O

Of O O
particular O O
importance O O
, O O
sufficient O O
time O O
must O O
elapse O O
before O O
initiating O O
TCA O O
treatment O O
in O O
a O O
patient O O
being O O
withdrawn O O
from O O
fluoxetine B-drug B-drug
, O O
given O O
the O O
long O O
half-life O O
of O O
the O O
parent O O
and O O
active O O
metabolite O O
( O O
at O O
least O O
5 O O
weeks O O
may O O
be O O
necessary O O
) O O
. O O

It O O
is O O
not O O
known O O
if O O
the O O
effects O O
of O O
butorphanol B-drug B-drug
are O O
altered O O
by O O
concomitant O O
medications O O
that O O
affect O O
hepatic O O
metabolism O O
of O O
drugs O O
( O O
erythromycin B-drug B-drug
, O O
etc O O
. O O
) O O
, O O
but O O
physicians O O
should O O
be O O
alert O O
to O O
the O O
possibility O O
that O O
a O O
smaller O O
initial O O
dose O O
and O O
longer O O
intervals O O
between O O
doses O O
may O O
be O O
needed O O
. O O

The O O
mean O O
C O O
max O O
, O O
T O O
max O O
, O O
and O O
AUC O O
of O O
the O O
acid O O
metabolite O O
of O O
terfenadine B-drug B-drug
were O O
not O O
significantly O O
changed O O
. O O

Beta-blocking B-group B-group
Agents I-group I-group
: O O
The O O
concomitant O O
use O O
of O O
Bepridil B-drug B-drug
and O O
beta-blocking B-group B-group
agents I-group I-group
has O O
been O O
well O O
tolerated O O
in O O
patients O O
with O O
stable O O
angina O O
. O O

The O O
possibility O O
of O O
increased O O
interaction O O
should O O
be O O
kept O O
in O O
mind O O
when O O
Orudis B-brand B-brand
doses O O
greater O O
than O O
50 O O
mg O O
as O O
a O O
single O O
dose O O
or O O
200 O O
mg O O
of O O
ketoprofen B-drug B-drug
per O O
day O O
are O O
used O O
concomitantly O O
with O O
highly O O
bound O O
drugs O O
. O O

Results O O
showed O O
that O O
, O O
depending O O
on O O
the O O
task O O
considered O O
, O O
the O O
same O O
pharmacological O O
treatment O O
produced O O
either O O
a O O
facilitation O O
or O O
an O O
impairment O O
of O O
acquisition O O
. O O

Co-administration O O
of O O
nelfinavir B-drug B-drug
at O O
steady-state O O
with O O
a O O
single O O
dose O O
of O O
azithromycin B-drug B-drug
. O O

TABLE O O
1 O O
Effects O O
on O O
Plasma O O
Concentrations O O
( O O
AUC O O
0-24 O O
hrs O O
) O O
of O O
Loratadine B-drug B-drug
and O O
Descarboethoxyloratadine B-drug B-drug
After O O
10 O O
Days O O
of O O
Coadministration O O
( O O
Loratadine B-drug B-drug
10 O O
mg O O
) O O
in O O
Normal O O
Volunteers O O

Serum O O
infliximab B-drug B-drug
concentrations O O
appeared O O
to O O
be O O
unaffected O O
by O O
baseline O O
use O O
of O O
medications O O
for O O
the O O
treatment O O
of O O
Crohn O O
s O O
disease O O
including O O
corticosteroids B-group B-group
, O O
antibiotics B-group B-group
( O O
metronidazole B-drug B-drug
or O O
ciprofloxacin B-drug B-drug
) O O
and O O
aminosalicylates O O
. O O

Erythromycin B-drug B-drug
has O O
been O O
reported O O
to O O
decrease O O
the O O
clearance O O
of O O
triazolam B-drug B-drug
and O O
midazolam B-drug B-drug
and O O
thus O O
may O O
increase O O
the O O
pharmacologic O O
effect O O
of O O
these O O
benzodiazepines B-group B-group
. O O

Drugs O O
Associated O O
With O O
Peripheral O O
Neuropathy O O
: O O
The O O
concomitant O O
use O O
of O O
HIVID B-drug B-drug
with O O
drugs O O
that O O
have O O
the O O
potential O O
to O O
cause O O
peripheral O O
neuropathy O O
should O O
be O O
avoided O O
where O O
possible O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

Elevated O O
plasma O O
levels O O
of O O
theophylline B-drug B-drug
have O O
been O O
reported O O
with O O
concomitant O O
quinolone B-group B-group
use O O
. O O

HAART O O
was O O
included O O
with O O
combination O O
therapy O O
from O O
January O O
1997 O O
. O O

Consequently O O
, O O
estazolam B-drug B-drug
should O O
be O O
avoided O O
in O O
patients O O
receiving O O
ketoconazole B-drug B-drug
and O O
itraconazole B-drug B-drug
, O O
which O O
are O O
very O O
potent O O
inhibitors O O
of O O
CYP3A O O
. O O

trimethoprim/sulfamethoxazole B-drug B-drug
; O O

We O O
conclude O O
that O O
an O O
ability O O
of O O
some O O
P O O
. O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

Drug O O
interactions O O
caused O O
by O O
inhibition O O
of O O
P-glycoprotein-mediated O O
drug O O
clearance O O
or O O
CYP-mediated O O
drug O O
clearance O O
with O O
the O O
listed O O
isoforms O O
are O O
unlikely O O
. O O

Drugs O O
other O O
than O O
those O O
listed O O
here O O
may O O
also O O
interact O O
with O O
glimepiride B-drug B-drug
or O O
affect O O
your O O
condition O O
. O O

In O O
a O O
clinical O O
trial O O
of O O
217 O O
pediatric O O
patients O O
( O O
12 O O
to O O
17 O O
years O O
) O O
with O O
severe O O
recalcitrant O O
nodular O O
acne O O
, O O
transient O O
elevations O O
in O O
CPK O O
were O O
observed O O
in O O
12 O O
% O O
of O O
patients O O
, O O
including O O
those O O
undergoing O O
strenuous O O
physical O O
activity O O
in O O
association O O
with O O
reported O O
musculoskeletal O O
adverse O O
events O O
such O O
as O O
back O O
pain O O
, O O
arthralgia O O
, O O
limb O O
injury O O
, O O
or O O
muscle O O
sprain O O
. O O

Recent O O
, O O
better O O
designed O O
studies O O
have O O
not O O
reported O O
these O O
adverse O O
effects O O
. O O

Administration O O
of O O
doxapram B-drug B-drug
to O O
patients O O
who O O
are O O
receiving O O
sympathomimetic B-group B-group
or O O
monoamine B-group B-group
oxidase I-group I-group
inhibiting I-group I-group
drugs I-group I-group
may O O
result O O
in O O
an O O
additive O O
pressor O O
effect O O
. O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reactions O O
. O O

Therefore O O
, O O
proton B-group B-group
pump I-group I-group
inhibitors I-group I-group
should O O
be O O
taken O O
at O O
least O O
30 O O
minutes O O
prior O O
to O O
sucralfate B-drug B-drug
. O O

Potential O O
for O O
Interaction O O
with O O
Drugs O O
that O O
Affect O O
Gastric O O
Acidity O O
: O O
Duloxetine B-drug B-drug
has O O
an O O
enteric O O
coating O O
that O O
resists O O
dissolution O O
until O O
reaching O O
a O O
segment O O
of O O
the O O
gastrointestinal O O
tract O O
where O O
the O O
pH O O
exceeds O O
5.5 O O
. O O

Non-steroidal B-group B-group
Anti-inflammatory I-group I-group
Drugs I-group I-group
: O O
In O O
some O O
patients O O
, O O
the O O
administration O O
of O O
a O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agent I-group I-group
can O O
reduce O O
the O O
diuretic O B-group
, O O
natriuretic O O
, O O
and O O
antihypertensive O O
effects O O
of O O
loop O O
, O O
potassium-sparing O O
and O O
thiazide B-group B-group
diuretics I-group I-group
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
bupropion B-drug B-drug
is O O
primarily O O
metabolized O O
to O O
hydroxybupropion B-drug_n B-drug_n
by O O
the O O
CYP2B6 O O
isoenzyme O O
. O O

In O O
vitro O O
, O O
the O O
UDP-glucuronyl O O
transferase O O
level O O
was O O
increased O O
, O O
indicating O O
induction O O
of O O
this O O
enzyme O O
. O O

In O O
Study O O
1 O O
, O O
patients O O
with O O
colorectal O O
cancer O O
were O O
given O O
irinotecan/5-FU/leucovorin B-drug B-drug
( O O
bolus-IFL O O
) O O
with O O
or O O
without O O
AVASTIN B-brand B-brand
. O O

Avoid O O
saw O O
palmetto O O
, O O
red O O
clover O O
, O O
ginseng O O
. O O

. O O

phase O O
2 O O
( O O
days O O
14-44 O O
) O O
: O O
fluoxetine B-drug B-drug
20 O O
mg/day O O
; O O

In O O
study O O
one O O
, O O
hyperglycaemic O O
clamps O O
( O O
5.6 O O
mmol/l O O
, O O
11.1 O O
mmol/ O O
1 O O
, O O
16.7 O O
mmol/l O O
) O O
were O O
carried O O
out O O
during O O
placebo O O
or O O
insulin B-drug B-drug
( O O
dose O O
1 O O
: O O
1 O O
mU/kg/min O O
; O O
dose O O
2 O O
: O O
2 O O
mU/kg/min O O
) O O
infusion O O
. O O

Omniscan B-brand B-brand
interferes O O
with O O
serum O O
calcium O O
measurements O O
with O O
some O O
colorimetric O O
( O O
complexometric O O
) O O
methods O O
commonly O O
used O O
in O O
hospitals O O
, O O
resulting O O
in O O
serum O O
calcium O O
concentrations O O
lower O O
than O O
the O O
true O O
values O O
. O O

Appropriate O O
dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O

Drug/ O O
Laboratory O O
Tests O O
Interactions O O
Hyperaminotransferasemia O O
: O O
Significant O O
elevations O O
of O O
aminotransferase O O
( O O
SGOT O O
[ O O
S-AST O O
] O O
and O O
SGPT O O
[ O O
S-ALT O O
] O O
) O O
levels O O
have O O
occurred O O
in O O
a O O
high O O
percentage O O
of O O
patients O O
( O O
and O O
healthy O O
subjects O O
) O O
who O O
have O O
received O O
heparin B-drug B-drug
sodium I-drug I-drug
. O O

The O O
effect O O
of O O
clofarabine B-drug B-drug
on O O
the O O
metabolism O O
of O O
cytochrome O O
p450 O O
substrates O O
has O O
not O O
been O O
studied O O
. O O

The O O
effect O O
of O O
natural O O
and O O
synthetic O O
galloyl O O
esters O O
on O O
glucocorticoid-induced O O
gene O O
expression O O
was O O
evaluated O O
by O O
using O O
rat O O
fibroblast O O
3Y1 O O
cells O O
stably O O
transfected O O
with O O
a O O
luciferase O O
reporter O O
gene O O
under O O
the O O
transcriptional O O
regulation O O
of O O
the O O
mouse O O
mammary O O
tumor O O
virus O O
promoter B-drug O
. O O

The O O
ECG O O
changes O O
and/or O O
hypokalemia O O
that O O
may O O
result O O
from O O
the O O
administration O O
of O O
non-potassium B-group B-group
sparing I-group I-group
diuretics I-group I-group
( O O
such O O
as O O
loop O O
or O O
thiazide B-group B-group
diuretics I-group I-group
) O O
can O O
be O O
acutely O O
worsened O O
by O O
beta-agonists B-group B-group
, O O
especially O O
when O O
the O O
recommended O O
dose O O
of O O
the O O
beta-agonist B-group B-group
is O O
exceeded O O
. O O

Corticotropin B-drug B-drug
may O O
accentuate O O
the O O
electrolyte O O
loss O O
associated O O
with O O
diuretic B-group B-group
therapy O O
. O O

Given O O
the O O
anticonvulsant O O
properties O O
of O O
carbamazepine B-drug B-drug
, O O
EQUETROTM B-brand B-brand
may O O
reduce O O
the O O
thyroid O O
function O O
as O O
has O O
been O O
reported O O
with O O
other O O
anticonvulsants B-group B-group
. O O

Concomitant O O
single O O
dose O O
administration O O
of O O
valdecoxib B-drug B-drug
20 O O
mg O O
with O O
multiple O O
doses O O
of O O
ketoconazole B-drug B-drug
and O O
fluconazole B-drug B-drug
produced O O
a O O
significant O O
increase O O
in O O
exposure O O
of O O
valdecoxib B-drug B-drug
. O O

Both O O
ibogaine B-drug_n B-drug_n
and O O
18-MC B-drug_n B-drug_n
enhance O O
the O O
locomotor O O
and/or O O
stereotypic O O
effects O O
of O O
stimulants O O
. O O

Protease B-group B-group
inhibitor I-group I-group
: O O
atazanavir B-drug B-drug

T3 O O
resin O O
uptake O O
is O O
decreased O O
, O O
reflecting O O
the O O
elevated O O
TBG O O
. O O

Therefore O O
, O O
patients O O
with O O
COPD O O
should O O
not O O
normally O O
be O O
treated O O
with O O
beta-blockers B-group B-group
. O O

The O O
interaction O O
of O O
intramuscularly O O
injected O O
ketamine B-drug B-drug
and O O
its O O
N-demethylated O O
metabolite O O
( O O
metabolite O O
I O O
) O O
with O O
halothane B-drug B-drug
was O O
evaluated O O
in O O
rats O O
. O O

It O O
is O O
recommended O O
that O O
the O O
dose O O
of O O
rifabutin B-drug B-drug
be O O
reduced O O
to O O
one-half O O
the O O
usual O O
dose O O
when O O
administered O O
with O O
VIRACEPT B-brand B-brand
. O O

however O O
, O O
patients O O
receiving O O
such O O
combined O O
therapy O O
should O O
be O O
monitored O O
closely O O
for O O
early O O
evidence O O
of O O
neurological O O
toxicity O O
and O O
treatment O O
discontinued O O
promptly O O
if O O
such O O
signs O O
appear O O
. O O

During O O
phenytoin B-drug B-drug
and O O
fluvoxamine O B-drug
treatment O O
, O O
ataxia O O
, O O
a O O
typical O O
side O O
effect O O
of O O
phenytoin B-drug B-drug
, O O
was O O
observed O O
. O O

1 O O
. O O

The O O
increased O O
plasma O O
concentration O O
of O O
terfenadine B-drug B-drug
or O O
its O O
metabolite O O
may O O
result O O
in O O
prolonged O O
QT O O
intervals O O
. O O

Phenytoin O B-drug
intoxication O O
induced O O
by O O
fluvoxamine B-drug B-drug
. O O

Clinically O O
significant O O
interactions O O
would O O
not O O
be O O
expected O O
since O O
the O O
NRTIs B-group B-group
are O O
metabolized O O
via O O
a O O
different O O
route O O
than O O
efavirenz B-drug B-drug
and O O
would O O
be O O
unlikely O O
to O O
compete O O
for O O
the O O
same O O
metabolic O O
enzymes O O
and O O
elimination O O
pathways O O
. O O

In O O
a O O
pharmacokinetic O O
interaction O O
study O O
with O O
warfarin B-drug B-drug
, O O
bioavailability O O
parameters O O
, O O
the O O
degree O O
of O O
protein O O
binding O O
, O O
and O O
the O O
anticoagulant O O
effect O O
( O O
measured O O
by O O
prothrombin O O
time O O
) O O
of O O
warfarin B-drug B-drug
were O O
not O O
significantly O O
changed O O
. O O

In O O
addition O O
, O O
certain O O
drugs O O
inhibit O O
the O O
activity O O
of O O
this O O
isozyme O O
and O O
make O O
normal O O
metabolizers O O
resemble O O
poor O O
metabolizers O O
. O O

A O O
method O O
to O O
maximize O O
the O O
therapeutic O O
benefit O O
of O O
gentamicin B-drug B-drug
while O O
minimizing O O
the O O
risk O O
of O O
nephrotoxicity O O
and O O
the O O
appearance O O
of O O
a O O
hot O O
kidney O O
on O O
scintigraphy O O
is O O
desirable O O
. O O

Drugs O O
which O O
may O O
enhance O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
TRACRIUM B-brand B-brand
include O O
: O O
enflurane B-drug B-drug
; O O

Patients O O
stabilized O O
on O O
oral O O
anticoagulants B-group B-group
who O O
are O O
found O O
to O O
require O O
thyroid B-group O
replacement O O
therapy O O
should O O
be O O
watched O O
very O O
closely O O
when O O
thyroid O O
is O O
started O O
. O O

The O O
second O O
study O O
was O O
identical O O
but O O
endogenous O O
insulin O O
secretion O O
was O O
blocked O O
with O O
somatostatin B-drug B-drug
. O O

If O O
other O O
muscle B-group B-group
relaxants I-group I-group
are O O
used O O
during O O
the O O
same O O
procedure O O
, O O
the O O
possibility O O
of O O
a O O
synergistic O O
or O O
antagonist O O
effect O O
should O O
be O O
considered O O
. O O

Magnesium- B-drug B-drug
and/or O O
aluminum-containing B-drug B-drug
antacids B-group B-group
, O O
products O O
containing O O
ferrous B-drug B-drug
sulfate I-drug I-drug
( O O
iron B-drug B-drug
) O O
, O O
multivitamin B-group B-group
preparations I-group I-group
containing O O
zinc B-drug B-drug
or O O
other O O
metal O O
cations O O
, O O
or O O
Videx B-brand B-brand
( O O
didanosine B-drug B-drug
) O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
should O O
not O O
be O O
taken O O
within O O
3 O O
hours O O
before O O
or O O
2 O O
hours O O
after O O
FACTIVE B-brand B-brand
. O O

The O O
concomitant O O
administration O O
of O O
either O O
cocaine B-drug B-drug
or O O
amphetamine B-drug B-drug
, O O
compounds O O
which O O
inhibit O O
neuronal O O
reuptake O O
of O O
norepinephrine O B-drug
, O O
disrupts O O
the O O
behavioral O O
response O O
of O O
the O O
genetically O O
nervous O O
E-strain O O
subjects O O
to O O
a O O
far O O
greater O O
extent O O
than O O
the O O
stable O O
A-strain O O
subjects O O
. O O

If O O
TYKERB B-brand B-brand
is O O
administered O O
with O O
drugs O O
that O O
inhibit O O
Pgp O O
, O O
increased O O
concentrations O O
of O O
lapatinib B-drug B-drug
are O O
likely O O
, O O
and O O
caution O O
should O O
be O O
exercised O O
. O O

Because O O
changes O O
in O O
glucose O O
concentrations O O
with O O
valdecoxib B-drug B-drug
coadministration O O
were O O
within O O
the O O
normal O O
variability O O
and O O
individual O O
glucose O O
concentrations O O
were O O
above O O
or O O
near O O
70 O O
mg/dL O O
, O O
dose O O
adjustment O O
for O O
glyburide B-drug B-drug
( O O
5 O O
mg O O
QD O O
and O O
10 O O
mg O O
BID O O
) O O
with O O
valdecoxib B-drug B-drug
coadministration O O
( O O
up O O
to O O
40 O O
mg O O
QD O O
) O O
is O O
not O O
indicated O O
. O O

False-positive O O
direct O O
Coombs O O
tests O O
have O O
been O O
reported O O
during O O
treatment O O
with O O
other O O
cephalosporins B-group B-group
. O O

Impaired O O
glucose O O
tolerance O O
. O O

Ketoconazole B-drug B-drug
: O O
When O O
a O O
single O O
125-mg O O
dose O O
of O O
Aprepitant B-drug B-drug
was O O
administered O O
on O O
Day5 O O
of O O
a O O

In O O
four O O
subjects O O
with O O
epilepsy O O
ingesting O O
valproate B-drug B-drug
, O O
the O O
steady-state O O
trough O O
( O O
Cmin O O
) O O
valproate B-drug B-drug
plasma O O
concentration O O
was O O
63 O O
16 O O
micrograms/mL O O
. O O

Anti-HIV B-group B-group
Reverse I-group I-group
Transcriptase I-group I-group
Inhibitors I-group I-group

Clofibric B-drug_n B-drug_n
acid I-drug_n I-drug_n
: O O
Combination O O
hormonal B-group B-group
contraceptives I-group I-group
may O O
increase O O
the O O
clearance O O
of O O
clofibric B-drug_n B-drug_n
acid I-drug_n I-drug_n
. O O

No O O
specific O O
studies O O
have O O
been O O
performed O O
and O O
caution O O
is O O
recommended O O
. O O

rash O O

Frequent O O
determination O O
of O O
prothrombin O O
time O O
and O O
close O O
monitoring O O
of O O
the O O
patient O O
is O O
essential O O
to O O
ascertain O O
when O O
adjustment O O
of O O
dosage O O
of O O
anticoagulant B-group B-group
may O O
be O O
needed O O
. O O

A O O
21 O O
( O O
17 O O
) O O
% O O
decrease O O
in O O
the O O
steady-state O O
AUC O O
of O O
ganciclovir B-drug B-drug
was O O
observed O O
when O O
VIDEX B-brand B-brand
was O O
administered O O
2 O O
hours O O
prior O O
to O O
ganciclovir B-drug B-drug
, O O
but O O
not O O
when O O
the O O
two O O
drugs O O
were O O
administered O O
simultaneously O O
( O O
n O O
= O O
12 O O
) O O
. O O

Cevimeline B-drug B-drug
might O O
interfere O O
with O O
desirable O O
antimuscarinic O O
effects O O
of O O
drugs O O
used O O
concomitantly O O
. O O

Statistical O O
analysis O O
: O O
Mantel-Haenszel O O
( O O
alpha O O
= O O
0.05 O O
) O O
. O O

Cyclosporine B-drug B-drug
doses O O
, O O
trough O O
concentrations O O
, O O
and O O
AUC O O
exhibited O O
similar O O
temporal O O
patterns O O
during O O
the O O
course O O
of O O
the O O
study O O
regardless O O
of O O
the O O
co-administered O O
everolimus B-drug B-drug
dose O O
level O O
( O O
P O O
= O O
.13 O O
, O O
.82 O O
, O O
and O O
.76 O O
, O O
respectively O O
) O O
. O O

No O O
drug O O
interactions O O
have O O
been O O
observed O O
with O O
the O O
Vitrasert B-brand B-brand
Implant O O
. O O

No O O
interactions O O
were O O
observed O O
. O O

An O O
interaction O O
study O O
with O O
warfarin B-drug B-drug
showed O O
no O O
clinically O O
significant O O
effect O O
of O O
anastrozole B-drug B-drug
on O O
warfarin B-drug B-drug
pharmacokinetics O O
or O O
anticoagulant O B-group
activity O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Naproxen B-drug B-drug
may O O
decrease O O
platelet O O
aggregation O O
and O O
prolong O O
bleeding O O
time O O
. O O

Intestinal O O
absorption O O
of O O
arsenate B-drug_n B-drug_n
in O O
the O O
chick O O
. O O

Ethanol B-drug B-drug
depressed O O
the O O
amplitudes O O
of O O
most O O
evoked O O
potential O O
components O O
in O O
comparison O O
to O O
saline O O
administration O O
. O O

alcohol B-drug B-drug
, O O
barbiturates B-drug B-group
and O O
other O O
CNS B-drug B-group
depressants I-drug I-group
; O O

An O O
immune O O
response O O
to O O
Campath B-brand B-brand
may O O
interfere O O
with O O
subsequent O O
diagnostic O O
serum O O
tests O O
that O O
utilize O O
antibodies B-group O

After O O
one O O
day O O
, O O
fecal O O
as O O
well O O
as O O
urinary O O
excretion O O
of O O
both O O
elements O O
had O O
already O O
responded O O
to O O
the O O
dietary O O
treatments O O
, O O
with O O
constant O O
values O O
being O O
reached O O
after O O
approximately O O
three O O
days O O
. O O

Epinephrine B-drug B-drug
also O O
should O O
be O O
used O O
cautiously O O
with O O
other O O
drugs O O
( O O
e.g. O O
, O O
digitalis B-group B-group
, O O
glycosides B-group B-group
) O O
that O O
sensitize O O
the O O
myocardium O O
to O O
the O O
actions O O
of O O
sympathomimetic B-group B-group
drugs I-group I-group
. O O

Significant O O
increases O O
In O O
AUC O O
( O O
27 O O
% O O
) O O
and O O
Cmax O O
( O O
58 O O
% O O
) O O
and O O
decreases O O
in O O
tmax O O
( O O
23 O O
% O O
) O O
of O O
propranolol B-drug B-drug
were O O
noted O O
in O O
this O O
study O O
. O O

Treatment O O
with O O
PEGASYS B-brand B-brand
once O O
weekly O O
for O O
4 O O
weeks O O
in O O
healthy O O
subjects O O
was O O
associated O O
with O O
an O O
inhibition O O
of O O
P450 O O
1A2 O O
and O O
a O O
25 O O
% O O
increase O O
in O O
theophylline B-drug B-drug
AUC O O
. O O

Itraconazole B-drug B-drug

Clinical O O
Comment O O

The O O
risks O O
of O O
using O O
Anafranil B-brand B-brand
in O O
combination O O
with O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

- O O
Quinidine B-drug B-drug
( O O
e.g. O O
, O O
Quinidex B-brand B-brand
) O O
or O O

Drug/Laboratory O O
Test O O
Interactions O O
Increases O O
in O O
lymphocyte O O
counts O O
related O O
to O O
the O O
pharmacologic O O
mechanism O O
of O O
action O O
are O O
frequently O O
observed O O
during O O
RAPTIVA B-brand B-brand
treatment O O
. O O

Because O O
many O O
drugs O O
are O O
excreted O O
in O O
human O O
milk O O
, O O
and O O
because O O
there O O
exists O O
the O O
potential O O
for O O
serious O O
adverse O O
reactions O O
in O O
nursing O O
infants O O
from O O
AMEVIVE B-brand B-brand
, O O
a O O
decision O O
should O O
be O O
made O O
whether O O
to O O
discontinue O O
nursing O O
while O O
taking O O
the O O
drug O O
or O O
to O O
discontinue O O
the O O
use O O
of O O
the O O
drug O O
, O O
taking O O
into O O
account O O
the O O
importance O O
of O O
the O O
drug O O
to O O
the O O
mother O O
. O O

Both O O
efavirenz B-drug B-drug
and O O
nevirapine B-drug B-drug
have O O
been O O
compared O O
to O O
triple O O
therapy O O
with O O
the O O
PI B-group O
indinavir B-drug B-drug
over O O
48 O O
weeks O O
as O O
initial O O
therapy O O
, O O
with O O
similar O O
responses O O
being O O
observed O O
with O O
nevirapine B-drug B-drug
regimens O O
and O O
superiority O O
observed O O
with O O
efavirenz B-drug B-drug
. O O

Several O O
drug O O
interaction O O
studies O O
have O O
been O O
completed O O
with O O
both O O
INVIRASE B-brand B-brand
and O O
FORTOVASE B-brand B-brand
. O O

Bexarotene B-drug B-drug
oxidative O O
metabolites O O
appear O O
to O O
be O O
formed O O
by O O
cytochrome O O
P450 O O
3A4 O O
. O O

If O O
you O O
think O O
you O O
are O O
taking O O
an O O
MAO B-group B-group
inhibitor I-group I-group
talk O O
to O O
your O O
doctor O O
or O O
pharmacist O O
. O O

The O O
effect O O
of O O
a O O
pulmonary B-group B-group
surfactant I-group I-group
extract O O
from O O
bovine O O
lung O O
, O O
Survanta B-brand B-brand
, O O
on O O
the O O
dissolution O O
rate O O
of O O
aerosol O O
particles O O
of O O
budesonide B-drug B-drug
was O O
determined O O
. O O

In O O
a O O
single O O
study O O
, O O
rats O O
given O O
high O O
intraperitoneal O O
doses O O
of O O
an O O
MAO B-group B-group
inhibitor I-group I-group
plus O O
disulfiram B-drug B-drug
experienced O O
severe O O
toxicity O O
, O O
including O O
convulsions O O
and O O
death O O
. O O

FACTIVE B-brand B-brand
had O O
no O O
significant O O
effect O O
on O O
the O O
anticoagulant O O
effect O O
of O O
warfarin B-drug B-drug
in O O
healthy O O
subjects O O
on O O
stable O O
warfarin B-drug B-drug
therapy O O
. O O

The O O
interindividual O O
pharmacokinetic O O
variability O O
for O O
AUC O O
was O O
85.4 O O
% O O
and O O
intraindividual O O
, O O
interoccasion O O
variability O O
was O O
40.8 O O
% O O
. O O

Excretion O O
of O O
thioethers O O
in O O
urine O O
after O O
exposure O O
to O O
electrophilic O O
chemicals O O
. O O

Expected O O
changes O O
in O O
laboratory O O
assessments O O
of O O
PT O O
and O O
INR O O
were O O
observed O O
after O O
warfarin B-drug B-drug
administration O O
, O O
but O O
these O O
changes O O
were O O
not O O
affected O O
by O O
concomitant O O
lenalidomide B-drug B-drug
administration O O
. O O

Propoxyphene B-drug B-drug
: O O
In O O
cases O O
of O O
propoxyphene B-drug B-drug
overdosage O O
, O O
amphetamine B-drug B-drug
CNS O O
stimulation O O
is O O
potentiated O O
and O O
fatal O O
convulsions O O
can O O
occur O O
. O O

Quinolones B-group B-group
have O O
also O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

Caution O O
should O O
be O O
exercised O O
with O O
these O O
drugs O O
when O O
treating O O
patients O O
receiving O O
TAXOTERE B-brand B-brand
as O O
there O O
is O O
a O O
potential O O
for O O
a O O
significant O O
interaction O O
. O O

Except O O
for O O
clindamycin-sensitive B-drug B-drug
isolates O O
, O O
synergy O O
was O O
usually O O
observed O O
only O O
at O O
concentrations O O
of O O
one O O
or O O
both O O
drugs O O
which O O
are O O
not O O
readily O O
obtainable O O
in O O
vivo O O
. O O

- O O
Cholestyramine B-drug B-drug
and O O
colestipol B-drug B-drug
resins B-group B-group
: O O
Cholestytamine B-drug B-drug
and O O
colestipol B-drug B-drug
resins B-group B-group
have O O
the O O
potential O O
of O O
binding O O
thiazide B-group B-group
diuretics I-group I-group
and O O
reducing O O
diuretic B-group B-group
absorption O O
from O O
the O O
gastrointestinal O O
tract O O

This O O
medicine O O
should O O
not O O
be O O
taken O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Patients O O
with O O
a O O
very O O
low O O
cardiac O O
capacity O O
should O O
be O O
advised O O
to O O
refrain O O
from O O
treatment O O
of O O
the O O
erection O O
disorder O O
. O O

As O O
binding O O
of O O
MHD B-drug_n B-drug_n
to O O
plasma O O
proteins O O
is O O
low O O
( O O
40 O O
% O O
) O O
, O O
clinically O O
significant O O
interactions O O
with O O
other O O
drugs O O
through O O
competition O O
for O O
protein O O
binding O O
sites O O
are O O
unlikely O O
. O O

Adverse O O
reactions O O
related O O
to O O
alpha B-drug O
interferons O O
, O O
such O O
as O O
CNS O O
, O O
cardiac O O
, O O
and O O
systemic O O
( O O
eg O O
, O O
flu-like O O
) O O
effects O O
may O O
be O O
more O O
severe O O
in O O
the O O
elderly O O
and O O
caution O O
should O O
be O O
exercised O O
in O O
the O O
use O O
of O O
PEGASYS B-brand B-brand
in O O
this O O
population O O
. O O

In O O
opioid-dependent B-group B-group
patients O O
, O O
mixed B-group B-group
agonist/antagonist I-group I-group
analgesics I-group I-group
may O O
precipitate O O
withdrawal O O
symptoms O O
. O O

Chirocaine B-brand B-drug
should O O
be O O
used O O
with O O
caution O O
in O O
patients O O
receiving O O
other O O
local O O
anesthetics B-group B-group
or O O
agents O O
structurally O O
related O O
to O O
amide-type O O
local O O
anesthetics O B-group
since O O
the O O
toxic O O
effects O O
of O O
these O O
drugs O O
could O O
be O O
additive O O
. O O

Misonidazole B-drug_n B-drug_n
reduced O O
the O O
antitumour O O
activity O O
of O O
oral O O
CCNU B-drug B-drug
by O O
dose O O
modifying O O
factors O O
( O O
DMF O O
) O O
of O O
0.58-0.71 O O
. O O

An O O
association O O
between O O
prilocaine B-drug B-drug
and O O
an O O
increased O O
risk O O
of O O
methaemoglobinaemia O O
, O O
particularly O O
in O O
infants O O
, O O
has O O
specifically O O
been O O
described O O
in O O
a O O
literature O O
case O O
report O O
. O O

Fenfluramine B-drug B-drug
may O O
increase O O
slightly O O
the O O
effect O O
of O O
antihypertensive B-group B-group
drugs I-group I-group
, O O
e.g. O O
, O O
guanethidine B-drug B-drug
, O O
methyldopa B-drug B-drug
, O O
reserpine B-drug B-drug
. O O

Cytochrome O O
P450 O O
1A2 O O
( O O
CYP1A2 O O
) O O
is O O
known O O
to O O
be O O
the O O
major O O
enzyme O O
involved O O
in O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

Exposure O O
of O O
the O O
muscle O O
to O O
ouabain B-drug B-drug
( O O
10 O O
( O O
-5 O O
) O O
M O O
) O O
markedly O O
increased O O
the O O
PTX-induced B-drug_n B-drug_n
release O O
. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
with O O
enalapril B-drug B-drug
or O O
enalaprilat B-drug B-drug
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-drug B-group
or O O
increasing O O
the O O
salt O O
intake O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
enalapril B-drug B-drug
or O O
enalaprilat B-drug B-drug
. O O

+15 O O
% O O
+0 O O
% O O
+17 O O
% O O
+13 O O
% O O

When O O
phenobarbital B-drug B-drug
is O O
added O O
to O O
or O O
withdrawn O O
from O O
treatment O O
, O O
dosage O O
adjustment O O
of O O
Nalfon B-brand B-brand
may O O
be O O
required O O
. O O

Digitalis B-group B-group
: O O
Immediate O O
Release O O
Capsules O O
: O O
Since O O
there O O
have O O
been O O
isolated O O
reports O O
of O O
patients O O
with O O
elevated O O
digoxin B-drug B-drug
levels O O
, O O
and O O
there O O
is O O
a O O
possible O O
interaction O O
between O O
digoxin B-drug B-drug
and O O
nifedipine B-drug B-drug
, O O
it O O
is O O
recommended O O
that O O
digoxin B-drug B-drug
levels O O
be O O
monitored O O
when O O
initiating O O
, O O
adjusting O O
, O O
and O O
discontinuing O O
nifedipine B-drug B-drug
to O O
avoid O O
possible O O
over- O O
or O O
under-digitalization O O
. O O

Cyclosporin B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
sirolimus B-drug B-drug

Thus O O
, O O
the O O
selective O O
regulation O O
of O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
subtypes O O
by O O
ginsenosides B-drug_n B-drug_n
in O O
bovine O O
chromaffin O O
cell O O
could O O
be O O
the O O
cellular O O
basis O O
of O O
antistress O O
effects O O
induced O O
by O O
ginseng B-drug B-drug_n
. O O

It O O
has O O
been O O
reported O O
that O O
the O O
addition O O
of O O
triamterene B-drug B-drug
to O O
a O O
maintenance O O
schedule O O
of O O
INDOCIN B-brand B-brand
resulted O O
in O O
reversible O O
acute O O
renal O O
failure O O
in O O
two O O
of O O
four O O
healthy O O
volunteers O O
. O O

As O O
with O O
other O O
drugs O O
primarily O O
being O O
metabolized O O
through O O
CYP3A4 O O
, O O
ingestion O O
of O O
grapefruit O O
or O O
grapefruit O O
juice O O
should O O
be O O
avoided O O
in O O
connection O O
with O O
budesonide B-drug B-drug
administration O O
. O O

. O O

Dexamethasone B-drug B-drug
had O O
a O O
similar O O
effect O O
in O O
the O O
presence O O
of O O
insulin B-drug B-drug
. O O

There O O
is O O
limited O O
experience O O
with O O
use O O
of O O
retinal O O
tamponades O O
in O O
conjunction O O
with O O
the O O
Vitrasert B-brand B-brand
Implant O O
. O O

Drugs O O
which O O
inhibit O O
CYP2D6 O O
and O O
CYP3A3/4 O O
also O O
inhibit O O
the O O
metabolism O O
of O O
cevimeline B-drug B-drug
. O O

Tubocurarine B-drug B-drug

Benzyl B-drug_n B-drug
alcohol I-drug_n I-drug
has O O
been O O
reported O O
to O O
be O O
associated O O
with O O
an O O
increased O O
incidence O O
of O O
neurological O O
and O O
other O O
complications O O
in O O
neonates O O
and O O
infants O O
, O O
which O O
are O O
sometimes O O
fatal O O
. O O

+135 O O
% O O

these O O
may O O
also O O
occur O O
in O O
neonates O O
whose O O
mothers O O
received O O
cephalosporins B-group B-group
before O O
delivery O O
. O O

Blood O O
glucose O O
concentrations O O
should O O
be O O
carefully O O
monitored O O
when O O
Itraconazole B-drug B-drug
and O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
are O O
coadministered O O
. O O

Prednisolone B-drug B-drug
: O O
Ethinyl B-drug B-drug
estradiol I-drug I-drug
may O O
inhibit O O
the O O
metabolism O O
of O O
prednisolone B-drug B-drug
, O O
leading O O
to O O
increased O O
plasma O O
concentrations O O
. O O

Coadministration O O
of O O
Aprepitant B-drug B-drug
with O O
drugs O O
that O O
induce O O
CYP3A4 O O
activity O O
may O O
result O O
in O O
reduced O O
plasma O O
concentrations O O
and O O
decreased O O
efficacy O O
of O O
Aprepitant B-drug B-drug
. O O

Diagnostic O O
dip-stick O O
methodology O O
, O O
used O O
to O O
detect O O
ketone O O
bodies O O
in O O
urine O O
, O O
has O O
resulted O O
in O O
false-positive O O
findings O O
in O O
some O O
patients O O
treated O O
with O O
Lodine B-brand B-brand
. O O

Concomitant O O
Administration O O
with O O
Racemic O O
Citalopram B-drug B-drug
Citalopram I-drug I-drug
- O O
Since O O
escitalopram B-drug B-drug
is O O
the O O
active O O
isomer O O
of O O
racemic O O
citalopram B-drug B-drug
( O O
Celexa B-brand B-brand
) O O
, O O
the O O
two O O
agents O O
should O O
not O O
be O O
coadministered O O
. O O

Calcium B-group B-group
channel I-group I-group
blockers I-group I-group

Antihypertensive B-group B-group
medications I-group I-group
, O O
other O O
, O O
especially O O
diazoxide B-drug B-drug
, O O
or O O
preanesthetic B-group O
and O O
anesthetic O B-group
agents O I-group
used O O
in O O
surgery O O
or O O
skeletal-muscle B-group B-group
relaxants I-group I-group
, O O
nondepolarizing O O
, O O
used O O
in O O
surgery O O

Clinical O O
Comment O O

Glyburide B-drug B-drug
: O O
The O O
concomitant O O
administration O O
of O O
ciprofloxacin B-drug B-drug
with O O
the O O
sulfonylurea B-group B-group
glyburide B-drug B-drug
has O O
, O O
on O O
rare O O
occasions O O
, O O
resulted O O
in O O
severe O O
hypoglycemia O O
. O O

However O O
, O O
theophylline B-drug B-drug
plasma O O
concentrations O O
should O O
be O O
monitored O O
, O O
with O O
dosage O O
adjustment O O
as O O
appropriate O O
, O O
in O O
patients O O
whose O O
pulmonary O O
disease O O
requires O O
maintaining O O
a O O
given O O
theophylline B-drug B-drug
plasma O O
concentration O O
for O O
optimal O O
pulmonary O O
function O O
or O O
in O O
patients O O
with O O
theophylline B-drug B-drug
concentrations O O
at O O
the O O
higher O O
end O O
of O O
the O O
therapeutic O O
range O O
. O O

Chronic O O
administration O O
of O O
phenobarbital B-drug B-drug
, O O
a O O
known O O
enzyme O O
inducer O O
, O O
may O O
be O O
associated O O
with O O
a O O
decrease O O
in O O
the O O
plasma O O
half-life O O
of O O
fenoprofen B-drug B-drug
. O O

Similarly O O
dialyzed O O
were O O
phenobarbital B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
and O O
theophylline B-drug B-drug
, O O
both O O
alone O O
at O O
therapeutic O O
concentrations O O
in O O
serum O O
and O O
with O O
ethanol B-drug B-drug
at O O
three O O
different O O
concentrations O O
in O O
serum O O
. O O

Do O O
not O O
take O O
this O O
medicine O O
with O O
St. O O
Johns O O
Wort O O
because O O
of O O
the O O
additive O O
effects O O
of O O
sertonin O O
. O O

ATROVENT B-brand B-brand
Inhalation O O
Aerosol O O
has O O
been O O
used O O
concomitantly O O
with O O
other O O
drugs O O
, O O
including O O
sympathomimetic B-group B-group
bronchodilators I-group I-group
, O O
methylxanthines B-group B-group
, O O
and O O
steroids B-group B-group
, O O
commonly O O
used O O
in O O
the O O
treatment O O
of O O
chronic O O
obstructive O O
pulmonary O O
disease O O
. O O

This O O
drug O O
may O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-group B-group
) O O
, O O
anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-group B-group
) O O
, O O
and O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
( O O
concurrent O O
use O O
with O O
antihistamines B-drug B-group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-drug B-group
) O O
. O O

This O O
could O O
lead O O
to O O
decreased O O
salicylate B-group B-group
serum O O
levels O O
or O O
increase O O
the O O
risk O O
of O O
salicylate B-group B-group
toxicity O O
when O O
corticosteroid B-drug B-group
is O O
withdrawn O O
. O O

Oral O O
Hypoglycemics B-group B-group
: O O
Diclofenac B-drug B-drug
does O O
not O O
alter O O
glucose O O
metabolism O O
in O O
normal O O
subjects O O
nor O O
does O O
it O O
alter O O
the O O
effects O O
of O O
oral O O
hypoglycemic B-group B-group
agents I-group I-group
. O O

After O O
extensive O O
intake O O
of O O
grapefruit O O
juice O O
( O O
which O O
inhibits O O
CYP3A4 O O
activity O O
predominantly O O
in O O
the O O
intestinal O O
mucosa O O
) O O
, O O
the O O
systemic O O
exposure O O
for O O
oral O O
budesonide B-drug B-drug
increased O O
about O O
two O O
times O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Blood O O
Glucose O O
Blood O O
glucose O O
measurement O O
must O O
be O O
done O O
with O O
a O O
glucose-specific O O
method O O
to O O
prevent O O
maltose O O
interference O O
with O O
test O O
results O O
. O O

Interaction O O
with O O
phenytoin B-drug B-drug
, O O
lidocaine B-drug B-drug
and O O
theophylline B-drug B-drug
has O O
also O O
been O O
reported O O
to O O
produce O O
adverse O O
clinical O O
effects O O
. O O

Carbamazepine B-drug B-drug
: O O
Elevated O O
carbamazepine B-drug B-drug
levels O O
have O O
been O O
reported O O
in O O
postmarketing O O
experience O O
when O O
SUPRAX B-brand B-brand
is O O
administered O O
concomitantly O O
. O O

Aspirin B-brand B-brand
increased O O
ulcerogenic O O
effect O O
; O O

Concurrent O O
use O O
of O O
tetracycline B-drug B-drug
may O O
render O O
oral O O
contraceptives B-group B-group
less O O
effective O O
. O O

These O O
results O O
suggest O O
that O O
KRM-1648 B-drug_n B-drug_n
has O O
a O O
great O O
potential O O
in O O
the O O
treatment O O
of O O
M O O
. O O

Two O O
different O O
types O O
of O O
therapy O O
with O O
magnesium B-drug B-drug
are O O
used O O
: O O
physiological O O
oral O O
magnesium B-drug B-drug
supplementation O O
which O O
is O O
totally O O
atoxic O O
since O O
it O O
palliates O O
magnesium B-drug B-drug
deficiencies O O
by O O
simply O O
normalizing O O
the O O
magnesium B-drug B-drug
intake O O
and O O
pharmacological O O
magnesium B-drug B-drug
therapy O O
which O O
may O O
induce O O
toxicity O O
since O O
it O O
creates O O
iatrogenic O O
magnesium B-drug B-drug
overload O O
. O O

No O O
data O O
are O O
available O O
on O O
potential O O
interactions O O
in O O
individuals O O
who O O
consume O O
greater O O
than O O
200 O O
mg O O
of O O
caffeine B-drug B-drug
per O O
day O O
or O O
in O O
those O O
, O O
such O O
as O O
the O O
geriatric O O
population O O
, O O
who O O
are O O
generally O O
believed O O
to O O
be O O
more O O
susceptible O O
to O O
the O O
development O O
of O O
drug-induced O O
CNS-related O O
adverse O O
effects O O
. O O

Theophylline B-drug B-drug
: O O
Twelve O O
healthy O O
male O O
volunteers O O
were O O
administered O O
one O O
200-mg O O
ceftibuten B-drug B-drug
capsule O O
twice O O
daily O O
for O O
6 O O
days O O
. O O

No O O
significant O O
interactions O O
were O O
found O O
between O O
nisoldipine B-drug B-drug
and O O
warfarin B-drug B-drug
or O O
digoxin B-drug B-drug
. O O

It O O
was O O
concluded O O
that O O
oral O O
oxycodone B-drug B-drug
and O O
levofloxacin B-drug B-drug
can O O
be O O
administered O O
concomitantly O O
without O O
a O O
significant O O
decrease O O
in O O
AUC O O
, O O
Cmax O O
, O O
or O O
tmax O O
. O O

The O O
cause O O
of O O
the O O
reported O O
association O O
has O O
not O O
been O O
established O O
. O O

Phosphate-Binding O O
Agents O O
: O O
Since O O
vitamin B-group B-group
D I-group I-group
also O O
has O O
an O O
effect O O
on O O
phosphate O O
transport O O
in O O
the O O
intestine O O
, O O
kidneys O O
and O O
bones O O
, O O
the O O
dosage O O
of O O
phosphate-binding O O
agents O O
must O O
be O O
adjusted O O
in O O
accordance O O
with O O
the O O
serum O O
phosphate O O
concentration O O
. O O

vasculitis O O

Such O O
patients O O
may O O
be O O
unresponsive O O
to O O
the O O
usual O O
doses O O
of O O
epinephrine B-drug B-drug
used O O
to O O
treat O O
allergic O O
reaction O O
. O O

Antacids B-group B-group
: O O
Nonclinical O O
data O O
demonstrate O O
that O O
the O O
solubility O O
of O O
dasatinib B-drug B-drug
is O O
pH O O
dependent O O
. O O

It O O
is O O
not O O
known O O
which O O
drug O O
clearance O O
mechanism O O
involved O O
in O O
caspofungin B-drug B-drug
disposition O O
may O O
be O O
inducible O O
. O O

Laboratory O O
Tests O O
Response O O
to O O
Plenaxis B-brand B-brand
should O O
be O O
monitored O O
by O O
measuring O O
serum O O
total O O
testosterone B-drug O
concentrations O O
just O O
prior O O
to O O
administration O O
on O O
Day O O
29 O O
and O O
every O O
8 O O
weeks O O
thereafter O O
. O O

In O O
the O O
present O O
study O O
we O O
evaluated O O
the O O
interference O O
of O O
antidepressants B-group B-group
with O O
blood O O
glucose O O
levels O O
of O O
diabetic O O
and O O
non-diabetic O O
rats O O
. O O

In O O
two O O
clinical O O
studies O O
, O O
cyclosporine B-drug B-drug
( O O
one O O
4 O O
mg/kg O O
dose O O
or O O
two O O
3 O O
mg/kg O O
doses O O
) O O
increased O O
the O O
AUC O O
of O O
caspofungin B-drug B-drug
by O O
approximately O O
35 O O
% O O
. O O

dietary O O
deficiencies O O
; O O

Women O O
should O O
practice O O
additional O O
methods O O
of O O
contraception O O
and O O
not O O
rely O O
on O O
hormonal O O
contraception O O
alone O O
when O O
taking O O
TRACLEER B-brand B-brand
. O O

Concomitant O O
use O O
of O O
barbiturates B-group B-group
usually O O
depresses O O
griseofulvin B-drug B-drug
activity O O
and O O
may O O
necessitate O O
raising O O
the O O
dosage O O
. O O

Tetracycline B-drug B-drug
, O O
a O O
bacteriostatic B-group B-group
antibiotic I-group I-group
, O O
may O O
antagonize O O
the O O
bactericidal O O
effect O O
of O O
penicillin B-drug B-drug
and O O
concurrent O O
use O O
of O O
these O O
drugs O O
should O O
be O O
avoided O O
. O O

There O O
have O O
been O O
no O O
formal O O
clinical O O
studies O O
to O O
evaluate O O
the O O
drug O O
interactions O O
of O O
TAXOTERE B-brand B-brand
with O O
other O O
medications O O
. O O

Amphetamines B-group B-group
may O O
enhance O O
the O O
effects O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
. O O

Immunologic O O

In O O
clinical O O
trials O O
, O O
the O O
concomitant O O
administration O O
of O O
sulfadoxine B-drug B-drug
and O O
pyrimethamine B-drug B-drug
did O O
not O O
alter O O
the O O
adverse O O
reaction O O
profile O O
. O O

Coadministration O O
of O O
VIRACEPT B-brand B-brand
and O O
drugs O O
that O O
induce O O
CYP3A O O
may O O
decrease O O
nelfinavir B-drug B-drug
plasma O O
concentrations O O
and O O
reduce O O
its O O
therapeutic O O
effect O O
. O O

CYP3A4 O O
inhibitors O O
: O O
May O O
increase O O
the O O
levels/effects O O
of O O
chlorpheniramine B-drug B-drug
. O O

Results O O
from O O
human O O
in O O
vitro O O
metabolism O O
studies O O
and O O
nonclinical O O
studies O O
show O O
that O O
REVLIMID B-brand B-brand
( O O
lenalidomide B-drug B-drug
) O O
is O O
neither O O
metabolized O O
by O O
nor O O
inhibits O O
or O O
induces O O
the O O
cytochrome O O
P450 O O
pathway O O
suggesting O O
that O O
lenalidomide B-drug B-drug
is O O
not O O
likely O O
to O O
cause O O
or O O
be O O
subject O O
to O O
P450-based O O
metabolic O O
drug O O
interactions O O
in O O
man O O
. O O

The O O
effects O O
of O O
ketamine B-drug B-drug
and O O
of O O
Innovar B-brand B-brand
anesthesia O O
on O O
digitalis B-group B-group
tolerance O O
in O O
dogs O O
. O O

The O O
potential O O
effects O O
of O O
fulvestrant B-drug B-drug
on O O
the O O
fertility O O
of O O
male O O
animals O O
were O O
not O O
studied O O
but O O
in O O
a O O
6-month O O
toxicology O O
study O O
, O O
male O O
rats O O
treated O O
with O O
intramuscular O O
doses O O
of O O
15 O O
mg/kg/30 O O
days O O
, O O
10 O O
mg/rat/30 O O
days O O
, O O
or O O
10 O O
mg/rat/15 O O
days O O
fulvestrant B-drug B-drug
showed O O
a O O
loss O O
of O O
spermatozoa O O
from O O
the O O
seminiferous O O
tubules O O
, O O
seminiferous O O
tubular O O
atrophy O O
, O O
and O O
degenerative O O
changes O O
in O O
the O O
epididymides O O
. O O

Talk O O
to O O
your O O
doctor O O
and O O
pharmacist O O
before O O
taking O O
any O O
prescription O O
or O O
over-the-counter O O
medicines O O
, O O
including O O
herbal O O
products O O
. O O

If O O
you O O
are O O
taking O O
medications O O
for O O
migraines O O
such O O
as O O
Imitrex B-brand B-brand
, O O
talk O O
to O O
your O O
doctor O O
before O O
starting O O
this O O
medicine O O
. O O

Consequently O O
, O O
it O O
is O O
recommended O O
that O O
fluvoxamine B-drug B-drug
not O O
be O O
used O O
in O O
combination O O
with O O
either O O
terbinafine B-drug B-drug
, O O
astemizole B-drug B-drug
, O O
or O O
cisapride B-drug B-drug
. O O

In O O
a O O
similar O O
study O O
with O O
tamsulosin B-drug B-drug
in O O
healthy O O
volunteers O O
, O O
1 O O
of O O
24 O O
subjects O O
dosed O O
with O O
Vardenafil B-drug B-drug
20 O O
mg O O
and O O
tamsulosin B-drug B-drug
0.4 O O
mg O O
separated O O
by O O
6 O O
hours O O
experienced O O
a O O
standing O O
systolic O O
blood O O
pressure O O
below O O
85 O O
mm O O
Hg O O
. O O

Doses O O
of O O
these O O
and O O
perhaps O O
other O O
medications O O
may O O
need O O
to O O
be O O
adjusted O O
in O O
patients O O
who O O
successfully O O
quit O O
smoking O O
. O O

However O O
, O O
no O O
related O O
changes O O
were O O
noted O O
in O O
the O O
QT0 O O
on O O
ECG O O
taken O O
at O O
2 O O
, O O
6 O O
, O O
and O O
24 O O
hours O O
after O O
the O O
coadministration O O
. O O

The O O
effect O O
of O O
gabapentin B-drug B-drug
on O O
cimetidine B-drug B-drug
was O O
not O O
evaluated O O
. O O

However O O
, O O
in O O
clinical O O
studies O O
the O O
consequences O O
of O O
concomitant O O
irbesartan B-drug B-drug
on O O
the O O
pharmacodynamics O O
of O O
warfarin B-drug B-drug
were O O
negligible O O
. O O

When O O
patients O O
have O O
received O O
such O O
drugs O O
, O O
the O O
dose O O
of O O
INAPSINE B-brand B-brand
required O O
will O O
be O O
less O O
than O O
usual O O
. O O

Pyrantel B-drug B-drug
( O O
e.g. O O
, O O
Antiminth B-drug B-brand
) O O
- O O
Taking O O
piperazine B-drug B-drug
and O O
pyrantel B-drug B-drug
together O O
may O O
decrease O O
the O O
effects O O
of O O
piperazine B-drug B-drug
. O O

The O O
clinical O O
significance O O
of O O
this O O
observation O O
is O O
unknown O O
. O O

The O O
administrative O O
arrangements O O
in O O
an O O
area O O
of O O
Scotland O O
were O O
accompanied O O
by O O
a O O
300 O O
% O O
increase O O
in O O
the O O
frequency O O
of O O
admissions O O
for O O
mania O O
, O O
whereas O O
in O O
an O O
area O O
of O O
the O O
West O O
Midlands O O
, O O
a O O
large O O
decrease O O
was O O
achieved O O
. O O

However O O
, O O
it O O
should O O
be O O
noted O O
that O O
both O O
products O O
are O O
capable O O
of O O
producing O O
transient O O
increases O O
in O O
blood O O
pressure O O
. O O

Probenecid B-drug B-drug
given O O
concurrently O O
increases O O
naproxen B-drug B-drug
anion O O
plasma O O
levels O O
and O O
extends O O
its O O
plasma O O
half-life O O
significantly O O
. O O

Concomitant O O
administration O O
of O O
ketoconazole B-drug B-drug
tablets O O
with O O
phenytoin B-drug B-drug
may O O
alter O O
the O O
metabolism O O
of O O
one O O
or O O
both O O
of O O
the O O
drugs O O
. O O

Adrenergic B-group B-group
blockers I-group I-group
Adrenergic I-group I-group
blockers I-group I-group
are O O
inhibited O O
by O O
amphetamines B-group B-group
. O O

Since O O
there O O
have O O
been O O
conflicting O O
results O O
regarding O O
the O O
effect O O
of O O
digoxin B-drug B-drug
levels O O
, O O
it O O
is O O
recommended O O
that O O
digoxin B-drug B-drug
levels O O
be O O
monitored O O
when O O
initiating O O
, O O
adjusting O O
, O O
and O O
discontinuing O O
diltiazem B-drug B-drug
hydrochloride I-drug I-drug
therapy O O
to O O
avoid O O
possible O O
over- O O
or O O
under-digitalization O O
. O O

However O O
, O O
caution O O
must O O
be O O
exercised O O
in O O
extrapolating O O
these O O
findings O O
to O O
the O O
clinical O O
situation O O
and O O
in O O
the O O
use O O
of O O
glipizide B-drug B-drug
with O O
these O O
drugs O O
. O O

The O O
daily O O
dose O O
of O O
dexamethasone B-drug B-drug
administered O O
in O O
clinical O O
studies O O
with O O
Aprepitant B-drug B-drug
reflects O O
an O O
approximate O O
50 O O
% O O
reduction O O
of O O
the O O
dose O O
of O O
dexamethasone B-drug B-drug
. O O

During O O
controlled O O
hypotensive O O
anesthesia O O
using O O
labetalol B-drug B-drug
HCl I-drug I-drug
in O O
association O O
with O O
halothane B-drug B-drug
, O O
high O O
concentrations O O
( O O
3 O O
% O O
or O O
above O O
) O O
of O O
halothane B-drug B-drug
should O O
not O O
be O O
used O O
because O O
the O O
degree O O
of O O
hypotension O O
will O O
be O O
increased O O
and O O
because O O
of O O
the O O
possibility O O
of O O
a O O
large O O
reduction O O
in O O
cardiac O O
output O O
and O O
an O O
increase O O
in O O
central O O
venous O O
pressure O O
. O O

It O O
is O O
desirable O O
to O O
monitor O O
TCA B-group B-group
plasma O O
levels O O
whenever O O
a O O
TCA B-group B-group
is O O
going O O
to O O
be O O
co-administered O O
with O O
another O O
drug O O
known O O
to O O
be O O
an O O
inhibitor O O
of O O
P450 O O
2D6 O O
. O O

Formal O O
drug O O
interaction O O
studies O O
with O O
Abciximab B-drug B-drug
have O O
not O O
been O O
conducted O O
. O O

Bosentan B-drug B-drug
had O O
no O O
relevant O O
inhibitory O O
effect O O
on O O
any O O
CYP O O
isoenzymes O O
tested O O
( O O
CYP1A2 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
CYP2D6 O O
, O O
CYP3A4 O O
) O O
. O O

Therefore O O
, O O
coagulation O O
indices O O
should O O
be O O
monitored O O
frequently O O
to O O
maintain O O
the O O
desired O O
anticoagulant O O
effect O O
. O O

indinavir I-drug B-drug
concentration O O

- O O
Lofexidine B-drug B-drug
may O O
enhance O O
the O O
CNS O O
depressive O O
effects O O
of O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
and O O
other O O
sedatives B-group B-group

When O O
s.c O O
. O O

Population O O
pharmacokinetic O O
analyses O O
revealed O O
that O O
MTX B-drug B-drug
, O O
NSAIDs B-group B-group
, O O
corticosteroids B-group B-group
, O O
and O O
TNF B-group B-group
blocking I-group I-group
agents I-group I-group
did O O
not O O
influence O O
abatacept B-drug B-drug
clearance O O
. O O

Carcinogenesis O O
, O O
Mutagenesis O O
, O O
Impairment O O
of O O
Fertility O O
Carcinogenesis O O
PEGASYS B-brand B-brand
has O O
not O O
been O O
tested O O
for O O
its O O
carcinogenic O O
potential O O
. O O

Alosetron B-drug B-drug
also O O
does O O
not O O
appear O O
to O O
induce O O
CYP O O
enzymes O O
2E1 O O
or O O
2C19 O O
. O O

There O O
is O O
now O O
strong O O
evidence O O
that O O
intensive O O
control O O
of O O
blood O O
glucose O O
can O O
significantly O O
reduce O O
and O O
retard O O
the O O
microvascular O O
complications O O
of O O
retinopathy O O
, O O
nephropathy O O
, O O
and O O
neuropathy O O
. O O

20 O O
mg O O
result O O
in O O
incomplete O O
depletion O O
which O O
becomes O O
complete O O
after O O
a O O
second O O
additional O O
dose O O
. O O

Excessive O O
widening O O
of O O
the O O
QRS O O
complex O O
and/or O O
prolongation O O
of O O
the O O
Q-T O O
interval O O
may O O
occur O O
in O O
these O O
situations O O
. O O

These O O
effects O O
of O O
calcium B-group B-group
blockers I-group I-group
on O O
platelet O O
function O O
and O O
arachidonic O O
acid O O
metabolism O O
could O O
contribute O O
in O O
part O O
to O O
their O O
efficacy O O
in O O
patients O O
with O O
ischemic O O
heart O O
disease O O
. O O

Antithrombotics B-group B-group

pruritus O O

Lovastatin B-drug B-drug

Palytoxin B-drug_n B-drug_n
( O O
PTX B-drug_n B-drug_n
) O O
, O O
C129H223N3O54 O O
, O O
isolated O O
from O O
marine O O
coelenterates O O
of O O
Palythoa O O
tuberculosa O O
, O O
caused O O
a O O
first O O
rapid O O
contraction O O
followed O O
by O O
the O O
slow O O
phasic O O
contraction O O
of O O
guinea-pig O O
vas O O
deferens O O
. O O

If O O
TRANXENE B-brand B-brand
tablets O O
are O O
used O O
to O O
treat O O
anxiety O O
associated O O
with O O
somatic O O
disease O O
states O O
, O O
careful O O
attention O O
must O O
be O O
paid O O
to O O
possible O O
drug O O
interaction O O
with O O
concomitant O O
medication O O
. O O

Cancer O O
chemotherapy O O

Drugs O O
Within O O
Class O O
Not O O
To O O
Be O O
Coadministered O O
With O O
SUSTIVA B-brand B-brand

Every O O
other O O
day O O
dosing O O
with O O
100m O O
g/kg O O
( O O
1200m O O
g/m2 O O
) O O
PEGASYS B-brand B-brand
( O O
equivalent O O
to O O
approximately O O
30 O O
times O O
the O O
recommended O O
human O O
dose O O
) O O
had O O
no O O
effects O O
on O O
cycle O O
duration O O
or O O
reproductive O O
hormone O O
status O O
. O O

Symptoms O O
resolved O O
when O O
clonidine B-drug B-drug
was O O
withdrawn O O
and O O
recurred O O
when O O
the O O
patient O O
was O O
rechallenged O O
with O O
clonidine B-drug B-drug
. O O

Rearrangements O O
of O O
genomes O O
have O O
been O O
found O O
to O O
accompany O O
cellular O O
aging O O
. O O

Anagrelide B-drug B-drug
demonstrates O O
some O O
limited O O
inhibitory O O
activity O O
towards O O
CYP1A2 O O
which O O
may O O
present O O
a O O
theoretical O O
potential O O
for O O
interaction O O
with O O
other O O
coadministered O O
medicinal O O
products O O
sharing O O
that O O
clearance O O
mechanism O O
e.g O O
. O O
theophylline B-drug B-drug
. O O

Cefuroxime B-drug B-drug
does O O
not O O
interfere O O
with O O
the O O
assay O O
of O O
serum O O
and O O
urine O O
creatinine O O
by O O
the O O
alkaline O O
picrate O O
method O O
. O O

Because O O
of O O
the O O
danger O O
of O O
a O O
potentially O O
fatal O O
prolongation O O
of O O
the O O
QTc O O
interval O O
, O O
halofantrine B-drug B-drug
must O O
not O O
be O O
given O O
simultaneously O O
with O O
or O O
subsequent O O
to O O
Mefloquine B-drug B-drug
. O O

He O O
was O O
treated O O
aggressively O O
with O O
intravenous O O
hydration O O
, O O
sodium B-drug B-drug
bicarbonate I-drug I-drug
, O O
and O O
hemodialysis O O
. O O

Alcohol B-drug B-drug
, O O
in O O
particular O O
, O O
has O O
been O O
found O O
to O O
exhibit O O
additive O O
effects O O
of O O
this O O
variety O O
. O O

indinavir I-drug B-drug
concentration O O

Since O O
the O O
pharmacokinetics O O
of O O
BUSULFEX B-brand B-brand
were O O
studied O O
in O O
patients O O
treated O O
with O O
phenytoin B-drug B-drug
, O O
the O O
clearance O O
of O O
BUSULFEX B-brand B-brand
at O O
the O O
recommended O O
dose O O
may O O
be O O
lower O O
and O O
exposure O O
( O O
AUC O O
) O O
higher O O
in O O
patients O O
not O O
treated O O
with O O
phenytoin B-drug B-drug
. O O

Effects O O
of O O
Other O O
Antiepileptic B-group B-group
Drugs I-group I-group
on O O
Felbatol B-brand B-brand
Phenytoin B-drug B-drug
: O O
Phenytoin B-drug B-drug
causes O O
an O O
approximate O O
doubling O O
of O O
the O O
clearance O O
of O O
Felbatol B-brand B-brand
( O O
felbamate B-drug B-drug
) O O
at O O
steady O O
state O O
and O O
, O O
therefore O O
, O O
the O O
addition O O
of O O
phenytoin B-drug B-drug
causes O O
an O O
approximate O O
45 O O
% O O
decrease O O
in O O
the O O
steady-state O O
trough O O
concentrations O O
of O O
Felbatol B-brand B-brand
as O O
compared O O
to O O
the O O
same O O
dose O O
of O O
Felbatol B-brand B-brand
given O O
as O O
monotherapy O O
. O O

[ O O
Pharmacologic O O
interactions O O
in O O
chronic O O
treatments O O
: O O
corrective O O
measures O O
for O O
its O O
prevention O O
in O O
a O O
basic O O
area O O
of O O
rural O O
health O O
] O O
OBJECTIVES O O
: O O
To O O
identify O O
the O O
pharmacological O O
interactions O O
of O O
clinical O O
relevance O O
( O O
PICR O O
) O O
in O O
the O O
medication O O
authorization O O
cards O O
( O O
MAC O O
) O O
of O O
the O O
chronically O O
ill O O
and O O
to O O
establish O O
strategies O O
to O O
minimise O O
their O O
appearance O O
. O O

As O O
a O O
result O O
, O O
drugs O O
that O O
are O O
metabolized O O
by O O
these O O
enzyme O O
systems O O
may O O
have O O
lower O O
than O O
expected O O
plasma O O
levels O O
when O O
coadministered O O
with O O
nevirapine B-drug B-drug
. O O

General O O
: O O
In O O
humans O O
, O O
valdecoxib B-drug B-drug
metabolism O O
is O O
predominantly O O
mediated O O
via O O
CYP O O
3A4 O O
and O O
2C9 O O
with O O
glucuronidation O O
being O O
a O O
further O O
( O O
20 O O
% O O
) O O
route O O
of O O
metabolism O O
. O O

International O O
Normalized O O
Ratio O O
( O O
INR O O
) O O
elevations O O
and/or O O
bleeding O O
events O O
have O O
been O O
reported O O
in O O
some O O
patients O O
taking O O
warfarin B-drug B-drug
while O O
on O O
IRESSA B-brand B-brand
therapy O O
. O O

There O O
have O O
been O O
case O O
reports O O
of O O
increased O O
steady-state O O
levels O O
of O O
quinidine B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
and O O
phenytoin B-drug B-drug
during O O
concomitant O O
therapy O O
with O O
amiodarone B-drug B-drug
. O O

Since O O
1988 O O
, O O
it O O
has O O
been O O
noted O O
that O O
incidence O O
of O O
melarsoprol B-drug B-drug
reaction O O
had O O
increased O O
systematically O O
between O O
June O O
and O O
October O O
of O O
each O O
year O O
, O O
indicating O O
strong O O
seasonal O O
variation O O
. O O

Treatment O O
plans O O
for O O
patients O O
taking O O
anticoagulants B-group B-group
can O O
become O O
complicated O O
. O O

It O O
is O O
recommended O O
that O O
glucose O O
tests O O
based O O
on O O
enzymatic O O
glucose O O
oxidase O O
reactions O O
( O O
such O O
as O O
CLINISTIX O O
or O O
TES-TAPE O O
) O O
be O O
used O O
. O O

Saquinavir I-drug B-drug

There O O
is O O
no O O
evidence O O
in O O
animal O O
or O O
human O O
studies O O
that O O
TORADOL B-brand B-brand
induces O O
or O O
inhibits O O
hepatic O O
enzymes O O
capable O O
of O O
metabolizing O O
itself O O
or O O
other O O
drugs O O

Coadministration O O
of O O
propoxyphene B-drug B-drug
decreased O O
the O O
maximum O O
plasma O O
concentration O O
of O O
alprazolam B-drug B-drug
by O O
6 O O
% O O
, O O
decreased O O
clearance O O
by O O
38 O O
% O O
, O O
and O O
increased O O
half-life O O
by O O
58 O O
% O O
. O O

No O O
formal O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

A O O
similar O O
association O O
, O O
though O O
less O O
marked O O
, O O
has O O
been O O
suggested O O
with O O
barbiturates B-group B-group
, O O
phenyl-butazone O O
, O O
phenytoin B-drug B-drug
sodium I-drug I-drug
, O O
carbamazepine B-drug B-drug
and O O
possibly O O
with O O
griseofulvin B-drug B-drug
, O O
ampicillin B-drug B-drug
, O O
and O O
tetracyclines B-group B-group
( O O
72 O O
) O O

Pharmacokinetic O O
interaction O O
between O O
single O O
oral O O
doses O O
of O O
diltiazem B-drug B-drug
and O O
sirolimus B-drug B-drug
in O O
healthy O O
volunteers O O
. O O

Resveratrol B-drug_n B-drug_n
( O O
5-35 O O
micromol/l O O
) O O
induced O O
concentration-dependent O O
relaxation O O
of O O
mesenteric O O
arteries O O
preconstricted O O
with O O
noradrenaline B-drug B-drug
( O O
8 O O
micromol/l O O
) O O
or O O
KCl B-drug B-drug
( O O
125 O O
mmol/l O O
) O O
from O O
both O O
lean O O
and O O
dietary-obese O O
rats O O
. O O

When O O
such O O
combined O O
therapy O O
is O O
contemplated O O
, O O
the O O
dose O O
of O O
one O O
or O O
both O O
agents O O
should O O
be O O
significantly O O
reduced O O
. O O

Clinical O O
studies O O
have O O
shown O O
that O O
atorvastatin B-drug B-drug
does O O
not O O
reduce O O
basal O O
plasma O O
cortisol O O
concentration O O
or O O
impair O O
adrenal O O
reserve O O
. O O

CNS-Active O O
Drugs O O
Ethanol B-drug B-drug
An O O
additive O O
effect O O
on O O
psychomotor O O
performance O O
was O O
seen O O
with O O
coadministration O O
of O O
eszopiclone B-drug B-drug
and O O
ethanol B-drug B-drug
0.70 O O
g/kg O O
for O O
up O O
to O O
4 O O
hours O O
after O O
ethanol B-drug B-drug
administration O O
. O O

In O O
response O O
to O O
cocaine B-drug B-drug
, O O
the O O
locomotor O O
activities O O
of O O
the O O
SST O O
were O O
not O O
significantly O O
different O O
from O O
the O O
RBC O O
group O O
. O O

In O O
previous O O
reports O O
we O O
have O O
shown O O
that O O
ginsenosides B-drug_n B-drug_n
inhibit O O
high O O
threshold O O
voltage-dependent O O
Ca O O
( O O
2+ O O
) O O
channels O O
in O O
neuronal O O
cells O O
. O O

oxyphenbutazone B-drug B-drug
; O O

The O O
plasma O O
concentrations O O
of O O
bosentan B-drug B-drug
were O O
not O O
affected O O
. O O

Hypoglycemics B-group B-group
and O O
endocrine O O
drugs O O
. O O

Antiarrhythmics B-group B-group
: O O
Amiodarone B-drug B-drug
, O O
bepridil B-drug B-drug
, O O
flecainide B-drug B-drug
, O O
propafenone B-drug B-drug
, O O
quinidine B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
. O O

H2-Receptor B-group B-group
Antagonists I-group I-group
: O O
Co-administration O O
of O O
a O O
single O O
dose O O
of O O
intravenously O O
administered O O
famotidine B-drug B-drug
( O O
20 O O
mg O O
) O O
reduced O O
the O O
oral O O
absorption O O
of O O
a O O
single O O
400 O O
mg O O
dose O O
of O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
administered O O
following O O
a O O
meal O O
, O O
as O O
evidenced O O
by O O
a O O
27 O O
% O O
decrease O O
in O O
mean O O
Cmax O O
and O O
a O O
22 O O
% O O
decrease O O
in O O
mean O O
AUC O O
. O O

Everolimus B-drug B-drug
exposure-response O O
relationships O O
between O O
area O O
under O O
the O O
blood O O
concentration-time O O
curve O O
( O O
AUC O O
) O O
and O O
changes O O
in O O
platelets O O
, O O
leukocytes O O
, O O
and O O
lipids O O
were O O
explored O O
with O O
the O O
median-effect O O
model O O
. O O

Thus O O
, O O
patients O O
should O O
be O O
cautioned O O
about O O
the O O
use O O
of O O
such O O
drugs O O
concurrently O O
with O O
LEXAPRO B-brand B-brand
. O O

Oils O O
may O O
enhance O O
absorption O O
. O O

Drugs O O
Highly O O
Bound O O
To O O
Plasma O O
Protein O O
Eszopiclone B-drug B-drug
is O O
not O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
52-59 O O
% O O
bound O O
) O O
; O O

however O O
, O O
a O O
comparison O O
of O O
fluvastatin B-drug B-drug
administration O O
with O O
the O O
evening O O
meal O O
or O O
at O O
bedtime O O
has O O
revealed O O
no O O
significant O O
differences O O
in O O
the O O
extent O O
of O O
bioavailability O O
( O O
area O O
under O O
the O O
curve O O
) O O
of O O
these O O
two O O
regimens O O
. O O

Patients O O
receiving O O
catecholamine-depleting O O
drugs O O
, O O
such O O
as O O
reserpine B-drug B-drug
or O O
guanethidine B-drug B-drug
, O O
should O O
be O O
closely O O
monitored O O
, O O
because O O
the O O
added O O
beta-adrenergic O O
blocking O O
action O O
of O O
ZEBETA B-brand B-brand
may O O
produce O O
excessive O O
reduction O O
of O O
sympathetic O O
activity O O
. O O

The O O
benefits O O
and O O
risks O O
of O O
using O O
TRICOR B-brand B-brand
with O O
immunosuppressants B-group B-group
and O O
other O O
potentially O O
nephrotoxic O O
agents O O
should O O
be O O
carefully O O
considered O O
, O O
and O O
the O O
lowest O O
effective O O
dose O O
employed O O

The O O
16,16-dimethylprostaglandin B-drug_n B-drug_n
E2 I-drug_n I-drug_n
( O O
dmPGE2 B-drug_n B-drug_n
) O O
-induced O O
diarrhea O O
was O O
analyzed O O
in O O
cecectomized O O
rats O O
prepared O O
by O O
resecting O O
the O O
cecum O O
and O O
its O O
vasculature O O
without O O
disturbing O O
the O O
ileocecal O O
junction O O
. O O

In O O
vitro O O
studies O O
in O O
human O O
liver O O
microsomes O O
suggest O O
that O O
decitabine B-drug B-drug
is O O
unlikely O O
to O O
inhibit O O
or O O
induce O O
cytochrome O O
P450 O O
enzymes O O
. O O

In O O
one O O
controlled O O
study O O
of O O
175 O O
patients O O
, O O
transient O O
drowsiness O O
was O O
observed O O
in O O
63 O O
% O O
of O O
those O O
receiving O O
baclofen B-drug B-drug
tablets O O
compared O O
to O O
36 O O
% O O
of O O
those O O
in O O
the O O
placebo O O
group O O
. O O

HMG-CoA B-drug B-group
Reductase I-drug I-group
Inhibitors I-drug I-group
: O O
Simvastatin B-drug B-drug
( O O
CYP3A4 B-drug O
substrate O O
) O O
in O O
combination O O
with O O
amiodarone B-drug B-drug
has O O
been O O
associated O O
with O O
reports O O
of O O
myopathy/rhabdomyolysis O O
. O O

The O O
majority O O
of O O
patients O O
in O O
rheumatoid O O
arthritis O O
or O O
Crohn O O
s O O
disease O O
clinical O O
studies O O
received O O
one O O
or O O
more O O
concomitant O O
medications O O
. O O

Danazol B-drug B-drug
: O O
The O O
risk O O
of O O
myopathy/rhabdomyolysis O O
is O O
increased O O
by O O
concomitant O O
administration O O
of O O
danazol B-drug B-drug
particularly O O
with O O
higher O O
doses O O
of O O
lovastatin B-drug B-drug
( O O
see O O
WARNINGS O O
, O O
Myopathy/Rhabdomyolysis O O
) O O
. O O

one-half O O
the O O
human O O
dose O O
on O O
BSA O O
) O O
when O O
administered O O
during O O
the O O
period O O
of O O
organogenesis O O
. O O

Close O O
observation O O
of O O
the O O
patient O O
is O O
recommended O O
when O O
a O O
beta-blocker B-group B-group
is O O
administered O O
to O O
patients O O
receiving O O
catecholamine-depleting O O
drugs O O
such O O
as O O
reserpine B-drug B-drug
, O O
because O O
of O O
possible O O
additive O O
effects O O
and O O
the O O
production O O
of O O
hypotension O O
and/or O O
marked O O
bradycardia O O
, O O
which O O
may O O
produce O O
vertigo O O
, O O
syncope O O
, O O
or O O
postural O O
hypotension O O
. O O

These O O
findings O O
suggest O O
that O O
the O O
phenotype O O
of O O
a O O
tumor O O
that O O
results O O
from O O
a O O
pulse O O
of O O
a O O
chemical O O
carcinogen O O
may O O
depend O O
upon O O
the O O
target O O
cell O O
. O O

Ergot B-group B-group
Derivatives I-group I-group
: O O
Dihydroergotamine B-drug B-drug
, O O
ergonovine B-drug B-drug
, O O
ergotamine B-drug B-drug
, O O
methylergonovine B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and O O
life-threatening O O
reactions O O
such O O
as O O
acute O O
ergot B-group O
toxicity O O
characterized O O
by O O
peripheral O O
vasospasm O O
and O O
ischemia O O
of O O
the O O
extremities O O
and O O
other O O
tissues O O
. O O

Measurement O O
of O O
nociception O O
was O O
performed O O
within O O
2 O O
h O O
after O O
benzodiazepine B-group B-group
administration O O
. O O

Epirubicin B-drug B-drug
is O O
extensively O O
metabolized O O
by O O
the O O
liver O O
. O O

After O O
consumption O O
of O O
alcohol B-drug B-drug
, O O
at O O
least O O
36 O O
hours O O
should O O
elapse O O
before O O
these O O
determinations O O
are O O
made O O
. O O

If O O
it O O
is O O
necessary O O
to O O
continue O O
the O O
diuretic B-group B-group
, O O
provide O O
close O O
medical O O
supervision O O
after O O
the O O
initial O O
dose O O
for O O
at O O
least O O
two O O
hours O O
and O O
until O O
blood O O
pressure O O
has O O
stabilized O O
for O O
at O O
least O O
an O O
additional O O
hour.. O O

The O O
magnitude O O
of O O
these O O
effects O O
may O O
depend O O
on O O
the O O
duration O O
of O O
administration O O
of O O
the O O
volatile O O
agents O O
. O O

Phenytoin B-drug B-drug
: O O
Population O O
pharmacokinetic O O
analyses O O
indicate O O
that O O
tiagabine B-drug B-drug
clearance O O
is O O
60 O O
% O O
greater O O
in O O
patients O O
taking O O
phenytoin B-drug B-drug
with O O
or O O
without O O
other O O
enzyme- O O
inducing O O
AEDs B-group B-group
. O O

In O O
addition O O
, O O
we O O
have O O
shown O O
that O O
RR B-drug_n B-drug_n
is O O
a O O
useful O O
pharmacological O O
tool O O
with O O
which O O
to O O
examine O O
the O O
InsP B-drug_n B-drug_n
( I-drug_n I-drug_n
3 I-drug_n I-drug_n
) I-drug_n I-drug_n
-mediated O O
responses O O
of O O
megakaryocytes O O
. O O

Conversely O O
, O O
the O O
administration O O
of O O
STADOL B-brand B-brand
NS I-brand I-brand
( O O
1 O O
mg O O
butorphanol B-drug B-drug
QID O O
) O O
did O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
a O O
300-mg O O
dose O O
of O O
cimetidine B-drug B-drug
. O O

Rifabutin B-drug B-drug

The O O
clinical O O
effects O O
of O O
this O O
combination O O
have O O
not O O
been O O
studied O O
. O O

No O O
drug O O
interactions O O
have O O
been O O
reported O O
. O O

The O O
next O O
chapter O O
presents O O
information O O
on O O
efficacy O O
and O O
pregnancy O O
outcomes O O
in O O
terms O O
of O O
pregnancy O O
rates O O
, O O
compliance O O
and O O
efficacy O O
, O O
ectopic O O
pregnancies O O
, O O
the O O
outcome O O
of O O
pregnancies O O
conceived O O
while O O
using O O
POCs B-group B-group
, O O
and O O
fertility O O
following O O
discontinuation O O
. O O

Interactions O O
between O O
Betaseron B-brand B-brand
and O O
other O O
drugs O O
have O O
not O O
been O O
fully O O
evaluated O O
. O O

There O O
have O O
been O O
no O O
reported O O
cases O O
from O O
spontaneous O O
reports O O
of O O
drug O O
interaction O O
between O O
SSRIs B-group B-group
and O O
D.H.E B-brand B-brand
. I-brand I-brand
45 I-brand I-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
. O O

increased O O
bilirubin O O

A O O
small O O
number O O
of O O
patients O O
received O O
epirubicin-based B-drug B-drug
chemotherapy O O
concomitantly O O
with O O
radiation O O
therapy O O
but O O
had O O
chemotherapy O O
interrupted O O
in O O
order O O
to O O
avoid O O
potential O O
overlapping O O
toxicities O O
. O O

Laboratory O O
Test O O
In O O
clinical O O
trials O O
, O O
no O O
clinically O O
relevant O O
laboratory O O
test O O
abnormalities O O
were O O
identified O O
as O O
causally O O
related O O
to O O
drug O O
during O O
short-term O O
treatment O O
with O O
guanfacine B-drug B-drug
. O O

These O O
reactions O O
consisted O O
of O O
erythema O O
, O O
pruritus O O
, O O
and O O
hypotension O O
and O O
occurred O O
within O O
hours O O
of O O
administration O O
of O O
chemotherapy O O
. O O

Although O O
much O O
statistical O O
work O O
has O O
focused O O
on O O
developing O O
mathematical O O
functions O O
to O O
model O O
the O O
joint O O
dose-response O O
curves O O
, O O
relatively O O
little O O
work O O
exists O O
in O O
regard O O
to O O
designing O O
experiments O O
for O O
assessing O O
joint O O
action O O
. O O

PEGASYS B-brand B-brand
is O O
recommended O O
for O O
use O O
in O O
women O O
of O O
childbearing O O
potential O O
only O O
when O O
they O O
are O O
using O O
effective O O
contraception O O
during O O
therapy O O
. O O

The O O
extent O O
to O O
which O O
SSRI-TCA B-group B-group
interactions O O
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

Lithium B-drug B-drug
carbonate I-drug I-drug
( O O
450 O O
mg O O
BID O O
for O O
7 O O
days O O
) O O
had O O
no O O
effect O O
on O O
valdecoxib B-drug B-drug
pharmacokinetics O O
. O O

Lithium B-drug B-drug
salts O O

therefore O O
, O O
these O O
combinations O O
should O O
be O O
used O O
with O O
caution O O
. O O

Phenobarbital B-drug B-drug

Vasospastic O O
reactions O O
have O O
been O O
reported O O
with O O
therapeutic O O
doses O O
of O O
ergotamine-containing B-drug B-drug
drugs O O
when O O
co-administered O O
with O O
these O O
antibiotics B-group B-group
. O O

Apparent O O
oral O O
clearance O O
and O O
volume O O
of O O
distribution O O
of O O
sirolimus B-drug B-drug
decreased O O
with O O
38 O O
% O O
and O O
45 O O
% O O
, O O
respectively O O
, O O
when O O
sirolimus B-drug B-drug
was O O
given O O
with O O
diltiazem B-drug B-drug
. O O

The O O
interaction O O
of O O
prostaglandin B-drug B-drug
F2alpha I-drug I-drug
and O O
synthetic O O
oxytocin B-drug B-drug
on O O
placental O O
vessels O O
was O O
studied O O
in O O
vitro O O
. O O

Urinary O O
alkalinizing O O
agents O O
increase O O
blood O O
levels O O
and O O
decrease O O
excretion O O
of O O
amphetamines B-group B-group
. O O

( O O
500 O O
mg O O
day O O
1 O O
, O O
250 O O
mg O O
QD O O
4 O O
days O O
) O O

METHODS O O
: O O
Hydrocortisone B-drug B-drug
( O O
100 O O
mg O O
) O O
and O O
d-amphetamine B-drug B-drug
( O O
20 O O
mg O O
) O O
were O O
administered O O
orally O O
to O O
16 O O
healthy O O
male O O
and O O
female O O
volunteers O O
in O O
a O O
four-session O O
, O O
placebo-controlled O O
, O O
within-subject O O
, O O
crossover O O
design O O
. O O

The O O
world O O
medical O O
literature O O
contains O O
43 O O
reports O O
of O O
deaths O O
associated O O
with O O
amphetamines B-drug B-group
in O O
a O O
35-year O O
period O O
. O O

Cardiovasculars O O
: O O
Cardiac B-drug B-group
glycosides I-drug I-group
: O O
In O O
patients O O
receiving O O
digoxin B-drug B-drug
therapy O O
, O O
administration O O
of O O
oral O O
amiodarone B-drug B-drug
regularly O O
results O O
in O O
an O O
increase O O
in O O
serum O O
digoxin B-drug B-drug
concentration O O
that O O
may O O
reach O O
toxic O O
levels O O
with O O
resultant O O
clinical O O
toxicity O O
. O O

Drugs O O
Metabolized O O
by O O
P450 O O
2D6 O O
: O O
The O O
biochemical O O
activity O O
of O O
the O O
drug O O
metabolizing O O
isozyme O O
cytochrome O O
P450 O O
2D6 O O
( O O
debrisoquin O O
hydroxylase O O
) O O
is O O
reduced O O
in O O
a O O
subset O O
of O O
the O O
caucasian O O
population O O
( O O
about O O
7 O O
to O O
10 O O
% O O
of O O
caucasians O O
are O O
so O O
called O O
poor O O
metabolizers O O
) O O
; O O

New O O
oral O O
therapies O O
for O O
type O O
2 O O
diabetes O O
mellitus O O
: O O
The O O
glitazones B-group B-group
or O O
insulin O B-drug
sensitizers O O
. O O

CONCLUSIONS O O
: O O
In O O
contrast O O
to O O
the O O
effects O O
of O O
glucocorticoids B-group B-group
in O O
rodent O O
studies O O
, O O
these O O
results O O
indicate O O
that O O
an O O
acute O O
increase O O
in O O
cortisol O O
does O O
not O O
enhance O O
the O O
psychostimulant O O
effects O O
of O O
d-amphetamine B-drug B-drug
in O O
humans O O
. O O

In O O
addition O O
, O O
ketoconazole B-drug B-drug
alone O O
can O O
inhibit O O
adrenal O O
corticosteroid B-drug O
synthesis O O
and O O
may O O
cause O O
adrenal O O
insufficiency O O
during O O
corticosteroid O O
withdrawal O O
. O O

Aspirin B-brand B-brand
: O O
Concomitant O O
administration O O
of O O
diclofenac B-drug B-drug
and O O
aspirin B-brand B-brand
is O O
not O O
recommended O O
because O O
diclofenac B-drug B-drug
is O O
displaced O O
from O O
its O O
binding O O
sites O O
during O O
the O O
concomitant O O
administration O O
of O O
aspirin B-brand B-brand
, O O
resulting O O
in O O
lower O O
plasma O O
concentrations O O
, O O
peak O O
plasma O O
levels O O
, O O
and O O
AUC O O
values O O
. O O

The O O
clearance O O
of O O
benzodiazepines B-group B-group
metabolized O O
by O O
glucuronidation O O
( O O
e. O O
g. O O
, O O
lorazepam B-drug B-drug
, O O
oxazepam B-drug B-drug
, O O
temazepam B-drug B-drug
) O O
is O O
unlikely O O
to O O
be O O
affected O O
by O O
fluvoxamine B-drug B-drug
. O O

The O O
pharmacokinetics O O
of O O
benzodiazepines B-group B-group
are O O
unaltered O O
in O O
the O O
presence O O
of O O
flumazenil B-drug B-drug
and O O
vice O O
versa O O
. O O

however O O
, O O
the O O
clinical O O
significance O O
is O O
unknown O O
. O O

Other O O
: O O
Neither O O
fosinopril B-drug B-drug
sodium I-drug I-drug
nor O O
its O O
metabolites O O
have O O
been O O
found O O
to O O
interact O O
with O O
food O O
. O O

On O O
the O O
basis O O
of O O
this O O
specificity O O
we O O
describe O O
a O O
simple O O
and O O
reliable O O
affinity O O
chromatography O O
procedure O O
for O O
the O O
purification O O
of O O
both O O
human O O
serum O O
and O O
colostrum O O
IgA O O
. O O

and O O
disulfiram B-drug B-drug
When O O
amitriptyline B-drug B-drug
HCl I-drug I-drug
is O O
given O O
with O O
anticholinergic B-drug B-group
agents O I-group
or O O
sympathomimetic B-drug B-group
drugs O I-group
, O O
including O O
epinephrine B-drug B-drug
combined O O
with O O
local O O
anesthetics B-drug B-group
, O O
close O O
supervision O O
and O O
careful O O
adjustment O O
of O O
dosages O O
are O O
required O O
. O O

Rifabutin B-drug B-drug
: O O
Coadministration O O
of O O
rifabutin B-drug B-drug
and O O
VIRACEPT B-brand B-brand
resulted O O
in O O
a O O
32 O O
% O O
decrease O O
in O O
nelfinavir B-drug B-drug
plasma O O
AUC O O
and O O
a O O
207 O O
% O O
increase O O
in O O
rifabutin B-drug B-drug
plasma O O
A.C O O
. O O

while O O
no O O
formal O O
interaction O O
studies O O
have O O
been O O
conducted O O
, O O
no O O
interactions O O
were O O
observed O O
. O O

Food O O
has O O
no O O
clinically O O
significant O O
effect O O
on O O
the O O
bioavailability O O
of O O
anagrelide B-drug B-drug
. O O

Although O O
no O O
studies O O
have O O
been O O
conducted O O
, O O
concomitant O O
administration O O
of O O
Itraconazole B-drug B-drug
and O O
phenytoin B-drug B-drug
may O O
alter O O
the O O
metabolism O O
of O O
phenytoin B-drug B-drug
; O O

Established O O
Drug O O
Interactions O O
( O O
continued O O
) O O

Potassium-sparing B-group B-group
diuretics I-group I-group
( O O
e.g. O O
, O O
spironolactone B-drug B-drug
, O O
triamterene B-drug B-drug
, O O
or O O
amiloride B-drug B-drug
) O O
, O O
potassium B-drug B-drug
supplements O O
, O O
or O O
potassium-containing B-drug O
salt O O
substitutes O O
may O O
lead O O
to O O
significant O O
increases O O
in O O
serum O O
potassium O O
. O O

This O O
observed O O
increase O O
in O O
the O O
bioavailability O O
of O O
fexofenadine B-drug B-drug
may O O
be O O
due O O
to O O
transport-related O O
effects O O
, O O
such O O
as O O
p-glycoprotein O O
. O O
in O O
vivo O O
animal O O
studies O O
also O O
suggest O O
that O O
in O O
addition O O
to O O
enhancing O O
absorption O O
, O O
ketoconazole B-drug B-drug
decreases O O
fexofenadine B-drug B-drug
gastrointestinal O O
secretion O O
, O O
while O O
erythromycin B-drug B-drug
may O O
also O O
decrease O O
biliary O O
excretion O O
. O O

No O O
pharmacokinetic O O
drug-drug O O
interaction O O
studies O O
were O O
conducted O O
with O O
PERSANTINE B-brand B-brand
( O O
dipyridamole B-drug B-drug
USP O O
) O O
Tablets O O
. O O

There O O
is O O
no O O
experience O O
with O O
co-administration O O
of O O
Angiomax B-brand B-brand
and O O
plasma O O
expanders O O
such O O
as O O
dextran B-drug B-drug
. O O

On O O
the O O
ninth O O
day O O
, O O
the O O
rats O O
were O O
sacrificed O O
and O O
aortic O O
rings O O
, O O
with O O
or O O
without O O
endothelium O O
, O O
were O O
used O O
to O O
generate O O
concentration-response O O
curves O O
to O O
noradrenaline B-drug B-drug
. O O

At O O
stable O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
concentrations O O
greater O O
than O O
1 O O
mM O O
, O O
fractional O O
mucosal O O
cell O O
accumulation O O
of O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
remains O O
constant O O
, O O
while O O
fractional O O
transfer O O
to O O
the O O
body O O
declines O O
. O O

Although O O
there O O
is O O
little O O
published O O
information O O
on O O
concomitant O O
administration O O
of O O
lidocaine B-drug B-drug
and O O
Bretylium B-drug B-drug
Tosylate I-drug I-drug
, O O
these O O
drugs O O
are O O
often O O
administered O O
concurrently O O
without O O
any O O
evidence O O
of O O
interactions O O
resulting O O
in O O
adverse O O
effects O O
or O O
diminished O O
efficacy O O
. O O

Plenaxis B-brand B-brand
is O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
96 O O
to O O
99 O O
% O O
) O O
. O O

The O O
concurrent O O
use O O
of O O
tetracycline B-drug B-drug
and O O
Penthrane B-brand B-brand
( O O
methoxyflurane B-drug B-drug
) O O
has O O
been O O
reported O O
to O O
result O O
in O O
fatal O O
renal O O
toxicity O O
. O O

Increased O O
nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
cephalosporins B-group B-group
and O O
aminoglycoside B-group B-group
antibiotics I-group I-group
. O O

with O O
divalent O O
or O O
trivalent O O
cations O O
such O O
as O O
iron B-drug B-drug
; O O

Patients O O
response O O
to O O
oral O O
anticoagulants B-group B-group
may O O
be O O
affected O O
by O O
his/her O O
thyroid O O
and O O
metabolic O O
status O O
. O O

However O O
, O O
the O O
relationship O O
to O O
nifedipine B-drug B-drug
therapy O O
is O O
uncertain O O
. O O

Cimetidine B-drug B-drug
increased O O
AUC O O
by O O
about O O
30 O O
% O O
but O O
caused O O
no O O
change O O
in O O
Cmax O O
. O O

Clinically O O
significant O O
QTc O O
prolongation O O
has O O
not O O
been O O
found O O
with O O
Mefloquineuine O O
alone O O
. O O

Acute O O
effect O O
of O O
different O O
antidepressants B-group B-group
on O O
glycemia O O
in O O
diabetic O O
and O O
non-diabetic O O
rats O O
. O O

In O O
a O O
separate O O
study O O
, O O
baboons O O
given O O
3 O O
doses O O
of O O
alefacept B-drug B-drug
at O O
1 O O
mg/kg O O
every O O
8 O O
weeks O O
were O O
found O O
to O O
have O O
centroblast O O
proliferation O O
in O O
B-cell O O
dependent O O
areas O O
in O O
the O O
germinal O O
centers O O
of O O
the O O
spleen O O
following O O
a O O
116-day O O
washout O O
period O O
. O O

Nevirapine I-drug B-drug

Although O O
there O O
was O O
no O O
effect O O
of O O
Aprepitant B-drug B-drug
on O O
the O O
plasma O O
AUC O O
of O O
R O O
( O O
+ O I-drug
) O I-drug
or O I-drug
S B-drug I-drug
( I-drug I-drug
- I-drug I-drug
) I-drug I-drug
warfarin I-drug I-drug
determined O O
on O O
Day B-drug O
3 I-drug O
, I-drug O
there O O
was O O
a O O
34 O O
% O O
decrease O O
in O O
S B-drug B-drug
( I-drug I-drug
- I-drug I-drug
) I-drug I-drug
warfarin I-drug I-drug
( O O
a O O
CYP2C9 O O
substrate O O
) O O
trough O O
concentration O O
accompanied O O
by O O
a O O
14 O O
% O O
decrease O O
in O O
the O O
prothrombin O O
time O O
( O O
reported O O
as O O
International O O
Normalized O O
Ratio O O
or O O
INR O O
) O O
5 O O
days O O
after O O
completion O O
of O O
dosing O O
with O O
Aprepitant B-drug B-drug
. O O

influenza B-group B-group
virus I-group I-group
vaccine I-group I-group
; O O

This O O
may O O
lead O O
to O O
reduced O O
clearance O O
of O O
caffeine B-drug B-drug
and O O
a O O
prolongation O O
of O O
its O O
plasma O O
half-life O O
. O O

Naproxen B-drug B-drug
and O O
other O O
NSAIDs B-group B-group
can O O
reduce O O
the O O
antihypertensive O O
effect O O
of O O
propranolol B-drug B-drug
and O O
other O O
beta-blockers B-group B-group
. O O

Routine O O
monitoring O O
should O O
be O O
performed O O
when O O
therapy O O
with O O
BEXTRA B-brand B-brand
is O O
either O O
initiated O O
or O O
discontinued O O
in O O
patients O O
on O O
anticonvulsant O B-group
therapy O O
. O O

These O O
cephalosporins B-group B-group
are O O
inhibitors O O
of O O
hepatic O O
vitamin O O
K O O
epoxide O O
reductase O O
. O O

CONCLUSION O O
: O O
Fluvoxamine B-drug B-drug
is O O
a O O
moderate O O
inhibitor O O
of O O
CYP2C9 O O
in O O
vivo O O
. O O

Calcium B-drug B-drug
, O O
particularly O O
if O O
administered O O
rapidly O O
by O O
the O O
intravenous O O
route O O
, O O
may O O
produce O O
serious O O
arrhythmias O O
in O O
digitalized O O
patients O O
. O O

Dextromethorphan B-drug B-drug
: O O
Dextromethorphan B-drug B-drug
is O O
primarily O O
metabolized O O
by O O
CYP O O
2D6 O O
and O O
to O O
a O O
lesser O O
extent O O
by O O
3A4 O O
. O O

Didanosine B-drug B-drug

However O O
, O O
preliminary O O
results O O
from O O
an O O
8-week O O
trial O O
showed O O
comparable O O
cognitive O O
enhancing O O
effects O O
of O O
olanzapine B-drug B-drug
and O O
risperidone B-drug B-drug
treatment O O
in O O
patients O O
with O O
schizophrenia O O
or O O
schizoaffective O O
disorder O O
. O O

The O O
physician O O
should O O
be O O
alert O O
for O O
possible O O
combined O O
drug O O
actions O O
, O O
desirable O O
or O O
undesirable O O
, O O
involving O O
ifosfamide B-drug B-drug
even O O
though O O
ifosfamide B-drug B-drug
has O O
been O O
used O O
successfully O O
concurrently O O
with O O
other O O
drugs O O
, O O
including O O
other O O
cytotoxic O B-group
drugs O I-group
. O O

Population O O
pharmacokinetic O O
studies O O
showed O O
higher O O
concentrations O O
of O O
cilostazol B-drug B-drug
among O O
patients O O
concurrently O O
treated O O
with O O
diltiazem B-drug B-drug
, O O
an O O
inhibitor O O
of O O
C.P.A.. O O

Lithium B-drug B-drug
: O O
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
. O O

Antihistamines B-group B-group
: O O
Benzodiazepines B-group B-group
GI O O
Motility O O
Agents O O
Anti-Migraine B-group B-group
Antifungal I-group I-group

Cimetidine B-drug B-drug
treatment O O
should O O
be O O
stopped O O
during O O
treatment O O
with O O
ELLENCE B-brand B-brand
. O O

Propoxyphene B-drug B-drug
: O O
The O O
concurrent O O
administration O O
of O O
propoxyphene B-drug B-drug
hydrochloride I-drug I-drug
does O O
not O O
affect O O
the O O
bioavailability O O
of O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
. O O

Alcohol B-drug B-drug
, O O
barbiturates B-group B-group
, O O
or O O
narcotics B-group B-group
: O O
potentiation O O
of O O
orthostatic O O
hypotension O O
may O O
occur O O
. O O

. O O

The O O
120 O O
mg/kg O O
dose O O
resulted O O
in O O
a O O
systemic O O
exposure O O
approximately O O
16 O O
times O O
the O O
human O O
plasma O O
area-under-the-curve O O
( O O
AUC O O
, O O
0-24 O O
hours O O
) O O
based O O
on O O
the O O
maximum O O
human O O
dose O O
of O O
80 O O
mg/day O O
. O O

This O O
should O O
be O O
considered O O
whenever O O
these O O
agents O O
are O O
prescribed O O
concomitantly O O
. O O

Effect O O
of O O
rofecoxib B-drug B-drug
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
in O O
healthy O O
volunteers O O
. O O

Probenecid B-drug B-drug
: O O
As O O
with O O
other O O
b-lactam B-group B-group
antibiotics I-group I-group
, O O
renal O O
excretion O O
of O O
loracarbef B-drug B-drug
is O O
inhibited O O
by O O
probenecid B-drug B-drug
and O O
resulted O O
in O O
an O O
approximate O O
80 O O
% O O
increase O O
in O O
the O O
AUC O O
for O O
loracarbef B-drug B-drug
. O O

Plasma O O
exposure O O
( O O
AUC O O
) O O
to O O
valdecoxib B-drug B-drug
was O O
increased O O
62 O O
% O O
when O O
coadministered O O
with O O
fluconazole B-drug B-drug
and O O
38 O O
% O O
when O O
coadministered O O
with O O
ketoconazole B-drug B-drug
. O O

Cyclosporine B-drug B-drug

vardenafil I-drug B-drug
concentration O O

Interaction O O
with O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
other O O
than O O
benzodiazepines B-group B-group
has O O
not O O
been O O
specifically O O
studied O O
; O O

Ketoconazole B-drug B-drug
did O O
not O O
affect O O
the O O
conversion O O
of O O
losartan B-drug B-drug
to O O
the O O
active O O
metabolite O O
after O O
intravenous O O
administration O O
of O O
losartan B-drug B-drug
, O O
and O O
erythromycin B-drug B-drug
had O O
no O O
clinically O O
significant O O
effect O O
after O O
oral O O
administration O O
. O O

Antidepressants B-group B-group
, O O
tricyclic B-group B-group
: O O
Amphetamines B-group B-group
may O O
enhance O O
the O O
activity O O
of O O
tricyclic B-group B-group
or O O
sympathomimetic B-group B-group
agents I-group I-group
; O O

Anagrelide B-drug B-drug
alone O O
had O O
no O O
effect O O
on O O
platelet O O
aggregation O O
, O O
but O O
did O O
slightly O O
enhance O O
the O O
inhibition O O
of O O
platelet O O
aggregation O O
by O O
aspirin B-brand B-brand
. O O

Substantial O O
intercurrent O O
ethanol B-drug B-drug
use O O
was O O
present O O
in O O
each O O
of O O
these O O
cases O O
, O O
and O O
this O O
may O O
have O O
contributed O O
to O O
the O O
abnormalities O O
seen O O
. O O

Therefore O O
, O O
concurrent O O
use O O
of O O
aspirin B-brand B-brand
and O O
ketoprofen B-drug B-drug
is O O
not O O
recommended O O
. O O

Tablets O O
: O O
The O O
benzodiazepines B-group B-group
, O O
including O O
lorazepam B-drug B-drug
, O O
produce O O
CNS-depressant O O
effects O O
when O O
administered O O
with O O
such O O
medications O O
as O O
barbiturates B-group B-group
or O O
alcohol B-drug B-drug
. O O

The O O
first O O
test O O
is O O
obtained O O
by O O
the O O
prescriber O O
when O O
the O O
decision O O
is O O
made O O
to O O
pursue O O
qualification O O
of O O
the O O
patient O O
for O O
Accutane B-brand B-brand
( O O
a O O
screening O O
test O O
) O O
. O O

High O O
oral O O
magnesium B-drug B-drug
doses O O
besides O O
their O O
laxative O O
action O O
may O O
bring O O
latent O O
complications O O
which O O
may O O
reduce O O
lifespan O O
. O O

phenylbutazone B-drug B-drug
; O O

Drug/Laboratory O O
Test O O
Interaction O O
Because O O
Xigris B-brand B-brand
may O O
affect O O
the O O
APTT O O
assay O O
, O O
Xigris B-brand B-brand
present O O
in O O
plasma O O
samples O O
may O O
interfere O O
with O O
one-stage O O
coagulation O O
assays O O
based O O
on O O
the O O
APTT O O
( O O
such O O
as O O
factor O O
VIII O O
, O O
IX O O
, O O
and O O
XI O O
assays O O
) O O
. O O

Methenamine B-drug B-drug
therapy O O
: O O
Urinary O O
excretion O O
of O O
amphetamines B-group B-group
is O O
increased O O
, O O
and O O
efficacy O O
is O O
reduced O O
, O O
by O O
acidifying B-group B-group
agents I-group I-group
used O O
in O O
methenamine B-drug B-drug
therapy O O
. O O

Rifampin B-drug B-drug
: O O
Rifampin B-drug B-drug
increases O O
the O O
metabolism O O
of O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
some O O
progestins B-group B-group
( O O
norethindrone B-drug B-drug
) O O
resulting O O
in O O
decreased O O
contraceptive O O
effectiveness O O
and O O
increased O O
menstrual O O
irregularities O O
. O O

Potentiation O O
of O O
coumarin-type B-group B-group
anticoagulants I-group I-group
has O O
been O O
observed O O
with O O
prolongation O O
of O O
the O O
prothrombin O O
time/INR O O
. O O

Further O O
, O O
misoprostol B-drug B-drug
is O O
reported O O
to O O
have O O
a O O
synergistic O O
effect O O
with O O
this O O
combination O O
in O O
ameliorating O O
intestinal O O
permeability O O
. O O

Phenothiazines B-group B-group
- O O
Taking O O
piperazine B-drug B-drug
and O O
a O O
phenothiazine B-group B-group
together O O
may O O
increase O O
the O O
risk O O
of O O
convulsions O O
( O O
seizures O O
) O O
. O O

However O O
, O O
cohort O O
data O O
and O O
selected O O
patient O O
data O O
from O O
clinical O O
trials O O
suggest O O
comparable O O
activity O O
to O O
PI-based B-group B-group
regimens O O
in O O
these O O
patients O O
. O O

Dicumarol B-drug B-drug
: O O
It O O
has O O
been O O
reported O O
that O O
allopurinol B-drug B-drug
prolongs O O
the O O
half-life O O
of O O
the O O
anticoagulant B-group B-group
, O O
dicumarol B-drug B-drug
. O O

Aspirin B-brand B-brand
: O O
Concomitant O O
administration O O
of O O
aspirin B-brand B-brand
with O O
valdecoxib B-drug B-drug
may O O
result O O
in O O
an O O
increased O O
risk O O
of O O
GI O O
ulceration O O
and O O
complications O O
compared O O
to O O
valdecoxib B-drug B-drug
alone O O
. O O

as O O
such O O
it O O
may O O
impair O O
intestinal O O
absorption O O
of O O
any O O
of O O
vitamin B-group B-group
D I-group I-group
. O O

Taken O O
together O O
, O O
these O O
findings O O
suggest O O
that O O
the O O
changes O O
in O O
the O O
Kd O O
of O O
D2 O O
in O O
the O O
NAC O O
and O O
the O O
Bmax O O
of O O
D2 O O
in O O
the O O
STR O O
may O O
contribute O O
to O O
the O O
differences O O
in O O
locomotor O O
responses O O
to O O
cocaine B-drug B-drug
exposure O O
in O O
these O O
mouse O O
lines O O
. O O

Barbiturates B-group B-group
may O O
decrease O O
the O O
effectiveness O O
of O O
oral O O
contraceptives B-group B-group
, O O
certain O O
antibiotics B-group B-group
, O O
quinidine B-drug B-drug
, O O
theophylline B-drug B-drug
, O O
corticosteroids B-group B-group
, O O
anticoagulants B-group B-group
, O O
and O O
beta B-group B-group
blockers I-group I-group
. O O

Glucose B-drug B-drug
, O O
alone O O
and O O
in O O
the O O
presence O O
of O O
theophylline B-drug B-drug
, O O
caused O O
subnormal O O
insulin O O
release O O
and O O
less O O
suppression O O
of O O
glucagon O O
release O O
in O O
the O O
diabectics O O
than O O
in O O
the O O
normals O O
. O O

Nucleophosmin/B23 O O
in O O
serum-deprived O O
( O O
0 O O
% O O
serum O O
) O O
NIH-3T3 O O
cells O O
was O O
found O O
to O O
be O O
highly O O
unstable O O
with O O
a O O
half-life O O
less O O
than O O
4 O O
h O O
. O O

Although O O
deferasirox B-drug B-drug
has O O
a O O
lower O O
affinity O O
for O O
aluminum B-drug B-drug
than O O
for O O
iron B-drug B-drug
, O O
Exjade B-brand B-brand
should O O
not O O
be O O
taken O O
with O O
aluminum-containing B-drug B-drug
antacid B-group B-group
preparations I-group I-group
. O O

However O O
, O O
under O O
certain O O
circumstances O O
, O O
e.g. O O
, O O
as O O
prophylaxis O O
after O O
myocardial O O
infarction O O
, O O
there O O
may O O
be O O
no O O
acceptable O O
alternatives O O
to O O
the O O
use O O
of O O
beta-blockers B-group B-group
in O O
patients O O
with O O
COPD O O
. O O

Concomitant O O
use O O
of O O
clozapine B-drug B-drug
with O O
other O O
drugs O O
metabolized O O
by O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
clozapine B-drug B-drug
or O O
the O O
other O O
drug O O
. O O

increased O O
serum O O
triglyceride O O
and O O
phospholipid O O
concentration O O
. O O

Digoxin B-drug B-drug
: O O
Digoxin B-drug B-drug
concentrations O O
are O O
increased O O
by O O
about O O
15 O O
% O O
when O O
digoxin B-drug B-drug
and O O
carvedilol B-drug B-drug
are O O
administered O O
concomitantly O O
. O O

This O O
drug O O
may O O
interact O O
with O O
alcohol B-drug B-drug
or O O
other O O
CNS B-group B-group
depressants I-group I-group
( O O
may O O
potentiate O O
the O O
CNS O O
depressant O O
effects O O
of O O
either O O
these O O
medications O O
or O O
antihistamines B-group B-group
) O O
, O O
anticholinergics B-group B-group
or O O
other O O
medications O O
with O O
anticholinergic O O
activity O O
( O O
anticholinergic O O
effects O O
may O O
be O O
potentiated O O
when O O
these O O
medications O O
are O O
used O O
concurrently O O
with O O
antihistamines B-group B-group
) O O
, O O
and O O
monoamine B-group B-group
oxidase I-group I-group
( I-group I-group
MAO I-group I-group
) I-group I-group
inhibitors I-group I-group
( O O
concurrent O O
use O O
with O O
antihistamines B-group B-group
may O O
prolong O O
and O O
intensify O O
the O O
anticholinergic O O
and O O
CNS O O
depressant O O
effects O O
of O O
antihistamines B-group B-group
) O O
. O O

Patients O O
receiving O O
both O O
drugs O O
should O O
be O O
observed O O
closely O O
to O O
determine O O
if O O
the O O
desired O O
diuretic O O
and/or O O
antihypertensive O O
effect O O
of O O
furosemide B-drug B-drug
is O O
achieved O O
. O O

Patients O O
should O O
not O O
be O O
re-treated O O
with O O
subsequent O O
cycles O O
of O O
TAXOL B-brand B-brand
until O O
neutrophils O O
recover O O
to O O
a O O
level O O
1500 O O
cells/mm3 O O
and O O
platelets O O
recover O O
to O O
a O O
level O O
100,000 O O
cells/mm3 O O
. O O

Anabolic B-group B-group
steroids I-group I-group
( O O
particularly O O
C-17 O O
alkylated O O
androgens B-group B-group
such O O
as O O
oxymetholone B-drug B-drug
, O O
methandrostenolone B-drug B-drug
, O O
norethandrolone B-drug B-drug
, O O
and O O
similar O O
compounds O O
) O O
enhanced O O
tendency O O
toward O O
edema O O
. O O

Physicians O O
are O O
provided O O
this O O
information O O
to O O
increase O O
awareness O O
of O O
the O O
potential O O
for O O
serious O O
interactions O O
when O O
cinoxacin B-drug B-drug
and O O
certain O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
are O O
administered O O
concomitantly O O
. O O

Furthermore O O
, O O
no O O
significant O O
difference O O
in O O
pharmacodynamic O O
effect O O
( O O
reduction O O
in O O
low-density O O
lipoprotein O O
cholesterol O O
levels O O
) O O
could O O
be O O
ascertained O O
between O O
mealtime O O
dosing O O
and O O
bedtime O O
dosing O O
. O O

5 O O
. O O

In O O
diabetic O O
patients O O
, O O
the O O
metabolic O O
effects O O
of O O
androgens B-group B-group
may O O
decrease O O
blood O O
glucose O O
and O O
therefore O O
, O O
insulin B-drug B-drug
requirements O O
. O O

The O O
incidence O O
of O O
hypertriglyceridemia O O
is O O
1 O O
patient O O
in O O
4 O O
on O O
Accutane B-brand B-brand
therapy O O

Dexamethasone B-drug B-drug
and O O
retinyl B-drug B-drug
acetate I-drug I-drug
similarly O O
inhibit O O
and O O
stimulate O O
EGF- B-drug_n B-drug_n
or O O
insulin-induced B-drug B-drug
proliferation O O
of O O
prostatic O O
epithelium O O
. O O

Cold O O
and O O
flu O O
remedies O O
. O O

Diflunisal B-drug B-drug
decreased O O
the O O
hyperuricemic O O
effect O O
of O O
furosemide B-drug B-drug
. O O

No O O
other O O
pharmacokinetic O O
parameters O O
were O O
changed O O
. O O

Use O O
of O O
Antithrombotics B-group B-group
Aspirin B-brand B-brand
and O O
heparin B-drug B-drug
have O O
been O O
administered O O
concomitantly O O
with O O
and O O
following O O
infusions O O
of O O
Activase B-brand B-brand
in O O
the O O
management O O
of O O
acute O O
myocardial O O
infarction O O
or O O
pulmonary O O
embolism O O
. O O

The O O
results O O
from O O
a O O
study O O
in O O
which O O
eight O O
HIV-infected O O
individuals O O
were O O
treated O O
with O O
zidovudine B-drug B-drug
, O O
8 O O
+/- O O
0.4 O O
mg/kg/day O O
, O O
showed O O
that O O
the O O
pharmacokinetics O O
of O O
zidovudine B-drug B-drug
were O O
not O O
affected O O
during O O
concomitant O O
administration O O
of O O
Itraconazole B-drug B-drug
, O O
100 O O
mg O O
b.i.d O O
. O O

The O O
concomitant O O
administration O O
of O O
quinolones B-group B-group
including O O
norfloxacin B-drug B-drug
with O O
glyburide B-drug B-drug
( O O
a O O
sulfonylurea B-group B-group
agent I-group I-group
) O O
has O O
, O O
on O O
rare O O
occasions O O
, O O
resulted O O
in O O
severe O O
hypoglycemia O O
. O O

Phenytoin B-drug B-drug
may O O
also O O
cause O O
increased O O
serum O O
concentrations O O
of O O
glucose O B-drug
, O O
alkaline O O
phosphatase O O
, O O
and O O
gamma O O
glutamyl O O
transpeptidase O O
( O O
GGT O O
) O O
. O O

The O O
risk O O
of O O
metabolic O O
interactions O O
caused O O
by O O
an O O
effect O O
on O O
an O O
individual O O
isoform O O
is O O
therefore O O
minimized O O
. O O

" O O
hippocampal-independent O O
" O O

Repeated O O
doses O O
of O O
colestipol B-drug B-drug
hydrochloride I-drug I-drug
given O O
prior O O
to O O
a O O
single O O
dose O O
of O O
propranolol B-drug B-drug
in O O
human O O
trials O O
have O O
been O O
reported O O
to O O
decrease O O
propranolol B-drug B-drug
absorption O O
. O O

Acetaminophen B-drug B-drug
and O O
methotrexate B-drug B-drug
- O O
L-methionine B-drug B-drug
may O O
decrease O O
hepatic O O
toxicity O O
in O O
those O O
with O O
acetaminophen B-drug B-drug
overdosage O O
or O O
in O O
those O O
taking O O
methotrexate B-drug B-drug
. O O

Cholestyramine B-drug B-drug
and O O
Charcoal B-drug B-drug
Administration O O
of O O
cholestyramine B-drug B-drug
or O O
activated B-drug B-drug
charcoal I-drug I-drug
in O O
patients O O
( O O
n=13 O O
) O O
and O O
volunteers O O
( O O
n=96 O O
) O O
resulted O O
in O O
a O O
rapid O O
and O O
significant O O
decrease O O
in O O
plasma O O
M1 O O
( O O
the O O
active O O
metabolite O O
of O O
leflunomide B-drug B-drug
) O O
concentration O O
. O O

In O O
some O O
patients O O
, O O
combined O O
use O O
of O O
INDOCIN B-brand B-brand
and O O
diflunisal B-drug B-drug
has O O
been O O
associated O O
with O O
fatal O O
gastrointestinal O O
hemorrhage O O
. O O

- O O
Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
may O O
reduce O O
the O O
efficacy O O
of O O
lofexidine B-drug B-drug
. O O

Furosemide B-drug B-drug
may O O
add O O
to O O
or O O
potentiate O O
the O O
therapeutic O O
effect O O
of O O
other O O
antihypertensive B-group B-group
drugs I-group I-group
. O O

dosage O O
adjustments O O
may O O
be O O
necessary O O
. O O
) O O

Synergism O O
was O O
observed O O
when O O
GL B-drug_n B-drug_n
was O O
combined O O
with O O
cefazolin B-drug B-drug
against O O
Bacillus O O
subtilis O O
and O O
Klebsiella O O
oxytoca O O
. O O

Etonogestrel B-drug B-drug
may O O
interact O O
with O O
the O O
following O O
medications O O
: O O
acetaminophen B-drug B-drug
( O O
Tylenol B-brand B-brand
) O O
, O O
antibiotics B-group B-group
such O O
as O O
ampicillin B-drug B-drug
and O O
tetracycline B-drug B-drug
, O O
anticonvulsants B-group B-group
( O O
Dilantin B-brand B-brand
, O O
Phenobarbital B-drug B-drug
, O O
Tegretol B-brand B-brand
, O O
Trileptal B-brand B-brand
, O O
Topamax B-brand B-brand
, O O
Felbatol B-brand B-brand
) O O
, O O
antifungals B-group B-group
( O O
Gris-PEG B-brand B-brand
, O O
Nizoral B-brand B-brand
, O O
Sporanox B-brand B-brand
) O O
, O O
atorvastatin B-drug B-drug
( O O
Lipitor B-brand B-brand
) O O
, O O
clofibrate B-drug B-drug
( O O
Atromid-S B-brand B-brand
) O O
, O O
cyclosporine B-drug B-drug
( O O
Neoral B-brand B-brand
, O O
Sandimmune B-brand B-brand
) O O
, O O
HIV O O
drugs O O
classified O O
as O O
protease B-group B-group
inhibitors I-group I-group
( O O
Agenerase B-brand B-brand
, O O
Crixivan B-brand B-brand
, O O
Fortovase B-brand B-brand
, O O
Invirase B-brand B-brand
, O O
Kaletra B-brand B-brand
, O O
Norvir B-brand B-brand
, O O
Viracept B-brand B-brand
) O O
, O O
morphine B-drug B-drug
( O O
Astramorph B-brand B-brand
, O O
Kadian B-brand B-brand
, O O
MS B-brand B-brand
Contin I-brand I-brand
) O O
, O O
phenylbutazone B-drug B-drug
, O O
prednisolone B-drug B-drug
( O O
Prelone B-brand B-brand
) O O
, O O
rifadin B-brand B-brand
( O O
rifampin B-drug B-drug
) O O
, O O
St. O O
Johns O O
wort O O
, O O
temazepam B-drug B-drug
, O O
theophylline B-drug B-drug
( O O
Theo-Dur B-brand B-brand
) O O
, O O
and O O
vitamin B-drug B-drug
C I-drug I-drug
. O O

The O O
three O O
study O O
periods O O
were O O
separated O O
by O O
a O O
21-day O O
washout O O
phase O O
. O O

Nephrotoxic O O
agents O O
: O O
Concomitant O O
administration O O
of O O
VISTIDE B-brand B-brand
and O O
agents O O
with O O
nephrotoxic O O
potential O O
[ O O
e.g. O O
, O O
intravenous O O
aminoglycosides B-group B-group
( O O
e.g. O O
, O O
tobramycin B-drug B-drug
, O O
gentamicin B-drug B-drug
, O O
and O O
amikacin B-drug B-drug
) O O
, O O
amphotericin B-drug B-drug
B I-drug I-drug
, O O
foscarnet B-drug B-drug
, O O
intravenous O O
pentamidine B-drug B-drug
, O O
vancomycin B-drug B-drug
, O O
and O O
non-steroidal B-group B-group
anti-inflammatory I-group I-group
agents I-group I-group
] O O
is O O
contraindicated O O
. O O

Antacids B-group B-group
: O O
Concomitant O O
administration O O
of O O
aluminum O B-drug
and O O
magnesium B-drug B-drug
hydroxides O O
does O O
not O O
interfere O O
with O O
absorption B-drug O
of O O
meclofenamate B-drug B-drug
sodium I-drug I-drug
. O O

Tell O O
your O O
doctor O O
if O O
you O O
are O O
taking O O
any O O
of O O
the O O
following O O
drugs O O
: O O
blood B-group B-group
thinners O I-group
( O O
Coumadin B-brand B-brand
) O O
other O O
antidepressants B-group B-group
metoprolol B-drug B-drug
antihistamines B-group B-group
carbamazepine B-drug B-drug
( O O
Tegretol B-brand B-brand
) O O
cimetidine B-drug B-drug
( O O
Tagamet B-brand B-brand
) O O
estrogens B-group B-group
fluoxetine B-drug B-drug
( O O
Prozac B-brand B-brand
) O O
intraconazole O O
( O O
Sporanox B-brand B-brand
) O O
ketoconazole B-drug B-drug
( O O
Nizoral B-brand B-brand
) O O
levodopa B-drug B-drug
lithium I-drug I-drug
muscle B-group B-group
relaxants I-group I-group
birth O O
control O O
pills O O
sleeping O O
pills O O
thyroid O O
medications O O

and/or O O
Drug/Laboratory O O
Test O O
Interactions O O
See O O
CLINICAL O O
PHARMACOLOGY O O
, O O
Pharmacokinetics O O
and O O
Drug O O
Interactions O O
. O O

Furosemide B-drug B-drug
should O O
not O O
be O O
used O O
concomitantly O O
with O O
ethacrynic B-drug B-drug
acid I-drug I-drug
because O O
of O O
the O O
possibility O O
of O O
ototoxicity O O
. O O

Vitamin B-group B-group
D I-group I-group
: O O
The O O
coadministration O O
of O O
any O O
of O O
the O O
vitamin B-group B-group
D I-group I-group
analogues I-group I-group
should O O
be O O
avoided O O
as O O
this O O
could O O
create O O
possible O O
additive O O
effects O O
and O O
hypercalcemia O O
. O O

A O O
variety O O
of O O
neurological O O
toxic O O
effects O O
and O O
malignant O O
hyperpyrexia O O
can O O
occur O O
, O O
sometimes O O
with O O
fatal O O
results O O
. O O

No O O
information O O
is O O
available O O
about O O
the O O
interaction O O
of O O
cephalexin B-drug B-drug
and O O
metformin B-drug B-drug
following O O
multiple O O
doses O O
of O O
either O O
drug O O
. O O

The O O
groups O O
then O O
took O O
500 O O
mg O O
of O O
tolbutamide B-drug B-drug
as O O
a O O
single O O
dose O O
( O O
day O O
0 O O
) O O
. O O

Indinavir B-drug B-drug

When O O
other O O
potent O O
parental O O
antihypertensive B-group B-group
drugs I-group I-group
, O O
such O O
as O O
diazoxide B-drug B-drug
, O O
are O O
used O O
in O O
combination O O
with O O
hydralazine B-drug B-drug
, O O
patients O O
should O O
be O O
continuously O O
observed O O
for O O
several O O
hours O O
for O O
any O O
excessive O O
fall O O
in O O
blood O O
pressure O O
. O O

Agents O O
Increasing O O
Serum O O
Potassium O O
: O O
PRINIVIL B-brand B-brand
attenuates O O
potassium O O
loss O O
caused O O
by O O
thiazide-type B-group B-group
diuretics I-group I-group
. O O

Effects O O
were O O
already O O
seen O O
with O O
doses O O
corresponding O O
to O O
relevant O O
plasma O O
levels O O
in O O
humans O O
, O O
and O O
the O O
intracellular O O
phosphorylation O O
of O O
zalcitabine B-drug B-drug
to O O
its O O
three O O
metabolites O O
( O O
including O O
the O O
active O O
zalcitabine O O
triphosphate O O
metabolite O O
) O O
was O O
significantly O O
inhibited O O
. O O

In O O
the O O
large O O
, O O
placebo-controlled O O
osteoporosis O O
Treatment O O
Study O O
, O O
aspirin B-brand B-brand
and O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
were O O
taken O O
by O O
62 O O
% O O
of O O
the O O
2946 O O
patients O O
. O O

Certain O O
drugs O O
including O O
thiazides B-group B-group
, O O
corticosteroids B-group B-group
, O O
thyroid B-group B-group
products I-group I-group
, O O
and O O
sympathomimetics B-group B-group
may O O
reduce O O
the O O
hypoglycemic O O
action O O
of O O
Starlix B-brand B-brand
and O O
other O O
oral O O
antidiabetic B-group B-group
drugs I-group I-group
. O O

Neuromuscular B-group B-group
Blockers I-group I-group
: O O
In O O
one O O
study O O
of O O
10 O O
healthy O O
volunteers O O
, O O
administration O O
of O O
PRECEDEX B-brand B-brand
for O O
45 O O
minutes O O
at O O
a O O
plasma O O
concentration O O
of O O
1 O O
( O O
one O O
) O O
ng/mL O O
resulted O O
in O O
no O O
clinically O O
meaningful O O
increases O O
in O O
the O O
magnitude O O
or O O
neuromuscular O O
blockade O O
associated O O
with O O
rocuronium B-drug B-drug
administration O O
. O O

A O O
variety O O
of O O
parametric O O
dose-response O O
models O O
based O O
on O O
either O O
the O O
normal O O
or O O
logistic O O
probability O O
distribution O O
have O O
been O O
proposed O O
in O O
the O O
literature O O
. O O

Drugs O O
with O O
parasympathomimetic O O
effects O O
administered O O
concurrently O O
with O O
cevimeline B-drug B-drug
can O O
be O O
expected O O
to O O
have O O
additive O O
effects O O
. O O

Thus O O
, O O
concomitant O O
therapy O O
with O O
warfarin B-drug B-drug
and O O
Lodine B-brand B-brand
should O O
not O O
require O O
dosage O O
adjustment O O
of O O
either O O
drug O O
. O O

A O O
study O O
in O O
14 O O
normal O O
male O O
and O O
female O O
volunteers O O
suggests O O
that O O
coadministration O O
of O O
cisapride B-drug B-drug
and O O
ketoconazole B-drug B-drug
can O O
result O O
in O O
prolongation O O
of O O
the O O
QT O O
interval O O
on O O
the O O
ECG O O
. O O

The O O
IC O O
( O O
50 O O
) O O
was O O
about O O
120 O O
microgram/ml O O
. O O

- O O
Phenothiazines B-group B-group
( O O
acetophenazine B-drug B-drug
[ O O
e.g. O O
, O O
Tindal B-brand B-brand
] O O
, O O
chlorpromazine B-drug B-drug
[ O O
e.g. O O
, O O
Thorazine B-brand B-brand
] O O
, O O
fluphenazine B-drug B-drug
[ O O
e.g. O O
, O O
Prolixin B-brand B-brand
] O O
, O O
mesoridazine B-brand B-brand
[ O O
e.g. O O
, O O
Serentil B-brand B-brand
] O O
, O O
perphenazine B-drug B-drug
[ O O
e.g. O O
, O O
Trilafon B-brand B-brand
] O O
, O O
prochlorperazine B-drug B-drug
[ O O
e.g. O O
, O O
Compazine B-brand B-brand
] O O
, O O
promazine B-drug B-drug
[ O O
e.g. O O
, O O
Sparine B-brand B-brand
] O O
, O O
promethazine B-drug B-drug
[ O O
e.g. O O
, O O
Phenergan B-brand B-brand
] O O
, O O
thioridazine B-drug B-drug
[ O O
e.g. O O
, O O
Mellaril B-brand B-brand
] O O
, O O
trifluoperazine B-drug B-drug
[ O O
e.g. O O
, O O
Stelazine B-brand B-brand
] O O
, O O
triflupromazine B-drug B-drug
[ O O
e.g. O O
, O O
Vesprin B-brand B-brand
] O O
, O O
trimeprazine B-drug B-drug
[ O O
e.g. O O
, O O
Temaril B-brand B-brand
] O O
) O O
or O O

Drug/Laboratory O O
Test O O
Interactions O O
Finasteride B-drug B-drug
had O O
no O O
effect O O
on O O
circulating O O
levels O O
of O O
cortisol O O
, O O
thyroid-stimulating O O
hormone O O
, O O
or O O
thyroxine O O
, O O
nor O O
did O O
it O O
affect O O
the O O
plasma O O
lipid O O
profile O O
( O O
e.g. O O
, O O
total O O
cholesterol O O
, O O
low-density O O
lipoproteins O O
, O O
high-density O O
lipoproteins O O
and O O
triglycerides O O
) O O
or O O
bone O O
mineral O O
density O O
. O O

Some O O
quinolones B-group B-group
, O O
including O O
ciprofloxacin B-drug B-drug
, O O
have O O
also O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
metabolism O O
of O O
caffeine B-drug B-drug
. O O

Simultaneous O O
administration O O
of O O
SPRYCEL B-brand B-brand
with O O
antacids B-group B-group
should O O
be O O
avoided O O
. O O

procainamide B-drug B-drug
; O O

Your O O
doctor O O
or O O
pharmacist O O
can O O
give O O
you O O
more O O
information O O
on O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Clonidine B-drug B-drug
hydrochloride I-drug I-drug
may O O
enhance O O
the O O
CNS-depressive O O
effects O O
of O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
or O O
other O O
sedatives B-group B-group
. O O

Warfarin B-drug B-drug
: O O
In O O
a O O
study O O
in O O
healthy O O
volunteers O O
, O O
no O O
clinically O O
relevant O O
pharmacokinetic O O
or O O
pharmacodynamic O O
interaction O O
between O O
isradipine B-drug B-drug
and O O
racemic O O
warfarin B-drug B-drug
was O O
seen O O
when O O
two O O
single O O
oral O O
doses O O
of O O
warfarin B-drug B-drug
( O O
0.7 O O
mg/kg O O
body O O
weight O O
) O O
were O O
administered O O
during O O
11 O O
days O O
of O O
multipledose O O
treatment O O
with O O
5 O O
mg O O
b.i.d O O
. O O
isradipine B-drug B-drug
. O O

These O O
events O O
were O O
also O O
reported O O
to O O
occur O O
when O O
contrast O O
media O O
was O O
given O O
several O O
months O O
after O O
interleukin-2 B-drug O
treatment O O
. O O

reliable O O
estimates O O
of O O
the O O
prevalence O O
of O O
reduced O O
P450 O O
2D6 O O
isozyme O O
activity O O
among O O
Asian O O
, O O
African O O
and O O
other O O
populations O O
are O O
not O O
yet O O
available O O
. O O

Established O O
and O O
Other O O
Potentially O O
Significant O O
Drug O O
Interactions O O
: O O
Alteration O O
in O O
Dose O O
or O O
Regimen O O
May O O
Be O O
Recommended O O
Based O O
on O O
Drug O O
Interaction O O
Studies O O
or O O
Predicted O O
Interaction O O

. O O

In O O
an O O
in O O
vivo O O
metabolic O O
probe O O
study O O
, O O
alosetron B-drug B-drug
did O O
not O O
inhibit O O
CYP2E1 O O
but O O
did O O
produce O O
30 O O
% O O
inhibition O O
of O O
both O O
CYP1A2 O O
and O O
N-acetyltransferase O O
. O O

2 O O
. O O

Saquinavir B-drug B-drug
: O O
The O O
combination O O
of O O
HIVID B-drug B-drug
, O O
saquinavir B-drug B-drug
, O O
and O O
ZDV B-drug B-drug
has O O
been O O
studied O O
( O O
as O O
triple O O
combination O O
) O O
in O O
adults O O
. O O

Serotonergic B-group B-group
Agents I-group I-group
: O O
Co-administration O O
of O O
linezolid B-drug B-drug
and O O
serotonergic B-group B-group
agents I-group I-group
was O O
not O O
associated O O
with O O
serotonin O O
syndrome O O
in O O
Phase O O
1 O O
, O O
2 O O
or O O
3 O O
studies O O
. O O

In O O
an O O
analysis O O
of O O
the O O
supraventricular O O
arrhythmia O O
and O O
DIAMOND O O
patient O O
populations O O
, O O
the O O
concomitant O O
administration O O
of O O
verapamil B-drug B-drug
with O O
dofetilide B-drug B-drug
was O O
associated O O
with O O
a O O
higher O O
occurrence O O
of O O
torsade O O
de O O
pointes O O
. O O

Digoxin B-drug B-drug
, O O
Nimodipine B-drug B-drug
and O O
Losartan B-drug B-drug
: O O
Bosentan B-drug B-drug
has O O
no O O
significant O O
pharmacokinetic O O
interactions O O
with O O
digoxin B-drug B-drug
and O O
nimodipine B-drug B-drug
, O O
and O O
losartan B-drug B-drug
has O O
no O O
significant O O
effect O O
on O O
plasma O O
levels O O
of O O
bosentan B-drug B-drug
. O O

In O O
general O O
, O O
if O O
a O O
patient O O
shows O O
no O O
signs O O
of O O
sedation O O
within O O
2 O O
hours O O
after O O
a O O
1-mg O O
dose O O
of O O
flumazenil B-drug B-drug
, O O
serious O O
resedation O O
at O O
a O O
later O O
time O O
is O O
unlikely O O
. O O

Mice O O
from O O
the O O
20th O O
generation O O
of O O
three O O
lines O O
divergently O O
selected O O
for O O
response O O
to O O
pentobarbital-induced B-drug B-drug
sedation O O
times O O
[ O O
long-sedation O O
time O O
( O O
LST O O
) O O
, O O
short O O
sedation O O
time O O
( O O
SST O O
) O O
, O O
and O O
randomly O O
bred O O
control O O
( O O
RBC O O
) O O
] O O
were O O
used O O
to O O
study O O
cocaine-induced B-drug B-drug
behavioral O O
sensitization O O
. O O

Bosentan B-drug B-drug
is O O
metabolized O O
by O O
CYP2C9 O O
and O O
CYP3A4 O O
. O O

No O O
teratogenic O O
effects O O
were O O
seen O O
in O O
the O O
offspring O O
delivered O O
at O O
term O O
. O O

Valproate B-drug B-drug
: O O
Tiagabine B-drug B-drug
causes O O
a O O
slight O O
decrease O O
( O O
about O O
10 O O
% O O
) O O
in O O
steady-state O O
valproate B-drug B-drug
concentrations O O
. O O

The O O
risks O O
of O O
using O O
Clozapine B-drug B-drug
in O O
combination O O
with O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

when O O
the O O
drugs O O
were O O
administered O O
together O O
, O O
the O O
effects O O
were O O
additive O O
. O O

It O O
is O O
suggested O O
to O O
monitor O O
both O O
ketoconazole B-drug B-drug
and O O
phenytoin B-drug B-drug
. O O

co-administration O O
of O O
phenytoin B-drug B-drug
may O O
produce O O
a O O
synergistic O O
anticonvulsant O O
action O O
. O O

Concomitant O O
use O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
drugs O O
that O O
can O O
inhibit O O
cytochrome O O
P450 O O
2D6 O O
may O O
require O O
lower O O
doses O O
than O O
usually O O
prescribed O O
for O O
either O O
the O O
tricyclic B-group B-group
antidepressant I-group I-group
or O O
the O O
other O O
drug O O
. O O

Since O O
caffeine B-drug B-drug
is O O
frequently O O
co-administered O O
with O O
acetaminophen B-drug B-drug
, O O
it O O
is O O
of O O
clinical O O
interest O O
to O O
study O O
the O O
effect O O
of O O
caffeine B-drug B-drug
on O O
the O O
hepatotoxicity O O
of O O
acetaminophen B-drug B-drug
. O O

Phenytoin B-drug B-drug
: O O
No O O
significant O O
differences O O
were O O
observed O O
in O O
mean O O
phenytoin B-drug B-drug
AUC O O
, O O
C O O
max O O
, O O
C O O
min O O
or O O
T O O
max O O
( O O
although O O
C O O
max O O
increased O O
by O O
11 O O
% O O
) O O
when O O
extended O O
phenytoin B-drug B-drug
sodium I-drug I-drug
capsules O O
( O O
100 O O
mg O O
tid O O
) O O
were O O
coadministered O O
with O O
lomefloxacin B-drug B-drug
( O O
400 O O
mg O O
qd O O
) O O
for O O
five O O
days O O
in O O
15 O O
healthy O O
males O O
. O O

These O O
precautions O O
probably O O
should O O
apply O O
to O O
digitoxin B-drug B-drug
administration O O
as O O
well O O
. O O

Phospholine B-drug B-drug
Iodide I-drug I-drug
potentiates O O
other O O
cholinesterase B-group B-group
inhibitors I-group I-group
such O O
as O O
succinylcholine B-drug B-drug
or O O
organophosphate B-drug_n B-drug_n
and O O
carbamate B-drug_n B-group
insecticides O I-group
. O O

Carbamazepine B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
the O O
degree O O
of O O
heart O O
block O O
produced O O
by O O
other O O
agents O O
. O O

Avoid O O
concomitant O O
use O O
unless O O
necessary O O
to O O
control O O
side O O
effects O O
of O O
amphotericin B-drug B-drug
B I-drug I-drug
. O O

Monoamine B-group B-group
Oxidase I-group I-group
Inhibitors I-group I-group
( O O
MAOIs B-group B-group
) O O

Fluoxetine B-drug B-drug
, O O
OCs B-group B-group
, O O
sertraline B-drug B-drug
, O O
diltiazem B-drug B-drug
, O O
macrolide B-group B-group
antibiotics I-group I-group
( O O
exercise O O
caution O O
) O O
. O O

Powder O O
x-ray O O
diffraction O O
, O O
differential O O
scanning O O
calorimetry O O
, O O
differential O O
thermal O O
analysis O O
, O O
and O O
scanning O O
electron O O
microscopy O O
were O O
used O O
to O O
characterize O O
the O O
aerosol O O
particles O O
and O O
starting O O
material O O
. O O

Probenecid B-drug B-drug
: O O
As O O
with O O
other O O
b-lactam B-group B-group
antibiotics I-group I-group
, O O
co-administration O O
of O O
probenecid B-drug B-drug
with O O
cefditoren B-drug B-drug
pivoxil I-drug I-drug
resulted O O
in O O
an O O
increase O O
in O O
the O O
plasma O O
exposure O O
of O O
cefditoren B-drug B-drug
, O O
with O O
a O O
49 O O
% O O
increase O O
in O O
mean O O
Cmax O O
, O O
a O O
122 O O
% O O
increase O O
in O O
mean O O
AUC O O
, O O
and O O
a O O
53 O O
% O O
increase O O
in O O
half-life O O
. O O

The O O
hypoglycemic O O
effect O O
of O O
tolbutamide B-drug B-drug
has O O
been O O
reported O O
to O O
increase O O
when O O
Atromid-S B-brand B-brand
is O O
given O O
concurrently O O
. O O

Hepatotoxic O O
medications O O
, O O
such O O
as O O
high-dose O O
methotrexate B-drug B-drug
, O O
may O O
impair O O
liver O O
function O O
and O O
increase O O
the O O
risk O O
of O O
toxicity O O
. O O

It O O
is O O
not O O
clear O O
whether O O
this O O
represents O O
an O O
interaction O O
with O O
TIKOSYN B-brand B-brand
or O O
the O O
presence O O
of O O
more O O
severe O O
structural O O
heart O O
disease O O
in O O
patients O O
on O O
digoxin B-drug B-drug
; O O

Some O O
reports O O
have O O
shown O O
that O O
the O O
concomitant O O
administration O O
of O O
thiazides B-group B-group
with O O
vitamin B-group B-group
D I-group I-group
causes O O
hypercalcemia O O
. O O

In O O
this O O
paper O O
, O O
we O O
show O O
that O O
the O O
precipitate O O
is O O
formed O O
after O O
the O O
interaction O O
of O O
jacalin B-drug_n B-drug_n
and O O
the O O
serum O O
protein O O
added O O
to O O
the O O
culture O O
medium O O
. O O

The O O
possibility O O
of O O
hypotensive O O
effects O O
can O O
be O O
minimized O O
by O O
either O O
discontinuing O O
the O O
diuretic B-group B-group
or O O
increasing O O
salt O O
intake O O
prior O O
to O O
initiation O O
of O O
treatment O O
with O O
fosinopril B-drug B-drug
sodium I-drug I-drug
. O O

Several O O
beta-adrenergic O O
neuroeffector O O
defects O O
occur O O
in O O
heart O O
failure O O
. O O

The O O
clinical O O
basis O O
of O O
this O O
drug O O
interaction O O
has O O
not O O
been O O
established O O
but O O
should O O
be O O
noted O O
when O O
allopurinol B-drug B-drug
is O O
given O O
to O O
patients O O
already O O
on O O
dicumarol B-drug B-drug
therapy O O
. O O

Methotrexate B-drug B-drug
: O O
Piperacillin B-drug B-drug
sodium I-drug I-drug
may O O
reduce O O
the O O
excretion O O
of O O
methotrexate B-drug B-drug
. O O

The O O
onset O O
of O O
80 O O
% O O
of O O
those O O
" O O
epidemic O O
" O O

Testicular O O
atrophy O O
was O O
seen O O
with O O
dexrazoxane B-drug B-drug
administration O O
at O O
doses O O
as O O
low O O
as O O
30 O O
mg/kg O O
weekly O O
for O O
6 O O
weeks O O
in O O
rats O O
( O O
1/3 O O
the O O
human O O
dose O O
on O O
a O O
mg/m O O
2 O O
basis O O
) O O
and O O
as O O
low O O
as O O
20 O O
mg/kg O O
weekly O O
for O O
13 O O
weeks O O
in O O
dogs O O
( O O
approximately O O
equal O O
to O O
the O O
human O O
dose O O
on O O
a O O
mg/m O O
2 O O
basis O O
) O O
. O O

Lithium B-drug B-drug
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
because O O
they O O
reduce O O
its O O
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium O B-drug
toxicity O O
. O O

Co-medications O O
that O O
induce O O
CYP3A4 O O
( O O
e.g. O O
, O O
dexamethasone B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
rifampin B-drug B-drug
, O O
phenobarbital B-drug B-drug
or O O
St O O
. O O

We O O
propose O O
these O O
pharmacokinetic O O
changes O O
to O O
be O O
the O O
underlying O O
mechanism O O
for O O
the O O
reduction O O
of O O
oral O O
CCNU B-drug B-drug
cytotoxicity O O
by O O
misonidazole B-drug_n B-drug_n
. O O

General O O
Interactions O O
: O O
Certain O O
drugs O O
could O O
increase O O
the O O
likelihood O O
of O O
potentially O O
serious O O
adverse O O
effects O O
with O O
bepridil B-drug B-drug
hydrochloride I-drug I-drug
. O O

The O O
response O O
to O O
Factrel B-brand B-brand
may O O
be O O
blunted O O
by O O
phenothiazines B-group B-group
and O O
dopamine B-group B-group
antagonists I-group I-group
which O O
cause O O
a O O
rise O O
in O O
prolactin O O
. O O

Caution O O
is O O
advised O O
when O O
beginning O O
, O O
discontinuing O O
, O O
or O O
changing O O
the O O
dose O O
of O O
DIAMOX B-brand B-brand
in O O
patients O O
receiving O O
primidone B-drug B-drug
. O O

Drugs O O
that O O
may O O
have O O
their O O
plasma O O
concentration O O
altered O O
by O O
Gleevec B-brand B-brand
Gleevec I-brand I-brand
increases O O
the O O
mean O O
cmax O O
and O O
AUC O O
of O O
simvastatin B-drug B-drug
( O O
CYP3A4 O O
substrate O O
) O O
2- O O
and O O
3.5-fold O O
, O O
respectively O O
, O O
suggesting O O
an O O
inhibition O O
of O O
the O O
CYP3A4 O O
by O O
Gleevec B-brand B-brand
. O O

While O O
all O O
the O O
selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
, O O
e.g. O O
, O O
citalopram B-drug B-drug
, O O
escitalopram B-drug B-drug
, O O
fluoxetine B-drug B-drug
, O O
sertraline B-drug B-drug
, O O
and O O
paroxetine B-drug B-drug
, O O
inhibit O O
P450 O O
2D6 O O
, O O
they O O
may O O
vary O O
in O O
the O O
extent O O
of O O
inhibition O O
. O O

During O O
clinical O O
trials O O
, O O
iloprost B-drug B-drug
was O O
used O O
concurrently O O
with O O
anticoagulants B-group B-group
, O O
diuretics B-group B-group
, O O
cardiac B-group B-group
glycosides I-group I-group
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
analgesics B-group B-group
, O O
antipyretics B-group B-group
, O O
nonsteroidal B-group B-group
antiinflammatories I-group I-group
, O O
corticosteroids B-group B-group
, O O
and O O
other O O
medications O O
. O O

Prolonged O O
daily O O
administration O O
of O O
picrotoxin B-drug_n B-drug_n
in O O
a O O
dose O O
of O O
1 O O
mg/kg O O
results O O
in O O
the O O
development O O
of O O
brain O O
edema O O
. O O

The O O
superiority O O
of O O
efavirenz B-drug B-drug
over O O
indinavir-based B-drug B-drug
regimens O O
has O O
been O O
observed O O
in O O
comparative O O
data O O
in O O
a O O
subset O O
of O O
patients O O
with O O
high O O
viral O O
loads O O
. O O

and O O
by O O
observations O O
now O O
appearing O O
on O O
the O O
relation O O
between O O
plasma O O
drug O O
levels O O
and O O
drug O O
effects O O
, O O
both O O
therapeutic O O
and O O
toxic O O
. O O

Thus O O
, O O
it O O
is O O
recommended O O
not O O
to O O
use O O
such O O
methods O O
for O O
12-24 O O
hours O O
after O O
administration O O
of O O
Omniscan B-brand B-brand
. O O

Cardiovascular O O
: O O
Hypotension O O
, O O
bradycardia O O
, O O
and O O
hypertension O O
have O O
been O O
observed O O
during O O
administration O O
of O O
TAXOL B-brand B-brand
, O O
but O O
generally O O
do O O
not O O
require O O
treatment O O
. O O

Antidiabetic B-group B-group
drugs I-group I-group
( O O
oral O O
agents O O
and O O
insulin B-drug B-drug
) O O
diminished O O
antidiabetic O O
effect O O
. O O

Digitalis B-group B-group
toxicity O O
may O O
be O O
aggravated O O
by O O
the O O
initial O O
release O O
of O O
norepinephrine O O
caused O O
by O O
Bretylium B-drug B-drug
Tosylate I-drug I-drug
Injection O O
. O O

The O O
dissolution O O
rate O O
of O O
the O O
aerosol O O
particles O O
in O O
saline O O
was O O
low O O
and O O
variable O O
. O O

However O O
, O O
because O O
both O O
of O O
these O O
compounds O O
have O O
CNS O O
effects O O
, O O
an O O
additive O O
pharmacodynamic O O
effect O O
is O O
possible O O
. O O

Pediatric O O
Use O O
The O O
safety O O
and O O
efficacy O O
of O O
FASLODEX B-brand B-brand
in O O
pediatric O O
patients O O
have O O
not O O
been O O
established O O
. O O

The O O
steady-state O O
Cmin O O
increased O O
to O O
78 O O
14 O O
micrograms/mL O O
when O O
1200 O O
mg/day O O
of O O
felbamate B-drug B-drug
was O O
coadministered O O
. O O

In O O
order O O
to O O
examine O O
some O O
molecular O O
mechanisms O O
of O O
PCP-induced B-drug_n B-drug_n
behavioral O O
changes O O
, O O
Northern O O
blot O O
analysis O O
of O O
total O O
RNA O O
from O O
prefrontal O O
cortical O O
tissues O O
of O O
mice O O
treated O O
with O O
PCP B-drug_n B-drug_n
, O O
DCG-IV B-drug_n B-drug_n
, O O
and O O
L-CCG-1 B-drug_n B-drug_n
was O O
carried O O
out O O
. O O

Clonidine B-drug B-drug
therapy O O
can O O
then O O
be O O
discontinued O O
several O O
days O O
later O O
by O O
gradually O O
decreasing O O
the O O
dosage O O
. O O

However O O
, O O
administration O O
of O O
4-methylpyrazole B-drug B-drug
( O O
90 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
to O O
rats O O
2 O O
hours O O
prior O O
to O O
1,3-difluoroacetone B-drug_n B-drug_n
( O O
100 O O
mg O O
kg O O
( O O
-1 O O
) O O
body O O
weight O O
) O O
was O O
ineffective O O
in O O
preventing O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-erythro-fluorocitrate I-drug_n I-drug_n
synthesis O O
and O O
did O O
not O O
diminish O O
fluoride O O
or O O
citrate O O
accumulation O O
in O O
vivo O O
. O O

When O O
Mefloquine B-drug B-drug
is O O
taken O O
concurrently O O
with O O
oral O O
live B-group B-group
typhoid I-group I-group
vaccines I-group I-group
, O O
attenuation O O
of O O
immunization O O
can O O
not O O
be O O
excluded O O
. O O

Therefore O O
, O O
fenofibrate B-drug B-drug
should O O
be O O
taken O O
at O O
least O O
1 O O
hour O O
before O O
or O O
4-6 O O
hours O O
after O O
a O O
bile B-group B-group
acid I-group I-group
binding I-group I-group
resin I-group I-group
to O O
avoid O O
impeding O O
its O O
absorption O O
. O O

no O O
change O O
in O O
pravastatin B-drug B-drug
AUC O O
and O O
Cmax O O
was O O
observed O O
during O O
diltiazem B-drug B-drug
coadministration O O
. O O

The O O
extent O O
to O O
which O O
SSRI-TCA B-group B-group
interactions O O
may O O
pose O O
clinical O O
problems O O
will O O
depend O O
on O O
the O O
degree O O
of O O
inhibition O O
, O O
and O O
the O O
pharmacokinetics O O
of O O
the O O
SSRI B-group B-group
involved O O
. O O

There O O
is O O
no O O
clinical O O
evidence O O
to O O
suggest O O
that O O
anagrelide B-drug B-drug
interacts O O
with O O
any O O
of O O
these O O
compounds O O
. O O

The O O
affinity O O
( O O
Kd O O
) O O
of O O
D2 O O
in O O
the O O
NAC O O
decreased O O
significantly O O
, O O
without O O
changes O O
in O O
density O O
( O O
Bmax O O
) O O
, O O
in O O
the O O
cocaine-treated B-drug B-drug
SST O O
and O O
RBC O O
mice O O
. O O

angioedema O O

Nonetheless O O
, O O
individual O O
patients O O
may O O
require O O
additional O O
titration O O
of O O
their O O
theophylline B-drug B-drug
dosage O O
when O O
lansoprazole B-drug B-drug
is O O
started O O
or O O
stopped O O
to O O
ensure O O
clinically O O
effective O O
blood O O
levels O O
. O O

Chloramphenicol B-drug B-drug
has O O
been O O
shown O O
to O O
be O O
antagonistic O O
to O O
beta-lactam B-group B-group
antibiotics I-group I-group
, O O
including O O
ceftazidime B-drug B-drug
, O O
based O O
on O O
in O O
vitro O O
studies O O
and O O
time O O
kill O O
curves O O
with O O
enteric O O
gram-negative O O
bacilli O O
. O O

Therefore O O
, O O
co-administration O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
with O O
other O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
isoenzyme O O
, O O
including O O
other O O
antidepressants B-group B-group
, O O
phenothiazines B-group B-group
, O O
carbamazepine B-drug B-drug
, O O
and O O
Type B-group B-group
1C I-group I-group
antiarrhythmics I-group I-group
( O O
eg O O
, O O
propafenone B-drug B-drug
, O O
flecainide B-drug B-drug
, O O
and O O
encainide B-drug B-drug
) O O
, O O
or O O
that O O
inhibit O O
this O O
enzyme O O
( O O
eg O O
, O O
quinidine B-drug B-drug
) O O
, O O
should O O
be O O
approached O O
with O O
caution O O
. O O

In O O
another O O
study O O
, O O
TORADOLIV/IM O O
was O O
given O O
with O O
two O O
doses O O
of O O
5000 O O
U O O
of O O
heparin B-drug B-drug
to O O
11 O O
healthy O O
volunteers O O
, O O
resulting O O
in O O
a O O
mean O O
template O O
bleeding O O
time O O
of O O
6.4 O O
minutes O O
( O O
3.2 O O
to O O
11.4 O O
min O O
) O O
compared O O
to O O
a O O
mean O O
of O O
6.0 O O
minutes O O
( O O
3.4 O O
to O O
7.5 O O
min O O
) O O
for O O
heparin B-drug B-drug
alone O O
and O O
5.1 O O
minutes O O
( O O
3.5 O O
to O O
8.5 O O
min O O
) O O
for O O
placebo O O
. O O

Coadministration O O
of O O
valdecoxib B-drug B-drug
and O O
Ortho-Novum B-brand B-brand
1/35 O O
increased O O
the O O
exposure O O
of O O
norethindrone B-drug B-drug
and O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
by O O
20 O O
% O O
and O O
34 O O
% O O
, O O
respectively O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Corticosteroids B-group B-group
may O O
affect O O
the O O
nitrobluetetrazolium O O
test O O
for O O
bacterial O O
infection O O
and O O
produce O O
false-negative O O
results O O

Ketoconazole B-drug B-drug
is O O
a O O
known O O
strong O O
inhibitor O O
of O O
CYP3A4 O O
. O O

Lithium B-drug B-drug
generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
because O O
they O O
reduce O O
lithiums B-drug B-drug
renal O O
clearance O O
and O O
add O O
a O O
high O O
risk O O
of O O
lithium B-drug B-drug
toxicity O O
. O O

Thus O O
, O O
careful O O
monitoring O O
of O O
clinical O O
status O O
is O O
warranted O O
when O O
rifampin B-drug B-drug
is O O
administered O O
or O O
discontinued O O
in O O
haloperidol-treated B-drug B-drug
patients O O
. O O

On O O
the O O
other O O
hand O O
, O O
intrathecal O O
naloxone B-drug B-drug
( O O
12-120 O O
micrograms O O
) O O
had O O
only O O
a O O
very O O
weak O O
effect O O
on O O
the O O
tail-flick O O
inhibition O O
induced O O
by O O
intraventricular O O
morphine B-drug B-drug
( O O
40 O O
micrograms O O
) O O
. O O

The O O
drug O O
interaction O O
data O O
described O O
in O O
this O O
section O O
were O O
obtained O O
from O O
studies O O
involving O O
either O O
healthy O O
subjects O O
or O O
patients O O
with O O
epilepsy O O
. O O

Concomitant O O
administration O O
of O O
diflunisal B-drug B-drug
and O O
acetaminophen B-drug B-drug
in O O
dogs O O
, O O
but O O
not O O
in O O
rats O O
, O O
at O O
approximately O O
2 O O
times O O
the O O
recommended O O
maximum O O
human O O
therapeutic O O
dose O O
of O O
each O O
( O O
40 O O
to O O
52 O O
mg/kg/day O O
of O O
diflunisal/acetaminophen B-drug B-drug
) O O
resulted O O
in O O
greater O O
gastrointestinal O O
toxicity O O
than O O
when O O
either O O
drug O O
was O O
administered O O
alone O O
. O O

Co-administration O O
of O O
naltrexone B-drug B-drug
with O O
Acamprosate B-drug B-drug
produced O O
a O O
25 O O
% O O
increase O O
in O O
AUC O O
and O O
a O O
33 O O
% O O
increase O O
in O O
the O O
Cmax O O
of O O
acamprosate B-drug B-drug
. O O

CONCLUSIONS O O
: O O
Everolimus B-drug B-drug
exhibited O O
dose-proportional O O
, O O
stable O O
exposure O O
during O O
the O O
first O O
post-transplant O O
year O O
. O O

Cholestyramine-Concomitant B-drug B-drug
intake O O
of O O
cholestyramine B-drug B-drug
and O O
vitamin B-group B-group
K I-group I-group
may O O
reduce O O
the O O
absorption O O
of O O
vitamin B-group B-group
K I-group I-group
. O O

Morphine B-drug B-drug
: O O
TORADOLIV/IM O O
has O O
been O O
administered O O
concurrently O O
with O O
morphine B-drug B-drug
in O O
several O O
clinical O O
trials O O
of O O
postoperative O O
pain O O
without O O
evidence O O
of O O
adverse O O
interactions O O
. O O

At O O
low-levels O O
of O O
exposure O O
the O O
toxicokinetic O O
interferences O O
between O O
solvents O O
have O O
generally O O
not O O
been O O
observed O O
in O O
man O O
and O O
presumably O O
a O O
threshold O O
limit O O
exists O O
. O O

Antiacid O B-group
, O O
clarithromycin B-drug B-drug
, O O
Didanosine B-drug B-drug
, O O
Fluconazole B-drug B-drug
, O O
Fluoxetine B-drug B-drug
, O O
Indanavir O O
, O O
Ketoconazole B-drug B-drug
, O O
Phenytoin B-drug B-drug
, O O
Phenobarbitol O O
, O O
carbamazepine B-drug B-drug
, O O
Rifabutin B-drug B-drug
, O O
Rifampin B-drug B-drug
, O O
Ritanovir O O
, O O
Saquinavir B-drug B-drug
. O O

disulfiram B-drug B-drug
; O O

Bentiromide B-drug B-drug
may O O
interact O O
with O O
acetaminophen B-drug B-drug
( O O
e.g. O O
, O O
Tylenol B-brand B-brand
) O O
, O O
chloramphenicol B-drug B-drug
( O O
e.g. O O
, O O
Chloromycetin B-brand B-brand
) O O
, O O
local O O
anesthetics B-group B-group
( O O
e.g. O O
, O O
benzocaine B-drug B-drug
and O O
lidocaine B-drug B-drug
) O O
, O O
para-aminobenzoic B-drug_n B-drug_n
acid I-drug_n I-drug_n
( O O
PABA B-drug_n B-drug_n
) O O
-containing O O
preparations O O
( O O
e.g. O O
, O O
sunscreens O O
and O O
some O O
multivitamins B-group B-group
) O O
, O O
procainamide B-drug B-drug
( O O
e.g. O O
, O O
Pronestyl B-brand B-brand
) O O
, O O
sulfonamides B-group B-group
( O O
sulfa O B-group
medicines O I-group
) O O
, O O
thiazide B-group B-group
diuretics I-group I-group
( O O
use O O
of O O
these O O
medicines O O
during O O
the O O
test O O
period O O
will O O
affect O O
the O O
test O O
results O O
) O O
, O O
and O O
pancreatic O O
supplements O O
( O O
use O O
of O O
pancreatic O O
supplements O O
may O O
give O O
false O O
test O O
results O O
) O O
. O O

When O O
used O O
in O O
external O O
subcutaneous O O
infusion O O
pumps O O
for O O
insulin B-drug B-drug
, O O
NovoLog B-brand B-brand
should O O
not O O
be O O
mixed O O
with O O
any O O
other O O
insulins B-group B-group
or O O
diluent O O
. O O

Digitalis B-group B-group
: O O
Vitamin B-group B-group
D I-group I-group
dosage O O
must O O
be O O
determined O O
with O O
care O O
in O O
patients O O
undergoing O O
treatment O O
with O O
digitalis B-group B-group
, O O
as O O
hypercalcemia O O
in O O
such O O
patients O O
may O O
precipitate O O
cardiac O O
arrhythmias O O
. O O

Anticholinergic B-group B-group
agents I-group I-group
may O O
potentially O O
alter O O
the O O
absorption O O
of O O
some O O
concomitantly O O
administered O O
drugs O O
due O O
to O O
effects O O
on O O
gastrointestinal O O
motility O O
. O O

Antacids B-group B-group
or O O
H B-group B-group
2 I-group I-group
receptor I-group I-group
antagonists I-group I-group
: O O
When O O
dirithromycin B-drug B-drug
is O O
administered O O
immediately O O
following O O
antacids B-group B-group
or O O
H B-group B-group
2 I-group I-group
-receptor I-group I-group
antagonists I-group I-group
, O O
the O O
absorption O O
of O O
dirithromycin B-drug B-drug
is O O
slightly O O
enhanced O O
. O O

In O O
particular O O
, O O
convulsions O O
have O O
been O O
reported O O
when O O
ethionamide B-drug B-drug
is O O
administered O O
with O O
cycloserine B-drug B-drug
and O O
special O O
care O O
should O O
be O O
taken O O
when O O
the O O
treatment O O
regimen O O
includes O O
both O O
of O O
these O O
drugs O O
. O O

Because O O
dopamine B-drug B-drug
is O O
metabolized O O
by O O
monoamine O O
oxidase O O
( O O
MAO O O
) O O
, O O
inhibition O O
of O O
this O O
enzyme O O
prolongs O O
and O O
potentiates O O
the O O
effect O O
of O O
dopamine B-drug B-drug
. O O

Also O O
included O O
in O O
this O O
paper O O
is O O
a O O
study O O
which O O
confirms O O
the O O
identity O O
of O O
the O O
HPLC O O
peak O O
as O O
being O O
homocysteine O O
by O O
forming O O
a O O
radioactive O O
derivative O O
of O O
this O O
particular O O
sulphydryl-containing O O
amino O O
acid O O
, O O
and O O
then O O
analysing O O
the O O
resulting O O
mixture O O
by O O
TLC O O
. O O

Digoxin B-drug B-drug
Keppra B-brand B-brand
( O O
1000 O O
mg O O
twice O O
daily O O
) O O
did O O
not O O
influence O O
the O O
pharmacokinetics O O
and O O
pharmacodynamics O O
( O O
ECG O O
) O O
of O O
digoxin B-drug B-drug
given O O
as O O
a O O
0.25 O O
mg O O
dose O O
every O O
day O O
. O O

Azithromycin B-drug B-drug
had O O
no O O
significant O O
effect O O
on O O
dideoxyinosine B-drug B-drug
pharmacokinetics O O
. O O

Macrolide B-group B-group
Antibiotics I-group I-group
( O O
e. O O
g. O O
erythromycin B-drug B-drug
and O O
troleandomycin B-drug B-drug
) O O
: O O
Agents O O
of O O
the O O
ergot B-group B-group
alkaloid I-group I-group
class I-group I-group
, O O
of O O
which O O
D.H.E B-brand B-brand
. I-brand I-brand
45 I-brand I-brand
( O O
dihydroergotamine B-drug B-drug
mesylate I-drug I-drug
) O O
Injection O O
, O O
USP O O
is O O
a O O
member O O
, O O
have O O
been O O
shown O O
to O O
interact O O
with O O
antibiotics B-group B-group
of O O
the O O
macrolide B-group B-group
class I-group I-group
, O O
resulting O O
in O O
increased O O
plasma O O
levels O O
of O O
unchanged O O
alkaloids O O
and O O
peripheral O O
vasoconstriction O O
. O O

Due O O
to O O
their O O
similar O O
mechanism O O
of O O
action O O
, O O
it O O
is O O
expected O O
that O O
the O O
neuromuscular O O
blockade O O
produced O O
by O O
any O O
of O O
the O O
non-depolarizing B-group B-group
muscle I-group I-group
relaxants I-group I-group
could O O
be O O
prolonged O O
in O O
the O O
presence O O
of O O
piperacillin B-drug B-drug
. O O

In O O
the O O
DIAMOND O O
trials O O
, O O
1252 O O
patients O O
were O O
treated O O
with O O
TIKOSYN B-brand B-brand
and O O
diuretics B-group B-group
concomitantly O O
of O O
whom O O
493 O O
died O O
compared O O
to O O
508 O O
deaths O O
among O O
the O O
1248 O O
patients O O
receiving O O
placebo O O
and O O
diuretics B-group B-group
. O O

7 O O
. O O

Increased O O
nephrotoxicity O O
has O O
been O O
reported O O
following O O
concomitant O O
administration O O
of O O
cephalosporins B-group B-group
and O O
aminoglycoside B-group B-group
antibiotics I-group I-group
. O O

Inhibitors O O
of O O
CYP2D6 O O
; O O

Co-administration O O
of O O
multiple O O
doses O O
of O O
10 O O
mg O O
of O O
lenalidomide B-drug B-drug
had O O
no O O
effect O O
on O O
the O O
single O O
dose O O
pharmacokinetics O O
of O O
R- O O
and O O
S- B-drug O
warfarin I-drug B-drug
. O O

Nimodipine B-drug B-drug
had O O
no O O
effect O O
on O O
ginsenosides B-drug_n B-drug_n
response O O
. O O

Specific O O
drug O O
interaction O O
studies O O
, O O
including O O
interactions O O
with O O
MTX B-drug B-drug
, O O
have O O
not O O
been O O
conducted O O
. O O

Based O O
on O O
these O O
data O O
, O O
Vardenafil B-drug B-drug
should O O
not O O
be O O
used O O
in O O
patients O O
on O O
alpha-blocker B-group B-group
therapy O O
. O O

In O O
a O O
12-month O O
controlled O O
trial O O
that O O
included O O
a O O
50 O O
mcg O O
once O O
daily O O
BROVANA B-brand B-brand
dose O O
, O O
30 O O
of O O
the O O
528 O O
BROVANA B-brand B-brand
-treated O O
subjects O O
received O O
concomitant O O
theophylline B-drug B-drug
at O O
study O O
entry O O
. O O

Fentanyl B-drug B-drug

Phenytoin B-drug B-drug
is O O
metabolized O O
by O O
hepatic O O
cytochrome O O
P450 O O
enzymes O O
and O O
is O O
particularly O O
susceptible O O
to O O
inhibitory O O
drug O O
interactions O O
because O O
it O O
is O O
subject O O
to O O
saturable O O
metabolism O O
. O O

No O O
information O O
provided O O

The O O
literature O O
suggests O O
that O O
more O O
than O O
one O O
mechanism O O
of O O
action O O
exists O O
for O O
them O O
. O O

In O O
view O O
of O O
the O O
long O O
and O O
variable O O
half-life O O
of O O
amiodarone B-drug B-drug
, O O
potential O O
for O O
drug O O
interactions O O
exists O O
not O O
only O O
with O O
concomitant O O
medication O O
but O O
also O O
with O O
drugs O O
administered O O
after O O
discontinuation O O
of O O
amiodarone B-drug B-drug
. O O

Concomitant O O
administration O O
of O O
FACTIVE B-brand B-brand
with O O
probenecid B-drug B-drug
resulted O O
in O O
a O O
45 O O
% O O
increase O O
in O O
systemic O O
exposure O O
to O O
gemifloxacin B-drug B-drug
. O O

Drugs O O
Metabolized O O
by O O
Catechol-O-methyltransferase O O
( O O
COMT O O
) O O
: O O
Hormone O O
levels O O
: O O
Levodopa B-drug B-drug
is O O
known O O
to O O
depress O O
prolactin O O
secretion O O
and O O
increase O O
growth O O
hormone O O
levels O O
. O O

Hepatic O O
: O O
There O O
is O O
limited O O
evidence O O
that O O
the O O
myelotoxicity O O
of O O
TAXOL B-brand B-brand
may O O
be O O
exacerbated O O
in O O
patients O O
with O O
serum O O
total O O
bilirubin O O
2 O O
times O O
ULN O O
. O O

Other O O
antiarrhythmic B-group B-group
drugs I-group I-group
( O O
eg O O
, O O
quinidine B-drug B-drug
, O O
procainamide B-drug B-drug
, O O
lidocaine B-drug B-drug
, O O
propranolol B-drug B-drug
) O O
have O O
occasionally O O
been O O
used O O
concurrently O O
with O O
Norpace B-brand B-brand
. O O

Therefore O O
, O O
the O O
potential O O
exists O O
for O O
interaction O O
between O O
carbamazepine B-drug B-drug
and O O
any O O
agent O O
that O O
inhibits O O
CYP3A4 O O
and/or O O
epoxide O O
hydrolase O O
. O O

Co-administration O O
of O O
MYOBLOC B-brand B-brand
and O O
aminoglycosides B-group B-group
or O O
other O O
agents O O
interfering O O
with O O
neuromuscular O O
transmission O O
( O O
e.g. O O
, O O
curare-like B-group B-group
compounds I-group I-group
) O O
should O O
only O O
be O O
performed O O
with O O
caution O O
as O O
the O O
effect O O
of O O
the O O
toxin B-drug O
may O O
be O O
potentiated O O
. O O

1 O O
mM O O
) O O
was O O
a O O
slight O O
degree O O
of O O
inhibition O O
( O O
14 O O
% O O
-30 O O
% O O
) O O
of O O
isoform O O
CYP2A6 O O
observed O O
. O O

Cimetidine B-drug B-drug
: O O
A O O
study O O
in O O
6 O O
healthy O O
volunteers O O
has O O
shown O O
a O O
significant O O
increase O O
in O O
peak O O
nifedipine B-drug B-drug
plasma O O
levels O O
( O O
80 O O
% O O
) O O
and O O
area-under-the-curve O O
( O O
74 O O
% O O
) O O
after O O
a O O
1 O O
week O O
course O O
of O O
cimetidine B-drug B-drug
at O O
1000 O O
mg O O
per O O
day O O
and O O
nifedipine B-drug B-drug
at O O
40 O O
mg O O
per O O
day O O
. O O

Lipids O O
: O O
In O O
clinical O O
studies O O
, O O
the O O
incidence O O
of O O
hypertriglyceridemia O O
was O O
66 O O
% O O
, O O
hypercholesterolemia O O
was O O
33 O O
% O O
and O O
that O O
of O O
decreased O O
HDL O O
was O O
40 O O
% O O
. O O

Alpha-agonists B-group B-group
, O O
as O O
a O O
class O O
, O O
may O O
reduce O O
pulse O O
and O O
blood O O
pressure O O
. O O

Experience O O
with O O
co-administration O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
and O O
Fentanyl B-drug B-drug
in O O
patients O O
is O O
limited O O
, O O
therefore O O
, O O
consideration O O
should O O
be O O
given O O
to O O
temporarily O O
suspending O O
use O O
of O O
HMG-CoA B-group B-group
reductase I-group I-group
inhibitors I-group I-group
in O O
patients O O
receiving O O
Fentanyl B-drug B-drug
. O O

Resistance O O
to O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
nondepolarizing B-group B-group
neuromuscular I-group I-group
blocking I-group I-group
agents I-group I-group
has O O
been O O
demonstrated O O
in O O
patients O O
chronically O O
administered O O
phenytoin B-drug B-drug
or O O
carbamazepine B-drug B-drug
. O O

Drug/ O O
Laboratory O O
Test O O
Interactions O O
AMERGE B-brand B-brand
Tablets O O
are O O
not O O
known O O
to O O
interfere O O
with O O
commonly O O
employed O O
clinical O O
laboratory O O
tests O O
. O O

It O O
is O O
important O O
for O O
older O O
adults O O
to O O
be O O
aware O O
of O O
the O O
relationship O O
between O O
folic B-drug B-drug
acid I-drug I-drug
and O O
vitamin B-drug B-drug
B12 I-drug I-drug
because O O
they O O
are O O
at O O
greater O O
risk O O
of O O
having O O
a O O
vitamin O O
B12 O O
deficiency O O
. O O

Much O O
less O O
caspase-3 O O
activity O O
was O O
noted O O
in O O
the O O
lysate O O
derived O O
from O O
serum-deprived O O
RAS-3T3 O O
cells O O
compared O O
with O O
that O O
in O O
the O O
lysate O O
of O O
serum-deprived O O
NIH-3T3 O O
cells O O
. O O

FORADIL B-brand B-brand
is O O
not O O
meant O O
to O O
relieve O O
acute O O
asthma O O
or O O
COPD O O
symptoms O O
and O O
extra O O
doses O O
should O O
not O O
be O O
used O O
for O O
that O O
purpose O O
. O O

Nevirapine I-drug B-drug
and O O
ketoconazole B-drug B-drug
should O O
not O O
beadministered O O
concomitantly O O
becausedecreases O O
in O O
ketoconazole B-drug B-drug
plasmaconcentrations O O
may O O
reduce O O
the O O
efficacy O O
of O O
the O O
drug O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
A O O
false O O
positive O O
reaction O O
for O O
glucose O O
in O O
the O O
urine O O
may O O
occur O O
with O O
Benedicts O O
solution O O
, O O
Fehlings O O
solution O O
or O O
with O O
CLINITEST O O
tablets O O
, O O
but O O
not O O
with O O
enzyme-based O O
tests O O
such O O
as O O
CLINISTIX O O
. O O

Examples O O
of O O
Drugs O O
in O O
Which O O
Plasma O O
Concentrations O O
May O O
Be O O
Increased O O
By O O
Co-administration O O
With O O
Nevirapine B-drug B-drug

Alcohol B-drug B-drug
: O O
There O O
was O O
no O O
significant O O
difference O O
between O O
aripiprazole B-drug B-drug
coadministered O O
with O O
ethanol B-drug B-drug
and O O
placebo O O
coadministered O O
with O O
ethanol B-drug B-drug
on O O
performance O O
of O O
gross O O
motor O O
skills O O
or O O
stimulus O O
response O O
in O O
healthy O O
subjects O O
. O O

Aprepitant B-drug B-drug
is O O
also O O
an O O
inducer O O
of O O
CYP2C9 O O
. O O

. O O

Drug O O
Laboratory O O
Test O O
Interactions O O
None O O
known O O
. O O

Although O O
specific O O
studies O O
have O O
not O O
been O O
performed O O
, O O
coadministration O O
with O O
drugs O O
that O O
are O O
mainly O O
metabolized O O
by O O
CYP3A4 O O
( O O
eg O O
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
dapsone B-drug B-drug
, O O
disopyramide B-drug B-drug
, O O
quinine B-drug B-drug
, O O
amiodarone B-drug B-drug
, O O
quinidine B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
tacrolimus B-drug B-drug
, O O
cyclosporine B-drug B-drug
, O O
ergot B-group B-group
derivatives I-group I-group
, O O
pimozide B-drug B-drug
, O O
carbamazepine B-drug B-drug
, O O
fentanyl B-drug B-drug
, O O
alfentanyl B-drug B-drug
, O O
alprazolam B-drug B-drug
, O O
and O O
triazolam B-drug B-drug
) O O
may O O
have O O
elevated O O
plasma O O
concentrations O O
when O O
coadministered O O
with O O
saquinavir B-drug B-drug
; O O

Drug/Laboratory O O
Test O O
Interaction O O
Fosinopril B-drug B-drug
may O O
cause O O
a O O
false O O
low O O
measurement O O
of O O
serum O O
digoxin B-drug B-drug
levels O O
with O O
the O O
Digi- O O
Tab O O
RIA O O
Kit O O
for O O
Digoxin B-drug B-drug
. O O

An O O
encephalopathic O O
syndrome O O
( O O
characterized O O
by O O
weakness O O
, O O
lethargy O O
, O O
fever O O
, O O
tremulousness O O
and O O
confusion O O
, O O
extrapyramidal O O
symptoms O O
, O O
leukocytosis O O
, O O
elevated O O
serum O O
enzymes O O
, O O
BUN O O
, O O
and O O
FBS O O
) O O
followed O O
by O O
irreversible O O
brain O O
damage O O
has O O
occurred O O
in O O
a O O
few O O
patients O O
treated O O
with O O
lithium B-drug B-drug
plus O O
HALDOL B-brand B-brand
. O O

InjectionSite O O
Reaction O O
: O O
Injection O O
site O O
reactions O O
, O O
including O O
reactions O O
secondary O O
to O O
extravasation O O
, O O
were O O
usually O O
mild O O
and O O
consisted O O
of O O
erythema O O
, O O
tenderness O O
, O O
skin O O
discoloration O O
, O O
or O O
swelling O O
at O O
the O O
injection O O
site O O
. O O

In O O
patients O O
receiving O O
treatment O O
with O O
SPRYCEL B-brand B-brand
, O O
close O O
monitoring O O
for O O
toxicity O O
and O O
a O O
SPRYCEL B-brand B-brand
dose O O
reduction O O
should O O
be O O
considered O O
if O O
systemic O O
administration O O
of O O
a O O
potent O O
CYP3A4 O O
inhibitor O O
can O O
not O O
be O O
avoided O O
. O O

Additional O O
dose O O
increases O O
should O O
be O O
based O O
on O O
clinical O O
evaluation O O
. O O

The O O
oral O O
bioavailability O O
of O O
enoxacin B-drug B-drug
is O O
reduced O O
by O O
60 O O
% O O
with O O
coadministration O O
of O O
ranitidine B-drug B-drug
. O O

ranitidine* B-drug B-drug
; O O

Antimicrobial O O
activity O O
of O O
GL B-drug_n B-drug_n
( O O
the O O
aqueous O O
extract O O
from O O
the O O
carpophores O O
of O O
Ganoderma O O
lucidum O O
( O O
FR O O
) O O
KARST O O
) O O
was O O
tested O O
in O O
vitro O O
against O O
Gram O O
positive O O
and O O
Gram O O
negative O O
bacteria O O
by O O
serial O O
broth O O
dilution O O
method O O
, O O
and O O
the O O
antimicrobial O O
activity O O
was O O
expressed O O
by O O
minimal O O
inhibitory O O
concentration O O
( O O
MIC O O
) O O
. O O

Ethanol B-drug B-drug
: O O
Clinical O O
evidence O O
has O O
shown O O
that O O
etretinate B-drug B-drug
can O O
be O O
formed O O
with O O
concurrent O O
ingestion O O
of O O
acitretin B-drug B-drug
and O O
ethanol B-drug B-drug
. O O

INTERVENTIONS O O
: O O
Each O O
subject O O
was O O
treated O O
according O O
to O O
the O O
following O O
sequence O O
: O O
baseline O O
; O O

Cyclosporine B-drug B-drug
: O O
Administration O O
of O O
nonsteroial B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
concomitantly O O
with O O
cyclosporine B-drug B-drug
has O O
been O O
associated O O
with O O
an O O
increase O O
in O O
cyclosporine-induced B-drug B-drug
toxicity O O
, O O
possibly O O
due O O
to O O
decreased O O
synthesis O O
of O O
renal O O
prostacyclin O O
. O O

Co-administration O O
of O O
BOTOX B-brand B-brand
and O O
aminoglycosides B-group B-group
or O O
other O O
agents O O
interfering O O
with O O
neuromuscular O O
transmission O O
( O O
e.g. O O
, O O
curare-like B-group B-group
compounds I-group I-group
) O O
should O O
only O O
be O O
performed O O
with O O
caution O O
as O O
the O O
effect O O
of O O
the O O
toxin B-drug O
may O O
be O O
potentiated O O
. O O

In O O
vitro O O
studies O O
have O O
shown O O
no O O
binding O O
displacement O O
between O O
entacapone B-drug B-drug
and O O
other O O
highly O O
bound O O
drugs O O
, O O
such O O
as O O
warfarin B-drug B-drug
, O O
salicylic B-drug B-drug
acid I-drug I-drug
, O O
phenylbutazone B-drug B-drug
, O O
and O O
diazepam B-drug B-drug
. O O

Compromised O O
norepinephrine B-drug B-drug
uptake-1 O O
in O O
functional O O
class O O
IV O O
can O O
not O O
be O O
further O O
increased O O
by O O
cocaine B-drug B-drug
and O O
desipramine B-drug B-drug
. O O

SINCE O O
CHOLESTYRAMINE B-drug B-drug
RESIN B-group B-group
MAY O O
BIND O O
OTHER O O
DRUGS O O
GIVEN O O
CONCURRENTLY O O
, O O
IT O O
IS O O
RECOMMENDED O O
THAT O O
PATIENTS O O
TAKE O O
OTHER O O
DRUGS O O
AT O O
LEAST O O
1 O O
HOUR O O
BEFORE O O
OR O O
4 O O
TO O O
6 O O
HOURS O O
AFTER O O
CHOLESTYRAMINE B-drug B-drug
RESIN B-group B-group
( O O
OR O O
AT O O
AS O O
GREAT O O
AN O O
INTERVAL O O
AS O O
POSSIBLE O O
) O O
TO O O
AVOID O O
IMPEDING O O
THEIR O O
ABSORPTION O O
. O O

Lansoprazole B-drug B-drug
causes O O
a O O
profound O O
and O O
long O O
lasting O O
inhibition O O
of O O
gastric O O
acid O O
secretion O O
; O O

Therefore O O
, O O
it O O
should O O
be O O
recognized O O
that O O
a O O
positive O O
Coombs O O
test O O
could O O
be O O
due O O
to O O
the O O
drug O O
. O O

Maalox B-brand B-brand
* O O
Coadministration O O
of O O
Maalox B-brand B-brand
TC I-brand I-brand
had O O
no O O
effect O O
on O O
nicardipine B-drug B-drug
HCl I-drug I-drug
absorption O O
. O O

Concomitant O O
use O O
of O O
antihistamines B-group B-group
with O O
alcohol B-drug B-drug
, O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
barbiturates B-group B-group
, O O
or O O
other O O
central B-group B-group
nervous I-group I-group
system I-group I-group
depressants I-group I-group
may O O
have O O
an O O
additive O O
effect O O
. O O

Table O O
8 O O

anabolic B-group B-group
steroids I-group I-group
; O O

adjust O O
dosage O O
of O O
antidiabetic B-group B-group
drug I-group I-group
upward O O
if O O
necessary O O
. O O

Carbamazepine B-drug B-drug
( O O
CBZ B-drug B-drug
) O O

Combinations O O
of O O
these O O
drugs O O
have O O
not O O
been O O
studied O O
and O O
coadministration O O
of O O
CRIXIVAN B-brand B-brand
and O O
atazanavir B-drug B-drug
is O O
not O O
recommended O O
. O O

Amphotericin B-drug B-drug
, O O
Foscarnet B-drug B-drug
, O O
and O O
Aminoglycosides B-group B-group
: O O
Drugs O O
such O O
as O O
amphotericin B-drug B-drug
, O O
foscarnet B-drug B-drug
, O O
and O O
aminoglycosides B-group B-group
may O O
increase O O
the O O
risk O O
of O O
developing O O
peripheral O O
neuropathy O O
or O O
other O O
HIVID-associated B-drug B-drug
adverse O O
events O O
by O O
interfering O O
with O O
the O O
renal O O
clearance O O
of O O
zalcitabine B-drug B-drug
( O O
thereby O O
raising O O
systemic O O
exposure O O
) O O
. O O

Antiepileptic B-group B-group
drugs I-group I-group
: O O
Potential O O
interactions O O
between O O
Trileptal B-brand B-brand
and O O
other O O
AEDs B-group B-group
were O O
assessed O O
in O O
clinical O O
studies O O
. O O

Selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
( O O
SSRIs B-group B-group
) O O
( O O
e.g. O O
, O O
fluoxetine B-drug B-drug
, O O
fluvoxamine B-drug B-drug
, O O
paroxetine B-drug B-drug
, O O
sertraline B-drug B-drug
) O O
have O O
been O O
reported O O
, O O
rarely O O
, O O
to O O
cause O O
weakness O O
, O O
hyperreflexia O O
, O O
and O O
incoordination O O
when O O
coadministered O O
with O O
5-HT1 B-group B-group
agonists I-group I-group
. O O

Short-term O O
pharmacokinetic O O
studies O O
have O O
demonstrated O O
that O O
concomitant O O
administration O O
of O O
warfarin B-drug B-drug
and O O
Lodine B-brand B-brand
( O O
etodolac B-drug B-drug
capsules O O
and O O
tablets O O
) O O
results O O
in O O
reduced O O
protein O O
binding O O
of O O
warfarin B-drug B-drug
, O O
but O O
there O O
was O O
no O O
change O O
in O O
the O O
clearance O O
of O O
free O O
warfarin B-drug B-drug
. O O

Antihistamines B-group B-group
may O O
enhance O O
the O O
effects O O
of O O
tricyclic B-group B-group
antidepressants I-group I-group
, O O
barbiturates B-group B-group
, O O
alcohol B-drug B-drug
, O O
and O O
other O O
CNS B-group B-group
depressants I-group I-group
. O O

Skeletal B-group B-group
muscle I-group I-group
relaxants I-group I-group
, O O
nondepolarizing O O
( O O
e.g. O O
, O O
tubocurarine B-drug B-drug
) O O
: O O
possible O O
increased O O
responsiveness O O
to O O
the O O
muscle B-group B-group
relaxant I-group I-group
. O O

Videx B-brand B-brand
( O O
Didanosine B-drug B-drug
) O O
chewable/buffered O O
tablets O O
or O O
the O O
pediatric O O
powder O O
for O O
oral O O
solution O O
should O O
not O O
be O O
administered O O
concomitantly O O
with O O
, O O
or O O
within O O
2 O O
hours O O
of O O
, O O
the O O
administration O O
of O O
norfloxacin B-drug B-drug
, O O
because O O
these O O
products O O
may O O
interfere O O
with O O
absorption O O
resulting O O
in O O
lower O O
serum O O
and O O
urine O O
levels O O
of O O
norfloxacin B-drug B-drug
. O O

If O O
desipramine B-drug B-drug
hydrochloride I-drug I-drug
is O O
to O O
be O O
combined O O
with O O
other O O
psychotropic B-group B-group
agents I-group I-group
such O O
as O O
tranquilizers B-group B-group
or O O
sedative/hypnotics B-group B-group
, O O
careful O O
consideration O O
should O O
be O O
given O O
to O O
the O O
pharmacology O O
of O O
the O O
agents O O
employed O O
since O O
the O O
sedative O O
effects O O
of O O
desipramine B-drug B-drug
and O O
benzodiazepines B-group B-group
( O O
e.g. O O
, O O
chlordiazepoxide B-drug B-drug
or O O
diazepam B-drug B-drug
) O O
are O O
additive O O
. O O

Nevertheless O O
, O O
caution O O
is O O
indicated O O
in O O
the O O
co-administration O O
of O O
T.A B-group B-group
. I-group O
with O O
any O O
of O O
the O O
SSRIs B-group B-group
and O O
also O O
in O O
switching O O
from O O
one O O
class O O
to O O
the O O
other O O
. O O

The O O
results O O
from O O
trials O O
using O O
the O O
intravenous O O
prodrug O O
are O O
reported O O
in O O
this O O
section O O
as O O
they O O
relate O O
to O O
the O O
role O O
of O O
valdecoxib B-drug B-drug
in O O
drug O O
interactions O O
. O O

ACE B-group B-group
Inhibitors I-group I-group
and O O
Angiotensin B-group B-group
II I-group I-group
Receptor I-group I-group
Antagonists I-group I-group
( O O
Congestive O O
Heart O O
Failure O O
Post-Myocardial O O
Infarction O O
) O O
- O O
In O O
EPHESUS O O
, O O
3020 O O
( O O
91 O O
% O O
) O O
patients O O
receiving O O
INSPRA B-brand B-brand
25 O O
to O O
50 O O
mg O O
also O O
received O O
ACE B-group B-group
inhibitors I-group I-group
or O O
angiotensin B-group B-group
II I-group I-group
receptor I-group I-group
antagonists I-group I-group
( O O
ACEI/ARB B-group B-group
) O O
. O O

Furosemide B-drug B-drug
may O O
increase O O
the O O
ototoxic O O
potential O O
of O O
aminoglycoside B-group B-group
antibiotics I-group I-group
, O O
especially O O
in O O
the O O
presence O O
of O O
impaired O O
renal O O
function O O
. O O

therefore O O
, O O
coadministration O O
of O O
Aprepitant B-drug B-drug
with O O
drugs O O
that O O
inhibit O O
CYP3A4 O O
activity O O
may O O
result O O
in O O
increased O O
plasma O O
concentrations O O
of O O
aprepitant B-drug B-drug
. O O

. O O

Concurrent O O
use O O
of O O
these O O
agents O O
should O O
generally O O
be O O
avoided O O
. O O

Thiazides B-group B-group
: O O
Thiazides B-group B-group
are O O
known O O
to O O
induce O O
hypercalcemia O O
by O O
the O O
reduction O O
of O O
calcium O O
excretion O O
in O O
urine O O
. O O

Drugs O O
that O O
are O O
known O O
to O O
prolong O O
the O O
QTc O O
interval O O
have O O
an O O
increased O O
risk O O
of O O
ventricular O O
arrhythmias O O
. O O

Exposure O O
from O O
the O O
proposed O O
topical O O
dose O O
is O O
about O O
1 O O
% O O
of O O
that O O
from O O
the O O
100 O O
mg O O
oral O O
dose O O
, O O
even O O
when O O
co-administered O O
with O O
TMP/SMX B-drug B-drug
. O O

Morphine B-drug B-drug
: O O
A O O
literature O O
article O O
reported O O
that O O
when O O
a O O
60-mg O O
controlled-release O O
morphine B-drug B-drug
capsule O O
was O O
administered O O
2 O O
hours O O
prior O O
to O O
a O O
600-mg O O
Neurontin B-brand B-brand
capsule O O
( O O
N=12 O O
) O O
, O O
mean O O
gabapentin B-drug B-drug
AUC O O
increased O O
by O O
44 O O
% O O
compared O O
to O O
gabapentin B-drug B-drug
administered O O
without O O
morphine B-drug B-drug
. O O

The O O
clearance O O
of O O
theophylline B-drug B-drug
was O O
decreased O O
approximately O O
3-fold O O
. O O

phenyramidol B-drug_n B-drug
; O O

Auranofin B-drug B-drug
should O O
be O O
avoided O O
by O O
patients O O
with O O
a O O
history O O
of O O
serious O O
reaction O O
to O O
any O O
gold B-group B-group
medication I-group I-group
, O O
including O O
Solganal B-brand B-brand
and O O
Myochrysine B-brand B-brand
. O O

However O O
, O O
on O O
a O O
body O O
surface O O
area O O
basis O O
, O O
this O O
dose O O
was O O
0.5 O O
times O O
maximum O O
recommended O O
human O O
24-hour O O
dose O O
of O O
ribavirin B-drug B-drug
. O O

ANTACID B-group B-group
( O O
Magnesium-Aluminum B-drug B-drug
Hydroxide I-drug I-drug
) O O
: O O
Cerivastatin B-drug B-drug
plasma O O
concentrations O O
were O O
not O O
affected O O
by O O
co-administration O O
of O O
antacid B-group B-group
. O O

Although O O
no O O
interaction O O
between O O
MAO B-group B-group
inhibitors I-group I-group
and O O
Levo-Dromoran B-brand B-brand
has O O
been O O
observed O O
, O O
it O O
is O O
not O O
recommended O O
for O O
use O O
with O O
MAO B-group B-group
inhibitors I-group I-group
. O O

Table O O
1 O O
Changes O O
in O O
Desloratadine B-drug B-drug
and O O
3-Hydroxydesloratadine B-drug_n B-drug_n
Pharmacokinetics O O
in O O
Healthy O O
Male O O
and O O
Female O O
Volunteers O O

If O O
it O O
is O O
necessary O O
to O O
continue O O
the O O
diuretic B-group B-group
, O O
initiate O O
therapy O O
with O O
PRINIVIL B-brand B-brand
at O O
a O O
dose O O
of O O
5 O O
mg O O
daily O O
, O O
and O O
provide O O
close O O
medical O O
supervision O O
after O O
the O O
initial O O
dose O O
until O O
blood O O
pressure O O
has O O
stabilized O O
. O O

Diabetics O O
who O O
take O O
EPA B-drug B-drug
supplements O O
should O O
be O O
monitored O O
by O O
their O O
physicians O O
. O O

if O O
plasma O O
levels O O
are O O
being O O
monitored O O
, O O
they O O
should O O
be O O
reassessed O O
. O O

In O O
adjuvant O O
trials O O
of O O
epirubicin-containing B-drug B-drug
CEF-120 O O
or O O
FEC-100 O O
chemotherapies O O
, O O
breast O O
irradiation O O
was O O
delayed O O
until O O
after O O
chemotherapy O O
was O O
completed O O
. O O

Phenytoin B-drug B-drug
is O O
a O O
potent O O
inducer O O
of O O
hepatic O O
drug-metabolizing O O
enzymes O O
. O O

Caution O O
is O O
warranted O O
and O O
clinical O O
monitoring O O
of O O
patients O O
is O O
recommended O O
. O O

In O O
both O O
species O O
, O O
( B-drug_n B-drug_n
- I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
, O O
but O O
not O O
( B-drug_n B-drug_n
+ I-drug_n I-drug_n
) I-drug_n I-drug_n
-NANM I-drug_n I-drug_n
, O O
antagonized O O
the O O
rate-decreasing O O
effects O O
of O O
morphine B-drug B-drug
on O O
FI O O
and O O
FR O O
responding O O
. O O

Glibenclamide B-drug B-drug
: O O
In O O
a O O
study O O
of O O
7 O O
healthy O O
male O O
volunteers O O
, O O
acitretin B-drug B-drug
treatment O O
potentiated O O
the O O
blood O O
glucose O O
lowering O O
effect O O
of O O
glibenclamide B-drug B-drug
( O O
a O O
sulfonylurea B-group B-group
similar O O
to O O
chlorpropamide B-drug B-drug
) O O
in O O
3 O O
of O O
the O O
7 O O
subjects O O
. O O

By O O
this O O
procedure O O
, O O
it O O
was O O
observed O O
that O O
arsenate B-drug_n B-drug_n
is O O
rapidly O O
and O O
essentially O O
completely O O
absorbed O O
( O O
80-95 O O
% O O
) O O
from O O
the O O
lumen O O
at O O
As B-drug_n B-drug_n
( I-drug_n I-drug_n
V I-drug_n I-drug_n
) I-drug_n I-drug_n
concentrations O O
up O O
to O O
5 O O
mM O O
, O O
declining O O
to O O
about O O
50 O O
% O O
absorption O O
at O O
50 O O
mM O O
. O O

There O O
have O O
been O O
reports O O
of O O
QTc O O
prolongation O O
, O O
with O O
or O O
without O O
TdP O O
, O O
in O O
patients O O
taking O O
amiodarone B-drug B-drug
when O O
fluoroquinolones B-drug B-group
, O O
macrolide B-drug B-group
antibiotics I-drug I-group
, O O
or O O
azoles O O
were O O
administered O O
concomitantly O O
. O O

cinchophen B-drug B-drug
; O O

Cholestyramine B-drug B-drug
resin B-group B-group
may O O
interfere O O
with O O
the O O
pharmacokinetics O O
of O O
drugs O O
that O O
undergo O O
enterohepatic O O
circulation O O
, O O
The O O
discontinuance O O
of O O
cholestyramine B-drug B-drug
resin B-group B-group
could O O
pose O O
a O O
hazard O O
to O O
health O O
if O O
a O O
potentially O O
toxic O O
drug O O
such O O
as O O
digitalis B-group B-group
has O O
been O O
filtrated O O
to O O
a O O
maintenance O O
level O O
while O O
the O O
patient O O
was O O
taking O O
cholestyramine B-drug B-drug
resin B-group B-group
. O O

Ibuprofen B-drug B-drug
- O O
L-arginine B-drug B-drug
may O O
increase O O
the O O
absorption O O
of O O
ibuprofen B-drug B-drug
if O O
taken O O
concomitantly O O
. O O

Prednisone/prednisolone B-drug B-drug
: O O
Rofecoxib B-drug B-drug
did O O
not O O
have O O
any O O
clinically O O
important O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
prednisolone B-drug B-drug
or O O
prednisone B-drug B-drug
. O O

Therefore O O
smaller O O
ALFENTA B-brand B-brand
doses O O
will O O
be O O
required O O
with O O
prolonged O O
administration O O
and O O
the O O
duration O O
of O O
action O O
of O O
ALFENTA B-brand B-brand
my O O
be O O
extended O O
. O O

Reductions O O
in O O
serum O O
endogenous O O
vitamin O O
D O O
concentrations O O
have O O
been O O
observed O O
following O O
the O O
administration O O
of O O
300 O O
mg/day O O
to O O
1200 O O
mg/day O O
ketoconazole B-drug B-drug
for O O
a O O
week O O
to O O
healthy O O
men O O
. O O

Methadone B-drug B-drug
dose O O
was O O
increased O O
by O O
a O O
mean O O
of O O
22 O O
% O O
to O O
alleviate O O
withdrawal O O
symptoms O O
. O O

. O O

The O O
concomitant O O
use O O
of O O
ENABLEX B-brand B-brand
with O O
other O O
anticholinergic B-group B-group
agents I-group I-group
may O O
increase O O
the O O
frequency O O
and/or O O
severity O O
of O O
dry O O
mouth O O
, O O
constipation O O
, O O
blurred O O
vision O O
and O O
other O O
anticholinergic O O
pharmacological O O
effects O O
. O O

You O O
may O O
require O O
a O O
dosage O O
adjustment O O
or O O
special O O
monitoring O O
if O O
you O O
are O O
taking O O
any O O
of O O
the O O
medicines O O
listed O O
above O O
. O O

Nateglinide B-drug B-drug
is O O
highly O O
bound O O
to O O
plasma O O
proteins O O
( O O
98 O O
% O O
) O O
, O O
mainly O O
albumin O O
. O O

- O O
Lithium B-drug B-drug
: O O
Generally O O
should O O
not O O
be O O
given O O
with O O
diuretics B-group B-group
. O O

Theophylline B-drug B-drug
: O O
As O O
with O O
some O O
other O O
quinolones B-group B-group
, O O
concurrent O O
administration O O
of O O
ciprofloxacin B-drug B-drug
with O O
theophylline B-drug B-drug
may O O
lead O O
to O O
elevated O O
serum O O
concentrations O O
of O O
theophylline B-drug B-drug
and O O
prolongation O O
of O O
its O O
elimination O O
half-life O O
. O O

This O O
problem O O
has O O
been O O
analysed O O
using O O
two O O
different O O
tasks O O
in O O
mice O O
: O O
a O O
bar-press O O
conditioning O O
and O O
a O O
spatial O O
discrimination O O
task O O
. O O

Patients O O
with O O
Hepatic O O
Impairment O O
In O O
vitro O O
and O O
in O O
vivo O O
evidence O O
suggest O O
that O O
erlotinib B-drug B-drug
is O O
cleared O O
primarily O O
by O O
the O O
liver O O
. O O

Of O O
over O O
3500 O O
patients O O
enrolled O O
in O O
the O O
Ibandronate B-drug B-drug
osteoporosis O O
Treatment O O
and O O
Prevention O O
Studies O O
, O O
15 O O
% O O
used O O
anti-peptic O O
agents O O
( O O
primarily O O
H2 B-group B-group
blockers I-group I-group
and O O
PPIs B-group B-group
) O O
. O O

Desloratadine B-drug B-drug
3-Hydroxydesloratadine B-drug_n I-drug

More O O
importantly O O
, O O
we O O
demonstrate O O
that O O
IgA O O
is O O
probably O O
the O O
major O O
serum O O
constituent O O
precipitated O O
by O O
the O O
lectin O O
and O O
that O O
no O O
IgG O O
or O O
IgM O O
can O O
be O O
detected O O
in O O
the O O
precipitates O O
. O O

The O O
effect O O
on O O
other O O
progestational B-group B-group
contraceptives I-group I-group
( O O
eg O O
, O O
implants O O
, O O
injectables O O
) O O
is O O
unknown O O
. O O

These O O
drugs O O
should O O
be O O
coad-ministered O O
with O O
caution O O
and O O
frequent O O
monitoring O O
of O O
serum O O
lithium B-drug B-drug
levels O O
is O O
recommended O O
. O O

dosage O O
adjustment O O
of O O
antigout B-group B-group
medications I-group I-group
may O O
be O O
necessary O O
to O O
control O O
hyperuricemia O O
and O O
gout O O
. O O
) O O

Drug/Laboratory O O
Test O O
Interactions O O
False O O
elevations O O
of O O
urinary O O
catecholamine O O
levels O O
may O O
occur O O
due O O
to O O
interference O O
with O O
the O O
fluorescence O O
test O O
. O O

In O O
these O O
six O O
cases O O
it O O
was O O
demonstrated O O
that O O
the O O
neuroleptics B-group B-group
dosage O O
was O O
inappropriate O O
, O O
being O O
either O O
too O O
high O O
or O O
too O O
low O O
as O O
judged O O
from O O
the O O
plasma O O
concentrations O O
. O O

This O O
may O O
lead O O
to O O
low O O
amiodarone B-drug B-drug
serum O O
levels O O
and O O
potential O O
decrease O O
in O O
efficacy O O
. O O

Vasopressors B-group B-group
: O O
Thyroxine B-drug B-drug
increases O O
the O O
adrenergic O O
effect O O
of O O
catecholamines O B-group
such O O
as O O
epinephrine B-drug B-drug
and O O
norepinephrine B-drug B-drug
. O O

Drugs O O
which O O
may O O
enhance O O
the O O
neuromuscular O O
blocking O O
action O O
of O O
TRACRIUM B-brand B-brand
include O O
: O O
enflurane B-drug B-drug
; O O
isoflurane B-drug B-drug
; O O
halothane B-drug B-drug
; O O
certain O O
antibiotics B-group B-group
, O O
especially O O
the O O
aminoglycosides B-group B-group
and O O
polymyxins B-group B-group
; O O
lithium B-drug B-drug
; O O
magnesium B-drug B-drug
salts O O
; O O
procainamide B-drug B-drug
; O O
and O O
quinidine B-drug B-drug
. O O

Furthermore O O
, O O
whenever O O
one O O
of O O
these O O
other O O
drugs O O
is O O
withdrawn O O
from O O
co-therapy O O
, O O
an O O
increased O O
dose O O
of O O
tricyclic B-group B-group
antidepressant I-group I-group
may O O
be O O
required O O
. O O

ACE B-group B-group
Inhibitors I-group I-group
: O O
Concomitant O O
use O O
of O O
ACE B-group B-group
inhibitors I-group I-group
may O O
increase O O
the O O
risk O O
of O O
renal O O
impairment O O
, O O
particularly O O
in O O
volume-depleted O O
patients O O
. O O

barbiturates B-group B-group
; O O

b O O
. O O

Paroxetine B-drug B-drug
: O O
Coadministration O O
of O O
a O O
single O O
dose O O
of O O
Sonata B-brand B-brand
20 O O
mg O O
and O O
paroxetine B-drug B-drug
20 O O
mg O O
daily O O
for O O
7 O O
days O O
did O O
not O O
produce O O
any O O
interaction O O
on O O
psychomotor O O
performance O O
. O O

ulcerans O O
was O O
measured O O
by O O
plate O O
counts O O
and O O
the O O
BACTEC O O
radiometric O O
method O O
. O O

The O O
objective O O
of O O
this O O
study O O
was O O
to O O
determine O O
if O O
there O O
is O O
a O O
pharmacokinetic O O
interaction O O
when O O
amprenavir B-drug B-drug
is O O
given O O
with O O
rifabutin B-drug B-drug
or O O
rifampin B-drug B-drug
and O O
to O O
determine O O
the O O
effects O O
of O O
these O O
drugs O O
on O O
the O O
erythromycin O O
breath O O
test O O
( O O
ERMBT O O
) O O
. O O

Stereoselective O O
behavioral O O
effects O O
of O O
N-allylnormetazocine B-drug_n B-drug_n
in O O
pigeons O O
and O O
squirrel O O
monkeys O O
. O O

The O O
effect O O
on O O
CYP1A2 O O
was O O
explored O O
further O O
in O O
a O O
clinical O O
interaction O O
study O O
with O O
theophylline B-drug B-drug
and O O
no O O
effect O O
on O O
metabolism O O
was O O
observed O O
. O O

Nabilone I-drug B-drug
should O O
be O O
administered O O
with O O
caution O O
to O O
patients O O
who O O
are O O
taking O O
other O O
psychoactive B-group B-group
drugs I-group I-group
or O O
CNS B-group B-group
depressants I-group I-group
, O O
including O O
alcohol B-drug B-drug
, O O
barbiturates B-group B-group
and O O
narcotic B-group B-group
analgesics I-group I-group
, O O
or O O
to O O
those O O
with O O
a O O
history O O
of O O
psychiatric O O
disorder O O
( O O
including O O
manic-depressive O O
illness O O
and O O
schizophrenia O O
) O O
. O O

Drug-Laboratory O O
Test O O
Interactions O O
There O O
are O O
no O O
known O O
interactions O O
between O O
CAMPTOSAR B-brand B-brand
and O O
laboratory O O
tests O O
. O O

Administration O O
of O O
lithium B-drug B-drug
prophylaxis O O
. O O

Sedatives/Hypnotics B-group B-group
: O O
triazolam B-drug B-drug
, O O
midazolam B-drug B-drug
CONTRAINDICATED O O
due O O
to O O
potential O O
for O O
serious O O
and/or O O
life-threatening O O
reactions O O
such O O
as O O
prolonged O O
or O O
increased O O
sedation O O
or O O
respiratory O O
depression O O
. O O

Drug O O
Class O O
Examples O O
of O O
Drugs O O

Dosage O O
adjustment O O
of O O
concomitant O O
medications O O
may O O
be O O
necessary O O
. O O

In O O
the O O
current O O
study O O
, O O
the O O
nonpredisposed O O
strain O O
C57BL/6N O O
was O O
also O O
shown O O
to O O
be O O
highly O O
susceptible O O
to O O
diethylnitrosamine O O
during O O
the O O
neonatal O O
period O O
. O O

Phenobarbital B-drug B-drug
( O O
Primidone B-drug B-drug
) O O
: O O
Population O O
pharmacokinetic O O
analyses O O
indicate O O
that O O
tiagabine B-drug B-drug
clearance O O
is O O
60 O O
% O O
greater O O
in O O
patients O O
taking O O
phenobarbital B-drug B-drug
( O O
primidone B-drug B-drug
) O O
with O O
or O O
without O O
other O O
enzyme-inducing O O
AEDs B-group B-group
. O O

BACKGROUND O O
: O O
Since O O
its O O
approval O O
by O O
the O O
US O O
Food O O
and O O
Drug O O
Administration O O
in O O
March O O
1998 O O
, O O
sildenafil B-drug B-drug
citrate I-drug I-drug
has O O
been O O
used O O
by O O
millions O O
of O O
men O O
for O O
the O O
treatment O O
of O O
erectile O O
dysfunction O O
. O O

unreliable O O
prothrombin O O
time O O
determinations O O
; O O

